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Abstract
The role of inflammation in the pathogenesis and progression of atherosclerosis has been 
conclusively demonstrated over the past two decades. Experimental studies have investigated the use of 
several immuno-modulatory agents as therapeutic or prophylactic treatments against this disease. The 
approach in the present study was to use the Chlamydophila pneumoniae major outer membrane protein 
(MOMP) as an immuno-modulatory treatment. Previous studies have shown that MOMP can attenuate T 
cell-mediated immune responses, thus prompting this study to assess whether MOMP could have an impact 
on atherosclerotic plaque development.
MOMP was delivered and expressed in animal and tissue culture models using two different 
vector systems; a heterologous Mycobacterium vaccae expression vector carrying constructs for MOMP 
expression, with and without signal peptide sequence (M vaccae-rMOMP+SPS or M. vaccae-vMOM?- 
SPS) and a DNA vaccine delivery system carrying the full length of MOMP gene (pcDNA-MOMP). For 
characterisation of the immune response, C57B1/6J mice were immunised intranasally with one prime dose 
and one booster dose following a two week interval. Flow cytometry analysis showed that rMOMP 
delivered from either M. vaccae (with signal peptide sequence) or from a eukaryotic expression plasmid, 
was capable of significantly increasing the percentage of CD4^ and CD8^  Treg cells compared to the 
control group. Additionally, rMOMP delivered by M. vaccae induced increased production of IL-10, while 
pcDNA-MOMP alone, decreased production of IFN-y secretion; indicating a shift towards an anti­
inflammatory immune response. The effect of rMOMP on the surface marker expression on mouse 
peritoneal macrophages and naïve CD4^ T cells was also investigated in vitro. The data revealed that 
rMOMP caused a significant reduction in the percentage of macrophages expressing the CD40 molecule; 
while increasing Treg numbers as indicated by increasing the number of CD4^ T cells expressing CTLA-4 
and CD25 markers. Moreover, pcDNA-MOMP treatment decreased the percentage of CD4^ T cells 
expressing CD3 receptors and reduced CD4^ T cell proliferation in vitro. Together, these studies suggest 
that MOMP inhibits the pro-inflammatory signals that promote pro-inflammatory T cell development.
Subsequently, the effect of MOMP on atherosclerosis development was examined using the apoE" 
mouse model of atherosclerosis. Animals received one inoculation and two boosters, three weeks apart. 
Intranasal administration of M. vaccae-rMOMP-SPS arrested 95% of atherosclerosis development in the 
brachiocephalic artery and induced smooth muscle cell proliferation in the aortic sinus of apoE' '^ mice. 
Concomitantly, both +SPS and -SPS M. vaccae-vMOM? vaccines enhanced the percentage of Treg cells in 
the population and the production of the anti-inflammatory cytokines IL-10, TGF-P and IL-4. These two 
vectors also resulted in a reduction in total and HDL-cholesterol levels. Conversely, DNA immunisation 
had no effect on atherosclerosis development or the immune response but did induce a reduction in 
triglycerides and HDL-cholesterol levels.
In conclusion, the results of this study suggest that immunisation with rMOMP-based vaccines 
could promote an athero-protective T-cell response by tempering pro-inflammatory signals. However, it is 
pertinent to note that the choice of delivery vector and the form of protein are critical in determining the 
immune response and thus the success of the treatment.
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CHAPTER 1
GENERAL INTRODUCTION
1.1. CARDIOVASCULAR DISEASE AND ATHEROSCLEROSIS: AN 
OVERVIEW
Cardiovascular disease (CVD) is the main cause of morbidity and mortality in the 
UK; followed by diseases such as cancer, diabetes and other chronic conditions. CVD 
kills more than 190,000 people annually, accounting for approximately a third of all 
deaths in the UK. CVD is also the major cause of premature death (before the age of 75), 
representing almost a third (29%) of premature deaths in men and over a fifth (21%) in 
women in 2007 (BHF, 2009-10). By the year 2020, it is estimated that CVD will be the 
World’s leading cause of death and disability (WHO, 2011). CVD includes all diseases 
that affect the heart and blood vessels (arteries and veins) (Myerburg, 1997). 
Atherosclerosis is the major underlying cause of this disease, and is characterised by 
hardening of the arterial wall, combined with deposition of fatty molecules and the 
recruitment of white blood cells, especially in the intimai layer of blood vessels. This 
hardening and accumulation leads to narrowing of the lumen of the artery and occludes 
blood flow, limiting oxygen supply to different organs and tissues and leading to further 
complications (Kumar, 2002 ).
1.1.1. Atherosclerosis
The first classification of atherosclerosis was provided by the World Health 
Organization (WHO) in 1958, who classified it according to the different stages of 
disease progression. These stages were designated as follows: fatty streak, atheroma, 
fibrous plaque and complicated lesions (Gaudio et al., 2006). In the 1990s, the American 
Heart Association (AHA) proposed a new morphological classification system using new 
sensitive technique based on eight lesion types denoted by Roman numerals indicating 
the sequence of lesion development (Krone et al., 2000, Stary et al., 1995).
According to the more recent classification by AHA, atherosclerosis is defined as
a chronic inflammatory disease in the wall of large and medium sized arteries, and is the
most common pathological change leading to CVD. Atherosclerosis is characterised by
two essential hallmarks: firstly, the accumulation of oxidised lipoprotein in the intima of
arteries and secondly, inflammatory changes leading to plaque formation, ultimately
causing thrombosis or stenosis (Hansson, 2005). In addition, atherosclerosis progression
is accelerated in patients suffering from classical autoimmune rheumatic diseases, such
as systemic lupus erythematosus (SLE), anti-phospholipids syndrome (APS), rheumatoid
arthritis (RA) and vasculitis, thus confirming the involvement of inflammatory and
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immune mechanisms in the process of plaque formation (Gordon et ah, 2001, Shoenfeld, 
2001).
The majority of atherosclerotic lesions develop in specific areas due mainly to 
haemo-dynamie factors. Shear-stress produced by non-turbulant laminar blood flow 
stimulates athero-proteetive mechanisms such as the expression of the enzyme 
superoxide dismutase and enhancement of the activity of nitric oxide synthase, which 
inhibit oxidative stress and suppress the expression of adhesion molecules and other 
inflammatory pathways respectively (Topper and Gimbrone, 1999, Guilia Russoa, 2002). 
Areas facing disturbed blood flow or a lack of laminar flow are more prone to lesion 
formation due to the reduced activity of such athero-proteetive mechanisms. Therefore, 
lesions are mainly associated with branch and curvature points of the vascular system 
(Giddens et ah, 1993, Libby et ah, 2002).
1.1.1.1. Risk factors involved in atherosclerosis development
Atherosclerosis is a chronic disease that starts in foetal development and progresses 
during childhood and adolescence and accelerates in adulthood (Napoli, 1997 , Napoli et ah, 
1999, Binder et ah, 2002). It has been reported that around 25% of coronary patients experience 
sudden death or non-fatal myocardial infarction without any prior symptoms due to 
atherosclerosis (Myerburg, 1997). Epidemiological studies have identified a number o f risk 
factors involved in atherosclerosis and its complications. The risk factors for atherosclerosis 
have been classified into different categories, these are: un-modifiable, modifiable and 
pathological. Un-modifiable factors are represented by age, gender, ethnicity or race and family 
history (genetic) (Dallongeville et ah, 1992), whereas modifiable factors include serum 
cholesterol and triglyceride levels (Lamarche et ah, 2001), a stressful life style causing high 
blood pressure, cigarette smoking, diabetes, obesity and alcohol intake (Hyman, 2001,, 
Lewington et ah, 2002, Castelli et ah, 1981, Fiorentino et ah, 1991, Gaede, 2003,, Haffner, 1998, 
Semenkovich, 2006, Kauhanen et ah, 1999). The pathological factors include autoimmune 
diseases (Abou-Raya and Abou-Raya, 2006), and infectious diseases caused by bacteria such as 
Chlamydophila pneumoniae and Helicobacter pylori, or by viruses (Mussa et ah, 2006). 
Recently, new risk factors have been proposed as novel markers for the prediction o f  CVD and 
atherosclerosis in clinical studies, especially in asymptomatic persons (Hackam and Anand, 2003, 
Kullo and Ballantyne, 2005). These risk factors are summarised in Table 1.1.
Table 1.1. Novel risk factors involved in atherosclerosis (Hackam, D.G. and S.S. Anand
Risk factors E xam ples
Inflammatory markers C-reactive p rotein  (CRP), interleukins (IL-6), serum  amyloid A, vascular and 
cellular adhesion molecules, soluble CD40 ligands (sCD40L) and num ber of 
Leukocytes.
Haem ostasis /  
Thrombosis markers
Fibrinogen, von W illebrand fac to r antigen,
plasm inogen activator inhibitor l(PA I-l), tissue-plasm inogen activator 
factors, D-dimer, fib rinopeptide A and prothrom bin fragm en t 1+2
Platelet related factors Platelet aggregation, p la te le t activity and 
p la te le t size and volum e
Lipid related factors Low-density lipoprotein (LDL), lipoprotein A, rem n an t lipoproteins, apo- 
lipoproteins A1 and B, high-density lipoprotein sub types and oxidized LDL
Other factors H om ocysteine, lipoprotein-associated  phosphor-lipase A2, m icro-album inuria, 
insulin resistance, apoE genotype, infectious agents: (Cytom egalovirus, Ch. 
pneumonia, H. pylori, Herpes simplex virus) and psychosocial factors.
1.1.1.2. Development o f atherosclerotic plaques
Atherosclerosis development may be a regressive process, whereby the plaque 
shrinks during the early stages of the disease, but is continuously progressive during 
intermediate and advanced stages, see Figure 1.1. In the following section, the 
progressive stages of atherosclerosis development are outlined.
Fatty streak development
The first stage of atherogenesis is the development of a fatty streak, which starts 
during childhood and can be visualised by light microscopy (Stary et al., 1995). This 
first step is initiated by the accumulation of lipoprotein particles, especially low density 
lipoprotein (LDL) in the arterial intima of the blood vessels (Berliner et al., 2001, 
Witztum and Berliner, 1998). Lipoproteins are small particles responsible for 
transporting cholesterol and triglycerides in the blood (Sacks et al., 2006). The 
accumulation of lipoprotein particles in the vascular wall depends on the interaction 
between apo-lipoprotein B (apoB); the main protein component of the LDL particles, and 
proteoglycans in the extracellular matrix (ECM) (Boren et al., 1998). There are several 
different types of circulating lipoproteins: very low density lipoproteins (VLDL), 
intermediate density lipoproteins (IDE), the foure-mentioned low density lipoproteins 
(LDL) and high density lipoproteins (HDL). Whereas LDL lipoproteins are regarded as
atherogenic, HDLs are known as athero-proteetive lipoproteins (steinberg, 1987, Reusch 
et ah, 1996).
In its native state, LDL is not normally atherogenic but becomes atherogenic 
upon oxidation, forming oxidised LDL (oxLDL) (Gaut and Heinecke, 2001, Pentikainen 
et al., 2000, steinberg, 1987, Ross, 1995, ). Several molecules act as receptors for LDL 
including the Lectin-like oxidized LDL receptor-1 (LOX-1), that is expressed by 
endothelial cells (ECs) (Niu et al., 2000), CD36 that is expressed on macrophages and 
scavenger receptor class B type I (SR-BI) that expressed in the liver, steroidogenic 
tissues and in macrophages within atherosclerotic plaques (Chinetti 2000, Hirano et al. 
1999). oxLDL initiates inflammation by activation of ECs, leading to expression of 
different adhesion molecules such as vascular adhesion molecule (VCAM-1), 
intracellular adhesion molecule -1 (ICAM-1) and P and E-selectin molecules; all are 
located in areas prone to lesion formation. oxLDL also initiates inflammation by 
triggering the secretion of pro-inflammatory cytokines such as Interleukin (IL)-ip, IL-la, 
tumor necrosis factor (TNF)-p and IL-6. These pro-inflammatory cytokines also enhance 
the expression of adhesion molecules on ECs creating a vicious cycle (Libby et al., 2002, 
Libby et al., 2006). Adhesion molecules contribute to the recruitment of leukocytes 
including monocytes, lymphocytes, mast cells and neutrophils into the arterial wall 
(Dong et al., 1998, Lusis, 2000, Ross, 1999, A, Suzuki et al., 1997).
Transmigration of leukocytes through ECs is mediated by chemotactic factors; 
the most common chemotactic factor is a proteolytic molecule of the complement 
system: C5a (Shagdarsuren et al., 2011). Additionally, several chemokines mediating 
this process are secreted by ECs, activated macrophages and smooth muscle cells 
(SMCs) (Gerszten et al., 2000). The most common chemokine involved in fatty streak 
development is monocyte chemotactic protein-1 (MCP-1), which is expressed during all 
stages of atherosclerosis development (Hansson and Berne, 2004, Walch et al., 2006). 
Upon entry, monocytes transform into macrophages, which is coherent with the first step 
in atherosclerosis pathogenesis being modulated mainly by macrophage-colony 
stimulating factor (M-CSF) (Napoli, 1997 , Gerrity, 1981, Napoli, 1997, , Yan and 
Hansson, 2007). Consequently, pattern recognition receptors (PRRs) on macrophages 
are up-regulated. For example, scavenger receptors and toll like receptors (TLRs); 
subtypes of PRRs are both up-regulated and, start to uptake lipid particles leading to 
foam cell formation and stimulate cellular signalling cascades to activate inflammation 
respectively. Stimulation of macrophages by oxLDL also induces the release of several
growth factors and cytokines that stimulate inflammation and activate both CD4^ T cells 
and CD8  ^T cells. These cell types have been detected within atherosclerotic plaques at 
all stages of development (Hansson and Libby, 2006, Frostegard et al., 1999) (Figure 1.1 
A & B ).
Formation of the fibrous cap (early fibro-atheroma or complex lesions)
This stage is initiated between the ages of 20 to 30 years and continues 
throughout life (Stary et al., 1995, Virmani et al., 2000, Burke et al., 2000, Eggen and 
Solberg, 1968). Fibrous cap formation is asymptomatic and can either progress to a 
complex atheroma or regress to a simpler plaque (Hansson et al., 2006). This stage is 
characterised by the initial migration and proliferation of SMCs into the intima area or 
sub-endothelial space (Libby et al., 2002). SMCs produce ECM proteins such as 
collagen, fibrin and proteoglycan, leading to the development of a fibrous cap (Ross, 
1999, A, Paulsson et al., 2000). Increasing extracellular lipid accumulation along with 
activated inflammatory cells, such as lymphocytes, natural killer cells (NK) and dendritic 
cells (DC) and the release of apoptotic factors, leads to necrotic core formation that 
resides in the central part of the intima and represents 30% to 50% of the arterial wall 
volume. The fibrous cap covers the necrotic core just beneath the endothelium (William 
Insull, 2009). Once the lesion reaches this stage, there are two possibilities; either the 
fibrous cap remains intact and the plaque is stable, or plaque development continues and 
becomes vulnerable and prone to rupture (William Insull, 2009, Hansson et al., 2006, 
Libby et al., 2002, Prati and Zimarino, 2011) (Figure 1.1 C).
Advanced atheroma and atherosclerotic plague rupture
This stage of plaque development is clinically silent and occurs between the ages 
of 55 to 65 years, until plaque rupture causes clinical manifestations (William Insull, 
2009, Cheruvu et al., 2007, Moreno et al., 2006). Histopathological studies have shown 
that the fibrous cap becomes weak and progression to atheroma (mature plaques) leads to 
physical disruption of the protective fibrous cap, thus exposing clotting factors to pro­
coagulants expressed in the lesions (Virmani et al., 2002) (Figure 1.1 D). Rupture of 
fibrous cap can have different clinical outcomes. Superficial erosion of the endothelial 
layer that covers the intima is responsible for one quarter of fatal thromboses. Erosion 
can be due to either apoptosis of the ECs, induced by cytolytic T cells and activated 
natural killer T (NKT) cells, or by a group of proteolytic enzymes called matrix
metalloproteinases (MMPs) that lead to degradation of the basement membrane of the 
endothelium layer (Rajavashisth et ah, 1999).
Another mechanism involved in the plaque rupture is the disruption of micro­
vessels that develop within atherosclerotic plaques. At this stage vessels become weak, 
fragile and susceptible to micro-haemorrhage, leading to thrombosis in situ during 
atherogenesis. This causes thrombin generation, which stimulates SMC migration and 
proliferation and induces platelets to secrete platelet derived growth factor (PDGF) and 
transforming growth factor beta (TGF-P), increasing micro-vascular haemorrhage within 
the intima of an atherosclerotic plaque (Zamir and Silver, 1992, Doyle and Caplice, 
2007). Several studies have suggested that macrophages could be also involved by 
producing angiogenic mediators such as acidic and basic fibroblast growth factors and 
vascular endothelial growth factor (VEGF) (Brogi et al., 1993, Ramos et al., 1998)
Fibrous cap rupture is the most common type of plaque rupture and is responsible 
for three quarters of all acute myocardial infarctions. The danger of this mechanism is 
that it is not only common, but is also asymptomatic. Pro-inflammatory mediators such 
as interferon (IFN)-y, which inhibits collagen production by SMCs by inducing apoptosis 
and activating MMP, enhance plaque vulnerability (Galis et al., 1994, Sukhova et al., 
1999, Herman et al., 2001, Halvorsen et al., 2008). Finally, although plaque ruptures can 
heal by the formation of fibrous tissue and collagen structures (Figure 1.1 D), they may 
rupture again during progression (Burke et al., 2001, Virmani et al., 2000). 
Unfortunately, clinical studies are currently incapable of predicting which plaques are 
more susceptible to rupture, therefore further studies are required to resolve this problem 
(Johnson and Jackson, 2001).
From first decade From third decade From fourth decade
«•lit t e
Growth mamiy by Lipid accumulation
mmimi
BUP»
atherosclerosis o Atherogenic factors: /  LDL«ft0!«!sre 
/  Oi»t3»t«S
fay HypertensionO
MCP-1 
VCAM
J j  'Ç r  C ,Q J Endothelial dysfunction
poar KSf-1 
CFGF TGF » ew \Anw«
Oj +NO
ONOO-
lon OT a eroscierosis
' Endothelial dysfunction 
' Inflammation 
' Foam cells 
’ VSMC activation
B. Early lesions
' Inflammation 
' Foam cell (fatty streak)
' VSfVlC migration and proliferation
r \  Fibrous cap
d egrada tion  and  
. a ^ ^ i j l a q u e  rup ture
Collaganases 
q 1  Elastases 
■f Stromelysms
Stable fibrocaklfic
C. Vulnerable plaque
• Lipid core: abundant foam cells
• Intense inflammation (shoulder region)
• Thin fibrous cap: VSMC apoptosis and 
replication
D. Advanced Plaque
• VSMC abundance
• Fibroblasts and matrix
• Extracellular calcification
F igu re 1 .1 . S c h e m a t ic  d iagram  s h o w in g  th e  d e v e lo p m e n ta l s t a g e s  o f  a th e r o s c le r o s i s  
an d  th e  p a th o lo g ic a l in flam m atory  m e c h a n is m s  co n tr ib u tin g  to  a th e r o s c le r o t ic  p la q u e  
p r o g r e s s io n . Upon triggering o f the vascular endothelium  by different factors, leukocytes 
accum ulate w ithin the intimai layer. Cytokines and growth factors are released by d ifferent 
inflam m atory cells and vascular smooth m uscle cells (VSMCs) (A). VSM Gs m igrate into the 
intima, proliferate and start to synthesise d ifferent extracellu lar m atrix (ECM) com ponents, 
form ing the fibrous cap o f the atherosclerotic lesion (B). A continued inflam m atory response 
induces the thinning o f the fibrous cap, which is susceptib le to rupture and th rom bosis (C). 
Fibro-calcified lesions, in the advanced stages, are induced by extracellu lar calcium, secreted 
by fibroblasts and VSM Cs (D). (This diagram  has been modified from (Dzau et al., 2002, 
Repine et al., 1998)).
1.1.L3. Immunological mechanisms underlying atherosclerosis development
Atherosclerosis is a chronic inflammatory disorder of the arterial walls where
both innate and adaptive immunity modulate initiation, progression and thrombotic 
complications (Hansson and Hermansson, 2011, Ishibashi et ah, 1994, Hansson, 2005, 
Andersson et ah, 2010). Figure 1.2 summarises both innate and adaptive responses, and 
these are discussed in more detail in the following sections.
1.1.1.3.1. The role of innate immunity in atherosclerosis development
The pathological inflammatory mechanisms involved in atherosclerosis 
development initiate by activation of innate immune system that relies on specific 
receptors mainly PRRs that detect and clear the harmful antigens and network of cellular 
components (Akira 2006, Lundberg 2010). Activation of innate immune system leads to 
induction of pro-inflammatory cytokines and antigen specific immune response. 
Stimulation of innate immune system begins with endothelial dysfunction, induced by 
different factors that can be classified into three main categories: exogenous activator 
molecules (bacterial or viral antigens, and bacterial cell membrane components such as 
peptidoglycan or lipo-polysaccharides ‘LPS’), endogenous activator molecules (heat 
shock protein 60 ‘HSP60’, oxLDL, (32 glycoprotein-1) and mechanical changes o f  blood 
flow  (Loppnow et ah, 2008, Kol et ah, 2000, Lundberg and Hansson, 2010). Induction of 
endothelial which is the primary barrier between blood and tissues leads to expression of 
several proinflammatory genes such as adhesion molecules, chemokines and cytokines 
that manipulate recrutiment of leukocyte into the vessel wall (Mestas et ah, 2008). 
Examples of network cellular components and receptors involved in activation of innate 
immune system are described later in the following paragraphes:
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F igu re 1 .2 . S c h e m a t ic  ch art d e sc r ib in g  th e  fa c to r s  an d  ce llu la r  e le m e n ts  in v o lv e d  in 
a th e r o s c le r o s is  d e v e lo p m e n t , (m odified from (Libby, 2009, Methe and W eis, 2007)).
Monocytes and Macrophages
Monocytes and macrophages are the most important leukocytes involved in all 
stages of atherosclerosis and play a key role in modulating other cellular effects 
(WooHard and Geissmann, 2010). Lipid accumulation and oxidation in the intima 
through interaction with ECM components like proteoglycans, trigger an inflammatory 
response (Glass and Witztum, 2001, Packard et al., 2009, Munro and Cotran, 1988, 
McEver, 1994). These inflammatory signals stimulate vascular endothelial cells to up- 
regulate the expression of adhesion molecules. Adhesion molecules are classified into 
three major groups according to their structure and function; these groups are the 
selectins, the immunoglobulin super-family and the integrins (Kume et al., 1992). 
Selectins are responsible for slowing down the circulation of leukocytes and are further
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divided into three groups. The first group is involved in leukocyte adhesion; P-selectin 
and E-selectin, which are expressed on ECs, and L-selectin, which is expressed on 
leukocytes. The second group of adhesion molecules belong to the immunoglobulin 
super-family and include molecules such as ICAM-1, VCAM-1 and platelet endothelial 
adhesion molecule (PECAM-1). These molecules are responsible for forming the 
adhesion with leukocytes (Khan et ak, 1995, Nageh et al., 1997). ICAM-1 expression is 
stimulated not only by exposure to pro-inflammatory cytokines such as IL-1, TNF-a and 
IFN-y but also by haemo-dynamic disturbance in the blood flow; whereas VCAM-1 
expression is mostly triggered by cytokines such as IL-1, TNF-a and lL-4. The third 
group of adhesion molecules are the integrins, which are hetero-dimeric cell surface 
receptors. This group of receptors are specialised receptors for leukocytes, which 
support adhesion and rolling of monocytes upon activation. The most common integrins 
involved in atherogenesis are: very late activating antigen-4 (VLA-4) and the p2 group 
(Luo and Springer, 2006, Springer and Lasky, 1991, Huo and Ley, 2001, Luo et ak, 
2007). Several studies have suggested that VLA-4 has the major role in the adhesion of 
monocytes to the inflamed endothelium (Imhof and Aurrand-Lions, 2004).
It is known that oxLDL induces the secretion of chemo-attractant factors such as 
MCP-1 that modulates the infiltration of monocytes into the intima by binding to 
chemokine C-C motif receptor 2 (CCR2) receptors expressed on monocytes. These 
monocytes subsequently differentiate into macrophages under the effect of M-CSF. This 
is a crucial step in the activation of innate immunity by up-regulating phagocytic receptor 
expression on macrophages and amplifying the inflammatory response. Macrophages 
amplify inflammation in the atherosclerotic lesion by secreting different pro- 
inflammatory cytokines and growth factors such as kL-l(3, TNF-a, IL-18, IL-6, MCP-1 
and M-CSF, and by acting as antigen presenting cells (APCs) in the atherosclerotic lesion 
(Rottenberg et ak, 1999, Takahashi et ak, 2002). These cells also play a crucial role in 
atherosclerotic plaque rupture and thrombosis by inhibiting SMC proliferation and 
consequently reducing the synthesis of collagen. Macrophages also increase the 
secretion of proteolytic enzymes such as MMP-1, -9, and -13, which mediate fibrous cap 
remodelling via collagenolysis and dysregulation of the ECM (Ross, 1999, A).
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Dendritic Cells
Dendritic cells (DCs) are innate immune cells that infiltrate and reside within the 
atherosclerotic plaques, particularly in the rupture prone shoulder region of the lesions 
(Bobryshev, 2000, Bobryshev, 2005). The number of DCs increase due to stimulation by 
oxLDL, which increases the synthesis of granulocyte macrophage-colony stimulating 
factor (GM-CSF) causing the differentiation of infiltrated monocytes into DCs 
(Shaposhnik et ak, 2007). An increasing number of DCs in human lesions is linearly 
correlated with plaque complexity, and this effect is associated with the expression of 
major histocompatibility class II (MHC class-II) and other co-stimulatory molecules 
(Erbel et ak, 2007). Unlike macrophages, DCs maintain antigen processing and 
presenting abilities to induce CD4^ T cell proliferation inside atherosclerotic lesions and 
to activate naïve T cells in secondary lymphoid organs (Packard et ak, 2008, Packard et 
ak, 2009).
Smooth Muscle Cells
Although smooth muscle cells (SMCs) are not a part of the immune system, they 
play a key role in its activation and modulation during atherosclerotic plaque 
development and are thus discussed herein. These cells represent the majority of the 
cellular elements of the arterial media layer and regulate the arterial tone to perform its 
function. Histological studies have found that there are two phenotypes of SMCs: 
synthetic SMCs, which represent mainly intimai SMCs, and contractile SMCs, which 
represent medial SMCs. Synthetic SMCs have the ability to produce a large amount of 
ECM molecules such as collagen, proteases and cytokines, and also express scavenger 
receptors, whereas contractile SMCs express proteins involved in contractile function, 
such as smooth muscle myosin and a-actin (Ang et ak, 1990, Owens et ak, 2004, 
Campbell and Campbell, 1994, Guo et ak, 1994, Worth et ak, 2001). Recent studies 
have reported that synthetic SMCs are more abundant in atherosclerotic lesions than the 
contractile phenotype. Interestingly, SMC phenotype switching has been observed in 
different models under the effect of different factors such as ECM proteins (Hedin et ak, 
1989, Thyberg and Hultgardh-Nilsson, 1994), cytokines (Hautmann et ak, 1997), shear 
stress (Reusch et ak, 1996), reactive oxygen species (Su et ak, 2001) and lipids 
(Pidkovka et ak, 2007). Macrophages are not the only cell type to transform into foam 
cells; SMCs also have the ability to uptake lipids (LDL and oxLDL) via SRs (Rong et ak.
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2003). The expression of these receptors is modulated by oxLDL and pro-inflammatory 
cytokines like IL-lp, TNF-a and M-CSF (Ruan et ak, 2006, Li et ak, 1995).
Like ECs, SMCs contribute to leukocyte recruitment into the lesions by 
expressing a variety of adhesion molecules such as ICAM-1, VCAM-1 and C-X3-C 
motif ligand 1 (CX3CL1). SMCs also suppress cellular apoptosis leading to propagation 
of the inflammatory response to lipids (Doran et ak, 2008, Braun et ak, 1999). 
Moreover, SMCs are capable of secreting a wide range of cytokines such as PDGF, TGF- 
P, macrophage inhibitory factor (MIF), IFN-y, and MCP-1. These cytokines have 
different functions, including activating and recruiting leukocytes, triggering 
proliferation of SMCs, stimulating endothelial dysfunction and inducing production of 
ECM (Raines and Ferri, 2005). SMCs are the main source of ECM production within 
lesions (Geng and Libby, 2002). This ECM is mainly made of proteoglycans; the 
components that ensnare lipoproteins from the blood stream, which is the first stage of 
atherosclerosis development (Chait and Wight, 2000, Horkko et ak, 2000). In addition, 
SMCs act as APCs to CD4^ T cells by expressing MHC class-II molecules under 
inflammatory conditions (Jonasson et ak, 1985).
SMCs can act as pro-atherogenic and anti-atherogenic elements depending on the 
stage of disease development. In the early stages, SMCs induce atherosclerosis 
progression by triggering the inflammatory mechanism via up-regulation of adhesion 
molecules. SMCs also mediate the retention of lipoproteins in the intima through 
proteoglycan secretion, enhancement of neo-intima formation, the triggering necrotic 
core formation by induction of foam cell transformation and apoptosis, and finally by 
priming the adaptive immune response (CD4^ T cells). On the contrary, once plaques 
have developed, SMCs are considered as anti-atherogenic mediators as they stabilise the 
plaque by maintaining the integrity of the fibrous cap (Schwartz et ak, 2000, Clarke et 
ak, 2008). However, it has been found that VSMC apoptosis; which is mediated via a 
Fas/FasL-dependent mechanism, promotes plaque rupture and thrombosis and 
accelerates plaque calcification and stenosis (Clarke et ak, 2008).
1.1.13.2. The role of adaptive immunity in atherosclerosis
The adaptive immunity component of disease progression is composed of highly 
specialised systemic cells that are divided between humoral and cellular immune 
responses. APCs initiate this response by processing and presenting antigens in the
context of MHC complex molecules, where they interact with T cell receptors (TCRs).
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CD4^ T helper cells recognise exogenous antigens presented on MHC class-II molecules, 
whereas CD8  ^cytotoxic T cells recognise antigenic peptides derived from infected cells 
presented on MHC class-I molecules. Both CD4^ and CD8  ^ T cells activate other 
receptors on the cell surface triggering secretion of a wide range of cytokines and 
chemokines; leading to activation and clonal expansion of naïve and memory T cells 
(Frostegard et ak, 1999, Baidya and Zeng, 2005). The adaptive immune system actively 
participates in the pathogenesis of atherosclerosis through cell-to-cell interactions 
between APCs and T cells, mediated by co-stimulatory molecules. These molecules, 
such as B7-1/CD80, B7-2/CD86 expressed by APCs, interact with CD28/cytotoxic T 
lymphocytes antigen-4 (CTLA-4) on T cells, resulting in the secretion of cytokines from 
activated T cells (cellular immune response) or the production of antibodies by B cells 
(humoral immune response) in a T cell-dependent or independent manner (Hansson and 
Berne, 2004).
The role of CD4^ T cells in atherosclerosis development
T cells can be detected in the adventitia of healthy arteries but the number and 
location of these T cells alters in atherosclerosis (Galkina and Ley, 2007). Under 
inflammatory conditions, T cells accumulate in the shoulder and in the fibrous cap, 
making up 20% of the total cell population, yet in the lipid core they represent no more 
than 10% of the cell population (Hansson et ak, 1988, Hansson, 1999, Galkina and Ley, 
2007). The ratio of T cells to macrophages in the lesions is 1:4 or 1:10 (Hansson and 
Hermansson, 2011). CD4^ T cells represent the majority of the T cell population in 
atherosclerotic plaques, especially the ones expressing the TCR a(3"^  CD4^ phenotype; 
whereas CD8  ^T cells and TCR yô"^  T cells represent a smaller percentage of the total 
number of T cells. The role of these populations of T cells in atherosclerosis 
development is unclear (Packard et ak, 2009).
T cell infiltration into the intima is mediated by several chemokines such as 
inducible protein-10, monokines induced by IFN-y, and IFN-inducible T cell a-chemo- 
attractant, secreted by macrophages and inflamed ECs. These chemokines interact with 
chemokine (C-X-C motif) receptor 3 (CXCR3) expressed on the surface of T cells in the 
plaques (Mach et ak, 1999a). Several studies have found that DCs and macrophages 
expressing MHC class-II molecules are detected close to T cells, pertaining to local 
activation and clonal expansion during atherogenesis (Robertson and Hansson, 2006, 
Paulsson et ak, 2000). Naïve CD4^ T cells can then differentiate into T helper (Th)l,
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Th2, follicular helper T cells (Tfh), T hl7 or regulatory T cells (Treg) depending on the 
cytokines present in the local environment (Figure 1.3).
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F igu re 1 .3 . CD4^ T c e l l s  d ifferen tia tio n  u p o n  a n tig e n  p r e se n ta tio n . CD4^ T cells differentia te into 
different populations (Th1, Th2, Th17, Treg and T h f cells) upon antigen presentation to naïve CD4^ T 
cells by an ARC. This process depends mainly on the cytokine milieu produced after activation. T h l 
is activated in response to in tracellu lar pathogens and acts via a cell-m ediated response leading to 
more inflammation. On the contrary, Th2 is activated in response to parasitic infections and acts via 
an antibody-m ediated response; leading to a lesser inflam m atory response. Naïve T cells can be 
differentiated also into Treg that suppress the immune response and inhibit T  cell activation and 
proliferation o f activated T cells. Figure cited from (Zhou et al., 2009).
Thl
In the early stages of atherosclerosis development, IFN-y, IL-12, lL-18, TNF and 
IL-6 cytokines combined with IgG2a antibody against oxLDL are detected, suggesting a 
pro-atherogenic effect of the Thl immune response (Zhou and Hansson, 1999). Human 
and experimental animal studies later confirmed the predominant role of the Thl cellular 
immune response theory, when 60% of atherosclerotic lesions reduced in size upon
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deletion of IL-12 and IL-18 genes or by administration of a Thl inhibitory drug and the 
reverse effect was observed upon administration of recombinant IFN-y (Robertson and 
Hansson, 2006, Hansson and Libby, 2006, Hansson, 2009). The precise location of Thl 
polarisation and whether it is induced within the plaques or outside of the plaques and 
then recruited into the lesion is unclear. However, the percentage of splenic Thl 
lymphocytes is directly proportional to the size of the plaques, suggesting that the more 
Thl accumulates in the lesions, the bigger lesions will be (Laurat et ah, 2001). Thl 
lymphocytes amplify the inflammatory response within plaques by inducing 
macrophages and ECs to secrete more pro-inflammatory cytokines, chemokines, free 
radicals, proteases, coagulation factors, and to express more adhesion molecules. 
Furthermore, these cells contribute to plaque rupture and thrombosis by inhibiting 
proliferation of SMCs, reducing synthetic collagen and decreasing cholesterol efflux via 
the IFN-y effect (Hansson, 2009, Libby et ak, 2009).
Th2
Th2 cells secrete a wide range of cytokines such as IL-4, IL-5, IL-6, IL-13, IL-10 
and TGF-p. IL-10 is a particularly potent anti-inflammatory cytokine that is capable of 
suppressing the inflammatory response in atherosclerotic lesions by inhibiting the 
proliferation of Thl and reducing MMP production (Binder et ak, 2002, Caligiuri et ak,
2003, Hansson et ak, 2006). This cytokine also enhances TGF-p secretion from cells 
such as macrophages, SMCs and platelets thereby contributing to athero-protection 
through enhancing SMC proliferation and collagen synthesis (Hansson and Robertson,
2004, Boyle et ak, 2003). In addition, TGF- p and IL-10 induce the proliferation and 
differentiation of Treg cells (Hansson et ak, 2006). However, the effect of Th2 cells on 
atherosclerosis development is still controversial as they have been found to have 
variable effects depending on the stage and the site of lesion development (Tedgui and 
Mallat, 2006, Hansson and Libby, 2006).
Treg
Tregs are a subset of T cells that have the ability to suppress innate and adaptive 
immune responses (Taams et ak, 2005, Taams and Akbar, 2005). These cells have a 
crucial role in atherosclerosis protection, as it has been found that depletion of Tregs 
causes induction of autoimmune diseases (Taleb et ak, 2008, Taleb et ak, 2010). Tregs 
are sub-divided mainly into natural Treg (nTreg) and induced Treg (iTreg) categories,
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depending on the origin of development; see Table 1.2. nTregs develop in the thymus as 
a functionally mature population and represent approximately 5-10% of the total 
peripheral CD4^ T cells. These cells are capable of recognising specific self antigens and 
express different surface molecules similar to those expressed on memory T cells such as 
CD25, CD45RB’°'^ , CD62L, CD 103 and CTLA-4, which up-regulate anti-inflammatory 
cytokine secretion. nTreg cells are characterised by the expression of the transcription 
factor forkhead box P3 (FoxP3) that codes for the fork head transcription factor family, 
necessary to mediate the suppressive effects of Treg on pathogen activated lymphocytes 
(de Boer et ak, 2007, Taams et ak, 2006, Taams and Akbar, 2005).
Alternatively, iTreg are generated in the periphery (Table 1.2) during an active 
immune response as result of cytokine activation by TGF-p and/or IL-10, repetitive 
stimulation by non-professional APCs, signals provided by complement receptors e.g. 
CD46 or triggering by low levels of co-stimulatory receptors (insufficient co-stimulatory 
signals) on APCs (Fehervari and Sakaguchi, 2004). Both TGF-p and IL-10 induce 
conversion of CD4^CD25' T cells into CD4^CD25^ T cells in the periphery (Mallat et ak, 
2007). iTreg cells have been divided into type 1 Treg (Trl), Th3, CD4^CD25% 
CD4^LAP^ and CD4^CD31^ categories depending on the nature of the inducer. For 
example, Treg cells induced by IL-10 are called Trl cells, whereas the Treg cells induced 
by TGF-p are called Th3 (Taleb et ak, 2008). In vitro studies have confirmed that Trl 
cells can be induced by repeated antigenic stimulation of naïve T cells and they are 
capable of inhibiting activated CD4^ T cells by secretion of IL-10 (Roncarolo et ak,
2001). The effect of this population of Treg on atherosclerosis development has been 
previously investigated and showed that Trl significantly reduces plaque size and 
improves its stability (Mallat et ak, 2003).
Both nTreg and iTreg cells have suppressive and anergic effects, either acting 
directly on T cells or indirectly via their effects on APCs. Generally, the suppressive 
effect of Tregs on activated T cells could be mediated by three different mechanisms; the 
first being by cell-cell contact via engagement of CTLA-4 on Treg with CD80/CD86 on 
APCs. This mechanism leads to suppression of APC function (Shevach, 2009, Paust et 
ak, 2004). The second mechanism acts via consumption and deprivation of growth 
factors such as IL-2, which are secreted mainly by effector T cells and are absorbed or 
consumed by CD25 receptors expressed on Treg. This leads to the activation of Treg 
genes such as FoxP3, which in turn suppresses IL-2 secretion in a feedback loop, causing 
apoptosis of effector T cells (Pandiyan et ak, 2007). The third mechanism is via the
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production of inhibitory cytokines, such as IL-10, TGF-P and IL-35 (Collison et al.,
2007). These inhibitory cytokines deactivate DCs, making them unable to stimulate 
effector T cells in a mechanism called ‘bystander immune suppression’. On the other 
hand, Tregs can inhibit effector T cells through a passive mechanism mediated by the 
interaction of Tregs with APC. This interaction stimulates the indolamine dioxygenase 
enzyme; an immuno-modulator that inhibits the response of effector T cells through 
tryptophan catabolism (Fallarino et al., 2003).
T ab le  1 .2 . M ain d if fe r e n c e s  b e tw e e n  n T reg an d  iTreg
F eatures N atural Treg (nTreg) Induced  Treg (ITreg)
Generation: site of 
developm ent
Thymus
Periphery such as gut associated 
lymphoid tissue 'GALT', spleen, lymph 
node and inflamed tissue.
Co-stimulatory m olecule  
required
CD28-CD80/CD86 CTLA-4-CD80/CD86
Cytokine requirem ent IL-10, IL-15 and TGF-p IL-10 and TGF-p
CD25 expression High Variable
Specificity
Self antigen or microbial antigen mimic 
self antigen
Cell-cell contac t
Tissue specific antigen (inflammation), 
foreign antigens, allergens, commensal 
microbial, neo-antigen ' tum our '  and 
allo-antigen
Mechanism of  
suppressive effect
(T cell-T ce ll /T  cell-APC contact), 
cytokine independen t
Cell-cell contac t (T cell-T ce ll /T  cell-APC 
contact), cytokine d e p en d en t
Subset and phenotype CDACD25^''®^ FoxP3^
- Trl: CD4YD25‘FoxP3'
- ThB: CD4^CD25^ '^^^FoxP3^
- CD31: C D 4Y D 31T oxP3^
- CD4^LAPk CD4YD25'LAP^
In the context of atherosclerosis, the athero-proteetive role of Th3 cells is 
mediated by inhibition of Thl and Th2 cell differentiation, collagen synthesis stimulation 
and down-regulation of adhesion molecule expression on ECs (Park et al., 2000, 
DiChiara et al., 2000, Border and Noble, 1994, Wang et al., 2011). Clinieal studies have 
found that there is an inverse relationship between the percentage of Tregs (nTreg, iTreg) 
and plaque progression (Mor et al., 2006, Yan and Hansson, 2007). Reeently, it has been 
reported that the size of atherosclerotic plaques in mice reduced upon administration of 
anti-CD3 antibodies. These antibodies reduced plaque size by inhibiting expression of
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the CD3/TCR complex, leading to stimulation of Treg proliferation and an increase in 
TGF-p secretion levels (Steffens et ah, 2006).
The role of B lymphocytes in atherosclerosis
B cells represent 15-20% of the lymphocyte pool. They infiltrate and reside within 
the adventitial layer of coronary arteries, surrounding advanced lesions and forming a 
tertiary lymphoid structure (Grabner et al., 2009). B cells have been functionally 
subdivided into three subclasses: Bel lymphocytes secrete IFN-y, IL-12 and 
lymphotoxin; Be2 lymphocytes secrete IL-2, IL-4 and IL-6, and regulatory B 
lymphocytes secrete IL-10 and protect against autoimmune disease (Sacks et al., 2006, 
Lund et al., 2005).
In human and experimental animal studies, it has been found that the titre of 
peripheral antibodies against oxLDL is linearly proportional to the lesion size. 
Therefore, it appears that B cells could also be pro-atherogenic mediators involved in 
atherogenesis via production of antibodies, antigen presentation and cytokine secretion 
(Ait-Oufella et ak, 2010, Salonen et ak, 1992, Yla-Herttuala et ak, 1994, Palinski et ak, 
1994). A previous study found that B cells up-regulate the expression of the GDI 
molecule under inflammatory conditions, leading to enhanced antigen presentation to NK 
cells, which enhance the inflammatory mechanism (Mizoguchi et ak, 2002). However, B 
cells also have an indirect athero-proteetive effect mediated by the production of 
protective antibodies that block antigen infiltration into the lesions and inhibit cytokine 
secretion (Packard et ak, 2009).
1.1.1.3.3. The role of other molecules and receptors in atherogenesis
In addition to the complex network of cellular components of the innate and 
adaptive immune responses involved in atherosclerosis development, different markers 
and receptors expressed on cell surfaces contribute to the inflammatory mechanism of 
this disease. T cell activation depends on two essential signals delivered by APCs. The 
first signal is generated by antigen recognition and is presented on MHC molecules, and 
the second signal is generated by co-stimulatory molecules and is expressed on the APC 
and interacts with specific receptors on T cells. These co-stimulatory molecules are
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triggered by different microbial antigens such as LPS, HSP60 or oxLDL, which induce 
specific signals by binding to innate PRRs such as TLR.
TLR
These receptors are expressed on the majority of vascular tissue cells such as 
SMCs and ECs as well as on other immune cells (Frantz et ah, 2007, Cole et ah, 2010b, 
Cole et ah, 2010a). TLR receptors have been detected in all stages of atherosclerosis 
development, in particular, TLR2 and TLR4 responsible for activating the inflammatory 
cascade signals mediated by nuclear transcription factor kappa-beta (NF-kP) (Lin et ah, 
2009). This concept has been confirmed by clinical studies that detected high levels of 
TLR2 and TLR4 expressed on residential cells of atherosclerotic lesions (Curtiss and 
Tobias, 2009, Xu et ah, 2001, Edfeldt et ah, 2002). These molecules interact with 
oxLDL and other components generated during LDL oxidation, leading to activation the 
pathological inflammatory mechanism (Miller et ah, 2003, Miller et ah, 2011). The 
expression level of TLR2 is highly up-regulated on ECs located in areas of disturbed 
blood flow, whereas in areas of laminar flow the expression levels of this molecule are 
significantly lower (Dunzendorfer et ah, 2004).
Animal studies have revealed that mutation of the TLR2 gene leads to a reduction 
in lipid accumulation and chemokine MCP-1 secretion levels in apolipoprotein (apoE) 
deficient mice (apoE'^' mice). This suggests a role of TLR2 in atherosclerosis 
development via modulating cholesterol efflux from ECs (Liu et ah, 2008, Seimon et ah, 
2010, West et ah, 2010). Additionally, clinical studies have shown that TLR4 is 
expressed on atherosclerotic macrophages and SMCs at the site of plaque rupture in 
patients with acute myocardial infarction (Xu et ah, 2001, Ishikawa et ah, 2008, Otsui et 
ah, 2007). Furthermore, previous studies have reported that TLR4 expression levels are 
up-regulated by IFN-y, leading to accelerated atherosclerotic lesion development via 
increased pro-inflammatory cytokine (TNF-a, IL-12) loop production and enhanced 
proliferation of SMCs (Loppnow et ah, 2008, Niessner et ah, 2007). To date, it is 
unclear whether TLR2 and TLR4 contribute to atherogenesis independently or in 
combination (Lin et ah, 2009). Conclusively however, TLRs are responsible for 
leukocytes infiltration, foam cell formation, antigen presentation and endothelial 
dysfunction (Mullick et ah, 2008, Hodgkinson and Ye, 2011).
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CD14
The contribution of CD 14 to atherosclerosis has also been investigated (Shimada et ah, 
2005). This receptor cooperates with TLR4 to transmit and activate intracellular 
inflammatory signals, mainly via the NF-Kp pathway (LeVan et al., 2001, Arbour et al., 
2000). CD 14 interacts mainly with LPS of Gram negative bacteria and is capable of 
recognising different lipid compositions in Gram positive bacteria (Arroyo-Espliguero et 
al., 2004). Several studies have found that CD 14 is implicated in atherosclerosis 
progression in different ways (Shimada et al., 2005, Hubacek et al., 1999). Interaction of 
CD 14 with antigens such as HSP60 of Ch. pneumoniae leads to activation not only of 
immune cells (e.g. macrophages) but also of vascular tissue cells (e.g. ECs) (Bulut et ak, 
2002). CD 14 activation stimulates leukocytes infiltration by inducing ECs to secrete 
pro-inflammatory cytokines such as IL-1 and TNF-a (Beekhuizen et ak, 1991). CD14 
has been used clinically as an activator and as an inflammatory marker that cooperates 
with C-reactive protein (CRP) to activate ECs (Zalai et ak, 2001). Clinical studies 
suggested that CD 14 expression levels increased in the serum of patients with acute 
coronary syndrome and were correlated with the levels of pro-inflammatory cytokines 
(Shimada et ak, 2000), suggesting its role as pro-atherogenic. However, apoE'^' /CD 14'^ " 
double knockout mice displayed no alterations to atherosclerosis development, unlike 
TLR4 and TLR2 deficient mice (Bjorkbacka et ak, 2004).
B7 family ligand and its receptors
Activation of PRRs up-regulates expression of other co-stimulatory molecules on 
APCs, which in turn stimulates the T cell response. The most significant co-stimulatory 
molecules are derived from B7 family and are well documented in the context of 
atherosclerosis development (Sharpe and Freeman, 2002). These ligand-receptor 
pathways have the ability to both positively and negatively regulate immune responses. 
B7.1 and B7.2 (CD80 and CD86 respectively) molecules are expressed on APCs, and 
bind to the CD28 receptor expressed on all mature T cells (95% of CD4^ human T cells 
and 45% of human CD8^ T cells). Approximately 10% of the total number of T cells 
located in the shoulder area of plaque lesions are found to express CD28 and therefore 
could potentially interact with co-stimulatory molecules (Krams et ak, 2003). This 
interaction stimulates IL-2 and anti-apoptotic gene expression as well as cellular 
proliferation. In contrast, B7 family receptors are capable of inhibiting T cell activation 
by binding with the inhibitory molecule, CTLA-4 (CD 152), which is a Treg marker and
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is expressed on activated T cells. This interaction inhibits the immune response and can 
reduce atherosclerosis progression via inhibition of T cell proliferation, cytokine 
production, and cell cycle progression (Paust et ak, 2004).
CD40/CD40L
CD40/CD40L interactions are well documented in literature describing their role 
in atherosclerosis development (Antoniades et ak, 2009). The interaction of these two 
molecules enhances the pathological mechanism of atherosclerosis at all stages. The 
CD40 molecule exists as trimer complex on a wide range of cells such as B cells, 
epithelial cells, fibroblasts, ECs, SMCs and platelets; the majority of these cells also 
express CD40L (Chan et ak, 2000, Schonbeck and Libby, 2001). This interaction 
pathway up-regulates co-stimulatory molecule expression on APCs (Gotsman et ak,
2008). Via this pathway, CD40 acts as an amplifier of B7 family co-stimulation (Grewal 
and Flavell, 1998). In the context of atherosclerosis development, CD40L is expressed 
on activated platelets with thrombin or thrombin receptor activators and released as a 
soluble CD40L (sCD40L) molecule (Weber et ak, 2001, Hermann et ak, 2001). sCD40L 
interacts with CD40 molecules expressed on ECs and monocytes, leading to the up- 
regulation of adhesion molecules on ECs and the migration and infiltration of monocytes 
to the intima (Zirlik et ak, 2007). Moreover, CD40/CD40L interactions induce 
infiltration of other cells into plaque lesions via maturation of DCs that interact and 
enhance migration of activated T cells (Pryshchep et ak, 2008). Animal studies 
confirmed that CD40/CD40L activation of ECs and VSMCs induces the production of 
pro-coagulant tissue factors and up-regulates adhesion molecule expression (Bavendiek 
et ak, 2002, Schonbeck et ak, 2000, Mach et ak, 1997).
Additionally, CD40/CD40L interactions mediate lipoprotein modification and 
foam cell formation by destabilising the endothelial nitric oxide synthase messenger and 
increasing vascular oxygen production, leading to oxidation of LDL (Poggi et ak, 2009, 
Engel et ak, 2009). Animal studies and in vitro experiments have shown that the 
interaction of CD40 with its ligands induces plaque instability via several mechanisms. 
One of these mechanisms involves enhancing MMP expression, increasing the rate of 
interstitial collagen degradation and leading to a thin fibrous cap (Schonbeck et ak, 2001, 
Packard et ak, 2009). It has been found that CD40L signalling disruption, either by 
genetic mutation or by the use of specific antibodies, significantly decreases lesion size
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and the percentage of macrophages and T cells present. Signalling disruption was also 
shown to down-regulate VCAM-1 expression and enhance the stability of the fibrous cap 
by increasing collagen production and decreasing proteolytic enzyme production 
(Lutgens et al., 2000, Mach et al., 1999b).
Another mechanism involved in plaque rupture mediated by CD40 signalling is 
the inhibition of EC migration at the site of plaque erosion, thus blocking the 
regeneration of endothelium (Schonbeck and Libby, 2001 A). CD40/CD40L signalling 
is known to enhance angiogenesis by up-regulating local vascular endothelial growth 
factor and basic fibroblastic growth factor expression causing intra-plaque 
neovascularisation. The same signalling has also been shown to induce thrombosis by 
promoting tissue factor expression on macrophages and ECs, leading to local pro­
coagulant and pro-thrombotic status (Leroyer et ak, 2008, Chen et ak, 2008).
CD3
CDS forms part of TCR complex. It has been found that CDS disruption using an 
anti-CDS antibody or genetic mutation decreases the expression of the CD3/TCR 
complex and increases the Treg population (Sasaki et ak, 2009). This effect has been 
used in different therapeutic experiments in order to inhibit the immune response, halting 
the progression of atherogenesis in mice exhibiting already developed atherosclerotic 
plaques (Steffens et ak, 2006, Sasaki et ak, 2009).
1.1.13.4. Cytokines Invoived in atherogenesis
A  wide spectrum of cytokines has been shown to play a crucial role in 
atherogenesis (Figure 1.4). Some of these cytokines have pro-atherogenic properties 
while others have anti-atherogenic properties. Cytokines are potent mediators of 
inflammation, having the ability to regulate many immune functions and dysfunctions. 
For instance, cytokines can enhance expression of adhesion molecules, stimulate 
penetration and migration of leukocytes or stimulate the production of new substances 
such as matrix degrading enzymes (Tedgui and Mallat, 2006, Raines and Ferri, 2005). 
The cytokines most relevant to this study are described in the following sections.
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IL-4
IL-4 is secreted mainly by Th2 cells and has a dual effect, acting as a pro- and 
anti- atherogenic mediator (Davenport and Tipping, 2003, Walch et al., 2006). Previous 
studies have revealed that lL-4 exerts its pro-atherogenic effect via up-regulation of P- 
seleetin (Khew-Goodall et al., 1999), 15-lipoxygenase (Lee et al., 2001) and VCAM-1 on 
vascular ECs (Barks et al., 1997). Conversely, the anti-atherogenie effect of lL-4 
manifests by inhibition of VSMC proliferation and inhibition of macrophage adhesion 
(Elliott et al., 1991, Vadiveloo et al., 1994). Interestingly, it has been found that lL-4'^' 
/apoE'' '^ mice exhibit smaller atherosclerotic plaques at 30 days of formation but after 45 
days, there is no difference in the size of the plaque lesions compared with apoE'^' mice. 
This suggests that the effect of lL-4 is variable, and is dependent on the stage and the 
time point of atherogenesis (Davenport and Tipping, 2003, King et al., 2007, King et al.,
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2002). Thus, the exact role of IL-4 in atherosclerosis development is still controversial 
and needs further study.
IL-10
IL-10 is an athero-proteetive and potent anti-inflammatory cytokine, secreted by 
several immune cells such as B cells, T cells, Treg cells and macrophages. The anti­
inflammatory effects of this cytokine are represented by inhibition of IFN-y and GM- 
CSF secretion by Thl cells and down-regulation of pro-inflammatory macrophages 
(Fiorentino et ak, 1991 B, Baidya and Zeng, 2005, Fiorentino et al., 1991a). This 
cytokine enhances plaque stability by triggering collagen synthesis and inhibiting tissue 
factor and protease enzyme secretion (Caligiuri et al., 2003, Potteaux et al., 2004). 
Clinical studies have found that levels of IL-10 are decreased in patients with CVD 
(Coronado et ak, 2009, Woszczek et ak, 2008, Smith et ak, 2001). Moreover, 
experimental animal studies have confirmed the anti-atherogenic role of IL-10 by using 
apoE’^’/lL-lO’^’ deficient mice that show not only an increase in plaque size but also 
susceptibility of these plaques to rupture and thrombosis. This deleterious effect has 
been reversed upon provision of exogenous IL-10 to LDL" ' or apoE'^’ mice (Namiki et 
ak, 2004, Soliman and Kee, 2008).
TGF-B
The cellular source of TGF-P varies, but it is secreted mainly by Treg cells in 
addition to macrophages, platelets, ECs, SMCs and DCs (Hansson, 2009, Robertson and 
Hansson, 2006). TGF-p is known to be an athero-proteetive cytokine, confirmed by the 
development of TGF-p deficient mice (Shull et ak, 1992). This animal model has shown 
enhanced activation and proliferation of T cells, suggesting the inherent inhibitive effect 
of TGF-p on proliferation of Thl and Th2 cells in particular (Marie et ak, 2006, Ait- 
Oufella et ak, 2009). Moreover, TGF-p has a crucial role in inducing Tregs in the 
periphery by up regulating FoxP3 gene expression (Cobbold et ak, 2004). Additionally, 
this cytokine modulates the suppressive effect of Tregs; this finding has been confirmed 
in vivo and in vitro by observing the unresponsive effect of adaptive transferred Tregs 
with mutated TGF-p receptors (Cobbold et ak, 2004).
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IL -2
IL-2 is secreted by all T cells, but Thl cells appear to secrete the highest levels. 
lL-2 is also secreted from cells such as macrophages, B cells and DCs and once released, 
promotes Thl proliferation while suppressing Th2 function. This cytokine shifts T cell 
proliferation to the Thl phenotype via autocrine stimulation in conjunction with lL-18 
(Nakahira et al., 2002, Kurt-Jones et al., 1987). The concentration of lL-2 has been 
found to be high in the serum of patients with heart disease and has been detected in 
atheroma of experimental animals, suggesting a pro-atherogenic role (Frostegard et al., 
1999, Upadhya et al., 2004, Mazzone et al., 1999).
IFN-y
IFN-y is implicated in atherogenesis both directly and indirectly via IL-12 and EL- 
18 respectively. This effect has been confirmed by using 1L-12‘'^‘ or lL-18 '^" knockout 
mice models (Mallat et al., 2001, Munder et al., 1998). IFN-y stimulates macrophage 
activation leading to the secretion of further pro-inflammatory cytokines (increasing the 
inflammatory loop) such as lL-1, TNF-a and IL-12, which in turn releases more oxygen 
radicals and MMP. Several studies have found that IFN-y has an important role in 
atherogenesis and its complications through inhibition of SMC proliferation and 
reduction of collagen synthesis (Tellides et al., 2000). Both of these effects lead to 
plaque rupture, thrombosis and stimulation of macrophage apoptosis (Hansson et al.,
1988). IFN-y has been reported to increase cellular expression of adhesion molecules on 
the surface of vascular ECs and increase the expression of MHC class-11 molecules on 
macrophages and VSMCs; suggesting induction of the T cell immune response (Li et al., 
1993, Jonasson et al., 1985, Boehm et al., 1997).
IFN-y also has important effects related to cholesterol metabolism and foam cell 
formation. This cytokine stimulates accumulation of lipids in atherosclerotic lesions in 
several different ways. For example, down-regulation of macrophage lipoprotein lipase 
(LPL), the cholesterol 27-hydroxylase enzyme and of enzyme agonists reduces 
cholesterol metabolism, whereas induction of ATP-binding cassette protein 1 (ABCl) 
stimulates cholesterol efflux (Jonasson et ak, 1990, Reiss et ak, 2001, Panousis and 
Zuckerman, 2000). A further role of IFN-y in the stimulation of foam cells was detected 
through the up-regulation of scavenger receptor expression (Minami et ak, 2001). 
Although this pro-inflammatory cytokine is secreted mainly by Thl cells, it is also 
secreted by different populations of immune system such as CD8  ^ T cells, NKT cells,
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NK cells and macrophages, indicating its wide-ranging effects (Gerdes et al., 2002, 
Tenger et al., 2005).
1.2. CHLAMYDIAE: AN OVERVIEW
The phylum Chlamydiae is a unique obligatory intracellular parasite that 
propagates in a distinct vacuole in the cytoplasm of eukaryotic cells, causing a variety of 
human and animal diseases (Barnes, 1989). These bacteria lack the ability to produce 
essential compounds such as adenosine tri-phosphate (ATP) and guanosine tri-phosphate 
(GTP), which are essential for their metabolic and respiratory activities. As such, these 
micro-organisms are called ‘energy parasites’, as they depend on the host’s cells to 
provide these compounds (Moulder, 1991). In addition, these bacteria are incapable of 
synthesising de novo nucleotides; depending mainly on the host nucleotide pools (Blasi 
et al., 2009, Saikku et al., 1988). The name Chlamydiae is derived from the Greek word 
“Chlamys” meaning cloak or mantle, since most people who have the disease are 
unaware of it due to its asymptomatic nature. Complications resulting from infection 
with these bacteria have been known for a long time, and have been described in ancient 
Egyptian, Greek and Chinese manuscripts. A ‘modem’ investigation and description of 
these bacteria was actually suggested by Halberstaedter and von Prowazek as long ago as 
1907 (Halberstaedter, 1907a, Halberstaedter, 1907b ).
1.2.1. Taxonomy
Chlamydiae was first classified as a protozoan and later as a virus until it was 
discovered that the cells have a double layer of cell wall and contain DNA, RNA and 
ribosomes and are able of synthesising structural proteins and enzymes (Grayston, 1989). 
Chlamydiae were subsequently classified as bacteria. Reeently, phylogenetic studies 
from several laboratories have found that these bacteria follow the Order, Chlamydiales, 
which is subdivided into four well documented distinct family groups based on 
phylogenetic, PCR and RNA analysis: Chlamydaicea, Simkaniacea, Waddliacea and 
Parachlamydia; each family consists of only one or two representatives (Everett and 
Hatch, 1991, Kuo et al., 2007). Family Chlamydaicea has been further divided into two 
genera: Chlamydia and Chlamydophila. The genus Chlamydia has three main species: 
Chlamydia trachomatis (infects humans). Chlamydia murdarium (with two strains MoPn
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and SFPD that infect mice and hamsters respectively) and Chlamydia suis (infects swine) 
(Morrison and Caldwell, 2002a). The genus Chlamydophila comprises of six species: 
Chlamydophila pneumoniae (infects humans, koalas and equine species), 
Chlamydophila pecorum (infects mammals like cattle, sheep, goats and swine), 
Chlamydophila psittaci (primarily infects birds), Chlamydophila abortus (endemic 
among ruminants such as cattle, sheep and goats and is associated with cases of horse 
abortion), Chlamydophila felis (endemic among domestic cats) and Chlamydophila 
caviae (infects guinea pigs) (Bush and Everett, 2001).
1.2.2. Chlamydophila pneumoniae
This study focuses on the Ch. pneumoniae species, which was firstly described by 
Grayston et al. in 1986 (Grayston et al., 1986). Ch. pneumoniae was first isolated in 
1965 from the eye of a Taiwanese child (noted as TW-183) during a trachoma vaccine 
trial in Taiwan (woolridge, 1966). Another strain was isolated in 1983 from the pharynx 
of a university student in Seattle (denoted as AR-39) (Grayston et al., 1986). Both strains 
were then called TWAR. Ch. pneumoniae is distinct from other chlamydial species as 
the morphological structure of intra-cytoplasmic inclusions look round and dense when 
stained with Giemsa. Electron microscope studies found that the morphological structure 
of TWAR elementary bodies are pear shaped and the cytoplasmic mass is round with 
large periplasmic space. Additionally, in the periplasmic space there are small, round 
electron-dense bodies which were attached to the cytoplasm by a string like structure 
(Chi et al., 1987). The reticulate bodies of this strain are similar to those of other 
Chlamydia strains and follow the same stages of life cycle development (Grayston et al., 
1989b). Furthermore, other distinct differences between Ch. pneumoniae and other 
Chlamydia species include no plasmids (extra chromosomal DNA) and distinct 
restriction endonuclease patterns (Campbell et al., 1987). TWAR organisms share less 
than 10% DNA homology with C. trachomatis and Ch. psittaci, whereas the population 
of TWAR strains showed 94% DNA homology with each other (Grayston et al., 1990, 
Grayston et al., 1989b).
Ch. pneumoniae represents the most common respiratory pathogen in human 
beings, causing many asymptomatic infections and is responsible for approximately 10% 
of pneumonia and up to 5% of bronchitis and sinusitis (Kuo et al., 1995). Everyone is 
susceptible to infection with this pathogen and will likely be infected at some point in life
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with subsequent re-infection being common (Campbell et ah, 1998). Serological studies 
reported that the percentage of children below 5 years old infected with this pathogen is 
low; this percentage reaches 50% in 20 year olds and rises to 80% in men and 70% in 
women in old age (Grayston et ah, 1989b). Ch. pneumoniae infection is also associated 
with other chronic diseases such as atherosclerosis (Campbell et ah, 1998), asthma 
(Hansbro et ah, 2004), multiple sclerosis (Sriram et ah, 1999), lung cancer (Chaturvedi et 
ah, 2010) and Alzheimer’s disease (Balin et ah, 1998). However, the mechanism by 
which Ch. pneumoniae infection contributes to these diseases is still questionable.
1.2.2.1. Structure
Like any Gram negative bacteria, all phases of the developmental cycle have a 
double cell membrane. However, the Ch. pneumoniae cell envelope lacks a 
peptidoglycan structure that is normally located in the space between the inner and the 
outer membranes (Moulder, 1991, Barbour et ah, 1982, Fox et ah, 1990). Previous 
studies have suggested that the peptidoglycan structure is substituted by the Chlamydiae 
outer membrane complex. This outer membrane complex is composed of three cysteine- 
rich proteins (see Figure 1.5). OmcA, encoded by outer membrane protein] (Omp3) 
gene is a small cysteine-rich protein that is not surface exposed and it is only synthesized 
during the last stage of life cycle development (Collett et ah, 1989). OmcB, encoded by 
the Omp2 gene is a 60kDa cysteine-rich protein exposed on the surface outer membrane 
(Ting et ah, 1995, Stephens and Lammel, 2001). The major outer membrane protein 
(MOM?) encoded by ompl, is described later in more detail (Caldwell et ah, 1981). The 
other group of the Chlamydophila outer membrane proteins are polymorphic membrane 
proteins (Pmps) (Longbottom et ah, 1996, Longbottom et ah, 1998, Knudsen et ah, 
1999). In addition, IPS; the main endotoxin in Gram negative bacteria has been detected 
on the surface of both extracellular infectious bodies called elementary bodies (EBs) and 
on reticulate bodies (RBs) during the intracellular replication stage (Birkelund et ah,
1989) and HSP60 is expressed throughout the whole life cycle of the bacteria (Kikuta et 
ah, 1991).
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F igu re 1 .5 . A s c h e m a t ic  d iagram  s h o w in g  th e  s tr u c tu r e  o f  th e  o u te r  m em b ra n e  o f  Ch. 
pneumoniae by e le c tr o n  m ic r o s c o p y . MOMP, LPS and a group o f polym orphic proteins (Pmp) 
are located on the surface o f the cell mem brane, w hereas the OmcB protein (Omp2) is set in the 
perip lasm ic space. Om cA {Omp3) is attached to the outer m em brane via lipid anchors and to the 
Omp2 via disulphide bonds (Christiansen and Birkelund, 2002)
1.2.2.2. Life cycle
In 1932, the first description of Chlamydiae’s life cycle was produced by Bedson 
and Blad using the light microscope (Bedson, 1932), followed by several electron 
microscope studies (Ward, 1983, Ward, 1995). The life cycle of Ch. pneumoniae has 
been shown to have a unique biphasic life cycle with two different morphological forms 
(Figure 1.6). The first phase involves the formation of infectious EBs that has unique 
pear shapes distinctive from other Chlamydia species. EB size is approximately 0.3pm, 
with a long axis (0.44 pm) and short axis (0.31 pm) with a rounded cytoplasmic mass 
(Chi et al., 1987). The second phase is RB, which is a rounded structure quite similar in 
the shape to those of other Chlamydia species (0.5-1 pm) (Moazed et al., 1999). 
Flowever, it has been reported more recently that RBs of Ch. pneumoniae are smaller in 
size and have a distinct structure and shape compared with other Chlamydia species 
(Wolf et al., 2000).
The life cycle of this pathogen begins by attachment of the pointed end of the
infectious EB to the host cell membrane (Kuo et al., 1988). EB attachment to eukaryotic
cells may be mediated by several Chlamydia components such as heparin sulphate-like
proteoglycan (Kuo et al., 1973, Zhang and Stephens, 1992), MOMP (Moulder, 1991, Su
et al., 1996), Omp2 (Hatch et al., 1984, Stephens et al., 2001), HSP70 (which act as a
chaperone, mediating the appropriate conformation of specific Chlamydia ligands)
(Peterson et al., 1996) and polymorphic outer membrane protein (POMP) (Longbottom et
al., 1998). These infectious bodies enter the host cells through an invagination process
mediated by either parasite-specified phagocytosis or receptor-mediated endocytosis
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(Kuo et al., 1988). To date, the precise mechanisms of attachment and entry are unclear 
and need further studies.
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F igu re 1.6. S c h e m a t ic  re p r e se n ta tio n  o f  th e  Ch. pneumoniae d e v e lo p m e n ta l c y c le .  Once 
Ch. pneumoniae internalises into the host cell, it inhibits the fusion o f the endosom e with 
lysosomes to evade the im m une response. The infectious phase starts by d ifferentiation and 
multiplication of EBs into m etabolically active RBs inside the inclusion vacuoles. A fte r several 
m ultiplications and under normal conditions, RBs re-differentiate back into EBs, w hich are 
released from the infected cells by lysis to infect o ther cells. Under stressfu l conditions such as 
shortage o f nutrition, antib iotic treatm ent or secretion o f IFN-y, a persistent phase w ith enlarged 
aberrant Chlam ydophila (cryptic bodies) develops. Once conditions improve, the aberrant form  
differentiates into EBs and a new life cycle begins (figure modified from (Beatty et al., 1994b)).
Once the EB gain access into the host cell, they undergo several changes, 
including de-eondensation of DNA and loss of disulphide cross-linkages within proteins 
on the outer membrane and this phase stays in intracellular isolated environment called 
inclusion vacuoles (Belland et al., 2004a, Moulder, 1991). At 8 hrs post-infection, EBs 
differentiate into metabolically active RBs using the host cell’s energy and nutrient 
materials (Belland et ah, 2004b, Daemen et ah, 1999). After 19 hrs and up to 36 hrs 
post-infection, RBs start to multiply inside the inclusion vacuoles (Haekstadt et ah, 
1997). At 48 hrs post-infeetion, RBs replicate by binary fission, leading to an increase in
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size of the inclusion vacuoles. In addition, Ch. pneumoniae has the ability to make 
multiple inclusion vacuoles of different sizes, showing different stages of development 
within the same infected cell. These inclusion vacuoles can be detected by electron 
microscopy and are shown to be located near to the host cell’s nuclei and the Golgi 
apparatus. Ch. pneumoniae has the ability to divert host vesicular traffic from the Golgi, 
in order to obtain lipids and other nutrients necessary for their metabolic processes, as 
well as modifying the inclusion membrane to escape lysosomal fusion and immune 
detection (Haekstadt et al., 1995).
After 48 hrs post-infection, the population inside the inclusion vacuoles is 
composed of 49% RBs, 28% EBs and 23% in an intermediate phase. After several 
multiplications, RBs differentiate once again into EBs that are then released from the 
host cells via exocytosis or host cell lysis, in order to invade other host cells and start 
another cycle. This last stage is known as a productive infection (Bavoil et al., 2000). At 
84 hrs post-infection, the intracellular development of Ch. pneumoniae is completed. 
Thus, the life cycle lasts between 32-84 hrs, depending on the growth conditions. In 
addition, Chlamydophila can persist in the host cells, causing asymptomatic infection if 
the cell cycle is disrupted for any reason. Such disturbances may be caused by host cell 
nutrient shortage, immune response activation (secretion of cytokines TNF-a, IFN-y) or 
by antibiotic treatment (Beatty et al., 1994c, Beatty et al., 1994a). These disturbance 
factors lead to morphological alteration of RBs, causing an incomplete growth cycle 
characterised by an enlarged form of RBs called cryptic bodies (CBs). These bodies may 
persist inside host cells for decades. Once such stressful factors are removed or 
recovered, CBs are able to differentiate again into infectious EBs (Beatty et ah, 1994b). 
The life cycle of Ch. pneumoniae is shown in Figure 1.6.
I.2.2.3.. Pathogenesis
The pathogencity of Ch. pneumoniae is a complex process as it depends on the 
type of cell infected and the genetic state of the replicative and non replicative stages of 
pathogenesis. This pathogen has the ability to infect and survive in a wide spectrum of 
host cells such as monocytes/macrophages, epithelial cells, ECs, SMCs and lymphocytes, 
and therefore has the ability to spread systemically throughout the host’s body 
(Kaukoranta-Tolvanen et ah, 1994, Gaydos et al., 1996, Fryer et al., 1997, Airenne et al., 
1999, Haranaga et al., 2001). These bacteria employ a diverse pathogenic strategy in
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order to secure their growth and development. For example, the bacteria can inhibit 
apoptosis, suppress antigen presentation, avoid interaction with phagocytes and 
lysosomes, as well as trigger autoimmunity via the use of mimicry molecules (Kem et 
ah, 2009). Ch. pneumoniae evades apoptosis by inhibiting apoptotic signalling cascades 
especially during chronic infection and even during the late stages of the infection where 
the cells that contain the inclusion bodies are more resistant to apoptosis (Perfettini et ah, 
2002, Yao et ah, 2007, Airenne et ah, 2002, Rajalingam et ah, 2001, Boelen et ah, 2007). 
In contrast, other studies suggest that Ch. pneumoniae induces the apoptotic process 
during the late stage of infection in order to release EBs from infected cells to allow the 
infection of other cells (Perfettini et ah, 2002, Jendro et ah, 2004). Other studies have 
found that Chlamydophila inhibits host cell apoptosis by several mechanisms such as 
degrading pro-apoptotic event BH3 protein, which is responsible for stimulating 
apoptotic effects (Kem et ah, 2009, Fischer et ah, 2004); inhibiting the production of 
mitochondrial cytochrome C, which is considered an important apoptotic triggering 
protein; by inhibiting caspase-3 and procasapase-3 and by triggering secretion of anti- 
apoptotic lL-8.
Ch. pneumoniae has the ability to prevent phagosomal and lysosomal 
interactions, especially during the first stage of EB entry. This process has been 
suggested to be mediated by specific genes expressed only at the early stage of infection 
(Haekstadt, 1998). Furthermore, this pathogen inhibits antigen presentation via two main 
mechanisms. The first mechanism suppresses IFN-y secretion, which normally induces 
MHC class-1 and 11 expression on APCs (Morrison and Morrison, 2000). The second 
mechanism is the induction of lL-10 secretion upon Chlamydophila infection, either by 
driving the Th2 immune response or by proliferation of pathogenic regulatory T cells 
(McGuirk et al., 2002, McHugh and Shevach, 2002). The other mechanism is via 
inhibition of APCs, which may be mediated by a specific protease such as chlamydial 
protease-like activity factor (CPAF) secreted by Chlamydophila, which degrades the host 
cell transcription factor RFX-5; a crucial molecule for MHC class-1 and 11 molecule 
expression (Zhong et ah, 2001, Dong et ah, 2005). Additionally, selective antigens of 
Chlamydia have been shown to contribute to the pathogenesis. For instance, antibodies 
against chlamydial HSP60 are able to cross react with human HSP60, causing an 
autoimmune response via antigen mimicry (Domeika et ah, 1998).
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I.2.2.4. The immune response to Ch. pneumoniae
Host immune responses to Ch. pneumoniae infection are complicated and remain 
unclear. Understanding the host immune response to Chlamydophila infection could 
give us not only a clear picture of the role of Chlamydophila in different chronic diseases 
but would also help to develop a promising vaccine for this pathogen (de Kruif et al., 
2005). The unique intracellular life cycle of Chlamydophila challenges several elements 
and multiple arms of the immune system making it difficult to resolve or control 
chlamydial infection and spread. A different population of host immune cells is involved 
in the protection against this pathogen. The roles of the innate and acquired immune 
systems in chlamydial infection and control are discussed below.
I.2.2.4.I. Innate immune response
The respiratory tract is the main portal of Ch. pneumoniae infection and is very 
rich in APCs. The first targets for Ch. pneumoniae invasion and replication are the 
epithelial cells that secrete a wide range of pro-inflammatory cytokines and chemo- 
attractants following bacterial infection (Gaydos et ah, 1996, Puolakkainen, 2009). One 
of these cytokines secreted upon infection is IL-8 (Yang et ah, 2003), which acts as a 
potent alarm for macrophages and neutrophils, calling them to the site of infection. Cell 
recruitment at the site of infection has dual function; one is to intentionally control 
bacterial infection and the other is to unintentionally transfer the pathogen to different 
tissues of the body after controlling the biological function of these cells. Neutrophils 
inhibit Chlamydophila infection through oxidative and non oxidative mechanisms (Yong 
et ah, 1986). Macrophages and other innate immune cells recruited at the site of 
infection secrete IFN-y, which has a protective effect in the early stage of Ch. 
pneumoniae infection by diminishing bacterial load (Rottenberg et ah, 2000).
Once Chlamydophila enters macrophages via pattern recognition receptors, such 
as mannose receptors (Kuo et ah, 2002), the pathogen is capable of surviving inside the 
macrophage by inhibiting phagolysosome fusion and the apoptotic cascade, as mentioned 
before. In this way, Chlamydophila causes a chronic infection and disseminates 
systemically. On the other hand, some studies have shown that infected alveolar 
macrophages inhibit or prevent completion of the Chlamydophila life cycle by secreting 
TNF-a (Haranaga et ah, 2003, Airenne et ah, 1999). Infected macrophages become 
ineffective APCs and cross-presentation via DCs takes over, which is considered the best
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immunological response mechanism to control Ch. pneumoniae dissemination (Steele et 
ah, 2004, Albert et ah, 1998).
The other immune candidates involved in the innate immune response are the 
DCs, which are professional APCs, acting as a link between the innate and the adaptive 
immune responses. DCs are capable of capturing and presenting antigens to many cells 
of the immune system. Several sub-populations of DC exist throughout the body, 
especially in the mucosal membranes that are in contact with the external environment. 
Briefly, immature DCs recognise pathogen associated molecular patterns (PAMPs) via 
TLRs or more specifically, via TLR2 (Prebeck et ah, 2001). This recognition leads to 
differentiation of DCs into mature APCs, characterised by enhanced expression of MHC 
molecules and other co-stimulatory molecules, and secretion of different pro- 
inflammatory cytokines (Su et ah, 1998). In vitro studies have shown that Ch. 
pneumoniae stimulates murine bone marrow-derived DCs to up-regulate expression of 
MHC class-II and other co-stimulatory molecules such as CD80, CD86 and CD40, 
besides activation of NF-Kp mainly via TLR2 and TLR4 pathways leading to DC 
maturation (Prebeck et ah, 2001, Costa et ah, 2002, Su et ah, 1998). Mature DCs migrate 
from the site of infection to the draining lymph node or spleen in order to present 
different antigens in the context of MHC class-11, to naïve T cells, leading to the 
induction of antigen-specific acquired immunity (Abbas et ah, 2007).
Other members of the innate immune response that play an important role in the 
defence against intracellular bacteria and viral infections, especially during the early 
stages of infection, are NK cells. These cells mediate cytotoxic activity via a 
perforin/granzyme mechanism. The role of NK cells in Chlamydophila infection is 
unclear and is still under investigation. However, it has been found that NK cells can be 
detected at the site of Ch. pneumoniae infection where they participate in controlling the 
invasion despite the inhibition of MHC class-1 expression caused by RFX-5 degradation 
or via Chlamydophila protease secretion. Therefore, it appears that NK cells detect these 
infected cells and control them, where other cells fail to (Binder et al., 2002, Dong et al., 
2005).
1.2.2A.2. Acquired immune response
Once APCs activate naïve T cells, the second line of the immune response is 
triggered. This response is represented by the cellular and the humoral immune
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responses as well as immunological memory (Abbas et al., 2007). These three 
components are discussed in more detail in the following sections.
T cell mediated immune response
Through activation of APCs and stimulation of specific cytokines, naïve T cells 
differentiate into either Thl cells, secreting IFN- y, TNF-a and IL-2 or Th2 cells, 
secreting IL-4, IL-5, IL-6, IL-10 or IL-13, depending on the cytokine profile of micro­
environment (Gumy et ah, 2004, Fiorentino et ah, 1991, Pfeiffer et ah, 1991). Due to the 
intracellular development of Ch. pneumoniae, there is sufficient evidence that Thl cells 
have a protective dominant role, causing clearance of infection through two main 
mechanisms. The first mechanism is destruction of the infected cells by cytotoxic T cells 
and other cells such as macrophages (Brunham and Peeling, 1994). CD8^ T cells protect 
against intracellular pathogens by recognizing pathogen antigens in the context of MHC 
class-1 molecules. The cytolytic effect of CD8  ^T cells is more effective and protective 
during the early stage of the Chlamydophila life cycle rather than during the late stage i.e. 
when Chlamydophila exists in cells as RBs before they are released as infective EBs. In 
addition, several studies confirmed that the protection against Ch. pneumoniae is more 
dependent on CD8  ^T cells than CD4^ T cells (Penttila et al., 2000, Debattista et al., 
2003, Mittal et al., 1996, Williams et al., 1997).
The second mechanism is the modulation of bacterial metabolism via IFN-y and 
TNF-a secretion (Rank et al., 1992). Several animal studies emphasise the protective 
role of IFN-y in Ch. pneumoniae infection (Penttila et al., 1999, Vuola et al., 2000). 
IFN-y has several mechanisms to control infection with this pathogen, ineluding the 
following: IFN-y highly induces nitric oxide synthesis by macrophages and epithelial 
cells causing resolution of Ch. pneumoniae infection (Rottenberg et ah, 2000, Rottenberg 
et al., 2002). Another mechanism is induction of indolamine-2,3-dioxygenase expression 
molecules (IDO), which catabolise the intracellular tryptophan of host cells leading to 
decreased viability of Ch. Pneumonia, which lacks the genes for tryptophan biosynthesis 
and depends mainly on the host cell’s resources (Beatty et al., 1994b, Beatty et al., 
1994a). Moreover, as well as IFN-y, IL-1 also has a crucial role in induction of IDO 
(Ward, 1995). IFN-y can also induce iron deprivation but the exact mechanism behind 
this effect is unclear and needs further study (Beatty et al., 1994a). Additionally, TNF-a 
secretion has pro-inflammatory activity and can provoke other cytokines to inhibit
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intracellular replication by stimulating apoptosis of infected cells (Guerra-Infante et al.,
1999). Conversely, when IFN-y secretion levels are low, as indicated in a weak Thl 
immune response and dominant Th2 immune response, this leads to persistent infection 
causing several chronic diseases (Beatty et al., 1994c).
Although the protective role of the Thl immune response aids in the resolution of 
Ch. pneumoniae infection, an excessive Thl response may cause a pathological 
inflammatory response, resulting in damage and tissue destruction via the action of CD8  ^
T cells (Debattista et ah, 2003). Therefore, stimulation of the anti-inflammatory cytokine 
IL-10 during Ch. pneumoniae infection may be essential in order to control pathological 
tissue damage (Romagnani, 1996). However, this anti-inflammatory cytokine induces 
persistent infection by down-regulating MHC complex expression (Caspar-Bauguil et al.,
2000). Ultimately, Thl and Th2 immune responses are required to work together in a co­
ordinate fashion in order to control Ch. pneumoniae infection without causing 
inflammatory tissue injuries (Halme et ah, 2000, Halme and Surcel, 1997).
B cell mediated immunity
The main function of humoral immunity is to neutralise and eliminate 
extracellular pathogens (bacteria, fungi, protozoa, etc) through activation of B 
lymphocytes to secrete IgM and other antibody isotypes (Abbas et ah, 2007). The role of 
humoral immunity antibody production in resolving Ch. pneumoniae infection is less 
significant than that of cell-mediated immunity due to the intracellular nature of this 
pathogen. However, the protective role of humoral immunity has obvious utility at the 
early stages of infection by inhibiting the entry of EBs, either by blocking cellular 
surface receptors or by modifying EB surface charge or hydrophobicity and thus 
preventing further infection (Kalayoglu et al., 2000). Moreover, several studies have 
found that the role of antibodies in Chlamydophila infection may be indirectly important 
through opsonisation of Chlamydophila’s antigen via an Fc receptor antigen uptake and 
processing mechanism. This leads to stimulation of the Thl immune response 
(Bjorkbacka et ah, 2004, Yang and Brunham, 1998). However, the role of B cells in 
chlamydial infection is still questionable and more research is required to elucidate their 
role fully (Yang and Brunham, 1998).
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I.2.2.4.3. The role of Ch. pneumoniae in atherosclerosis
In 1911, Frothingham stated that “acute infectious diseases may cause some 
pretty general lesions throughout the arterial system, either from the diffuse action of 
toxins or from widespread invasion of arterial system by infecting organisms” 
(Frothingham, 1911). The idea that infectious agents are involved in atherosclerosis 
progression was suggested as long ago as the late 1800s and early 1900s (Catherine, 
2005). More specifically, the correlation between vascular disease and infection with 
Ch. pneumoniae was suggested in the 1940s and 1960 (Leinonen and Saikku, 2002).
Recently, Ch. pneumoniae has also been associated with atherosclerosis and 
coronary heart disease (CHD). This correlation has been demonstrated by sero- 
epidemiological studies indicating high titres of anti Ch. pneumoniae antibodies in the 
majority of patients with CHD (Saikku et al., 1988). Furthermore, this pathogen has 
been detected in atherosclerotic plaques from the early stage (fatty streak); the first 
deteetion was reported by Shor in 1992 (Shor et al., 1992). A high incidence of Ch. 
pneumoniae in the arteries of patients with atherosclerosis has also been reported (79%) 
compared with low incidences in the healthy control group (4%) (Wong et ah, 1999a, 
Wong et al., 1999c). This detection has been confirmed using several methods, including 
immuno-cytochemistry, transmission electron microscopy and molecular biology 
techniques (Phillips et ah, 2000, Sessa et ah, 2005, Sessa et ah, 2009). Ch. pneumoniae 
DNA has also been detected in peripheral blood mononuclear cells of acute coronary 
syndrome patients (Caroline, 2008, Palikhe et ah, 2009). Thus, it is possible that a 
chronie anti-C/z. pneumoniae antibody may be used as a risk marker for atherosclerosis 
(Wong et ah, 1999b). However, other studies failed to confirm the association between 
Ch. pneumoniae infection and cardiovascular disease (Danesh et ah, 2000). To date, it is 
unclear whether Ch. pneumoniae causes atherosclerosis or accelerates the disease; hence 
this area is still questionable.
Ch. pneumoniae fulfils most but not all of Koeh’s postulates criteria, which were
proposed in 1886 in order to determine the causal relationship between a pathogen and a
disease (Catherine, 2005). The first postulate is that the pathogen must be present in
nearly all cases of disease development. Accumulative sero-epidemological and
histopathological studies detected that 68% of patients suffering from acute myocardial
infarction had high levels of Ch. pneumoniae IgG and IgA titres compared with 17% of
controls (Saikku et ah, 1988, Saikku et ah, 1992, Huittinen et ah, 2003). In 1992, Shor et
al. detected Ch. pneumoniae in atherosclerotic plaques by transmission electron
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microscopy using genus-specific and species-specific monoclonal antibodies (Shor et 
ah, 1992). Additionally, several studies using different techniques such as PCR, 
immuno-cytochemical staining and immuno-fluorescence in situ hybridisation identified 
Ch. pneumoniae in atherosclerotic plaques (Shor et al., 1992, Gibbs et al., 1998). 
However, there are some studies opposing this relationship (Danesh et ah, 1997, Danesh 
et ah, 2000). The second postulate is that the pathogen must be isolated from a diseased 
host and grown. This postulate has been confirmed by isolating Ch. pneumoniae from 
atheroma plaques and propagating by serial subculture (Ramirez, 1996, Maas, 1998). 
The third postulate states that the disease must be reproduced when the culture is 
inoculated into a healthy host. This postulate has been fulfilled, since animal models 
such as New Zealand rabbits and apoE'^' mice showed progression of atherosclerotic 
lesions after infection with Ch. pneumoniae (Laitinen et ah, 1997b, Laitinen et ah, 1997a, 
Moazed et ah, 1999, Muhlstein, 1998). The fourth postulate is that the organism must be 
recovered from an experimentally infected host. Immunohistochemical staining and 
direct culture after intranasal infection techniques have identified Ch. pneumoniae in 
both the New Zealand rabbit and apoE' '^ mice, thus satisfying Koch’s fourth postulate 
(Moazed et ah, 1999, Laitinen et ah, 1997b).
Ch. pneumoniae may contribute in the pathogenesis of atherosclerosis by 
triggering the initial injury, inducing the atherogenesis, accelerating the progression of 
pre-existing disease, or stimulating disease complications such as plaque rupture and 
myocardial infarction (Campbell et ah, 1998) (Figure 1.7). The pathogenesis of Ch. 
pneumoniae in atherogenesis is explained in more detail in the following paragraphs.
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F igu re 1 .7 . T h e co n tr ib u tio n  o f  Ch. pneumoniae  in d ifferen t s t a g e s  o f  a th e r o s c le r o s is  
d e v e lo p m e n t, (m odified from: (Watson and Alp, 2008)).
Many sources of evidence suggest that Ch. pneumoniae plays a role in ail stages 
of atherosclerosis, starting from the initial inflammatory lesion to the plaque rupture. 
This organism infects the respiratory tract and has the ability to infect other cells of the 
body such as monocytes and macrophages that may disseminate the pathogen throughout
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the body (Yang et ah, 1995). Infected macrophages not only infiltrate sub-endothelial 
layers of the arteries but also infect endothelial cells, leading to stimulation of 
inflammatory reactions, such as expression of leukocyte adhesion molecules on the 
surface of endothelial cells and triggering the secretion of inflammatory cytokines (Gibbs 
et al., 1998). This process is initiated by activation of NF-Kp, and is known as 
endothelial dysfunction. As a result of this process, endothelial cells secrete a wide range 
of inflammatory markers, such as growth factors (e.g. PDGF and heparin binding 
endothelial growth factor) (Coombes and Mahony, 1999, Coombes and Mahony, 2001), 
express adhesion molecules (VCAM-1, ICAM-1 and E-selectin) and secrete pro- 
inflammatory cytokines (TNF-a, IL-1, IL-2, IL-6 and IL-8). As a result of this 
mechanism, more leukocytes such as macrophages proliferate in the sub-endothelial layer 
(Molestina et al., 1999).
Ch. pneumoniae stimulates foam cells formation, which is the hallmark of early 
atherosclerotic lesions (fatty streak) and this is achieved via different mechanisms. For 
instance, macrophages may be induced to take up not only oxLDL but also native LDL 
after upregulation of scavenger and LDL receptors expression (Kalayoglu et al., 1999, 
Kalayoglu and Byrne, 1998). Furthermore, Chlamydophila LPS and HSP60 induce 
oxidation of cellular LDL, leading to further foam cell formation (Kalayoglu et al., 
1999). Ch. pneumoniae contributes in the fibrous cap formation where it stimulates 
endothelial cells to secrete growth factors and triggers macrophages to release cytokines. 
Therefore, SMCs are stimulated to proliferate and migrate from the media to the intimai 
layer where they secrete ECM components such as fibrin, proteoglycans and collagen, 
which make up the main composition of fibrous cap.
Furthermore, several studies have suggested the contribution of Ch. pneumoniae 
in plaque destabilization, rupture and thrombosis (Lysenko and Solov'eva, 2010). This 
could be mediated by the effect of Chlamydophila HSP60 that stimulates macrophages to 
secrete MMP and TNF-a, causing thinning and weakening of the plaque caps (Kol and 
Libby, 1998). HSP60 also stimulates infected ECs and SMCs to produce PAI-1, which 
has a probable role in thrombosis after plaque rupture (Fryer et al., 1997). In addition, 
Ch. pneumonia infection induces necrotic death of vascular endothelial cells, leading to 
plaque erosion and thrombosis (Marino et al., 2008, Lysenko and Solov'eva, 2010).
Ch. pneumoniae is not only involved in all stages of atherosclerosis but also 
stimulates several risk factors in atherosclerosis (Figure 1.8). One of these risk factors is
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high levels of fibrinogen, which increases platelet aggregation and thrombosis (Meade et 
al., 1985, Chooi and Gallus, 1989). Previous studies have suggested that there is a 
relationship between Ch. pneumoniae sero-positivity and the level of fibrinogen in the 
plasma (Mendall et al., 1995, Toss et al., 1998). Moreover, sero-epidemological studies 
found that Ch. pneumoniae infection could have an effect on serum lipid levels. Patients 
with chronic Ch. pneumoniae infection have been shown to have high levels of 
triglyceride and low levels of HDL-c in their serum (Laurila et al., 1997). This 
observation may be related to the effect of pro-inflammatory cytokines, especially TNF- 
a, which elevates both plasma triglyceride and cholesterol levels (Kaukoranta-Tolvanen 
et al., 1996, Feingold and Grunfeld, 1987).
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F igu re 1 .8 . T h e  p a th o g e n ic  m e c h a n is m s  o f  Ch. pneumoniae  in th e  s t im u la tio n  o f  
a t h e r o s c le r o s is  d e v e lo p m e n t . (Modified from  (Leinonen and Saikku, 2002, Sum m ersgill et al. 
2000, P feifer et al., 1993)).
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1.3. MAJOR OUTER MEMBRANE PROTEIN (MOMP)
1.3.1. MOMP structure
In 1981, the structure of MOMP was described for the first time by Caldwell 
(Caldwell et al., 1981). This 40 kDa protein, encoded by ompl (previously known as 
ompA), is the dominant structure in the cell membrane of the EB and the RB of 
Chlamydophila, representing approximately 60% of the total outer membrane structure 
(Stephens et al., 1986). The molar ratio of MOMP protein in EB envelopes is five 
MOMP molecules to two omp3 to one omp2 (Everett and Hatch, 1991). MOMP 
structure is modified as the life cycle of the bacterium progresses. For example, MOMP 
has multiple disulfide bonds that are cross linked in EB, and these completely disappear 
in the RB phase (Newhall and Jones, 1983, Hatch et al., 1984). Several studies have 
focused on describing the structure of MOMP using techniques such as chemical 
modification using enzymatic digestion followed by mass spectrometric analysis of 
peptides, SDS-PAGE and 2-dimensional gel electrophoresis (Juul et al., 2007, Hatch, 
1996, Caldwell et al., 1981, Caldwell and Judd, 1982). The main challenge for most of 
these analyses was finding a method for MOMP isolation and purification from EBs, as 
the protein can easily aggregate when oxidised or through interaction with other cysteine 
rich proteins (Dascher et al., 1993, Manning and Stewart, 1993).
The N-terminal region of MOMP in all Chlamydia species is the same, 
suggesting that it may have been conserved due to its essential involvement in the 
attachment to other membrane structures. Previous studies have shown that MOMP 
consists of four variable domains (VS1-VS4), which are surface-exposed and may 
contribute to chlamydial infectivity (Figure 1.9). These domains are flanked by five 
conserved sequences (CS1-CS5), that are hidden in the periplasm (Su et al., 1988, 
Stephens et al., 1987, Baehr et al., 1988, Conlan et al., 1988, Pitch et al., 1993). The 
variable domains in Ch. pneumoniae are more conserved compared with other 
Chlamydia species such as C. trachomatis, where the difference of the variable domains 
is no more than 5% among 11 strains of Ch. pneumoniae (Campbell et al., 1990, Peterson 
et al., 1996). In fact, the location of Ch. pneumoniae MOMP in the cell membrane is still 
controversial as it has not been yet confirmed if Ch. pneumoniae MOMP is surface 
exposed or not. Previous observations have speculated that MOMP lies beneath other 
Chlamydophila antigens (Christiansen et al., 1997, Christiansen et al., 1999). However, 
a recent study suggested that MOMP of Ch. pneumoniae is surface exposed, as the
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antibodies used could detect conformational epitopes within the MOMP molecule that 
can not be detected with sera raised against the denatured protein (Daemen et al., 1999).
VD4
External
COŒ4
Membrane
F igu re 1 .9 . D e sc r ip t iv e  m o d e l o f  Ch. pneum oniae  MOMP. MOMP is com posed o f 16 
mem brane spanning p-sheets that appear as a barrel-like structure with long external loops. 
External loops (including variable domains, (VD)) are labelled, and cysteine residues are shaded 
red (Findlay et al., 2005).
Several studies have proposed the use of the four variable domains of MOMP for 
vaccine development (Taylor-Robinson, 1989). These variable domains form loops that 
protrude from the surface of Chlamydophila’s EB and might be accessible to neutralising 
antibodies. The loops might also be responsible for Chlamydophila’s host cell 
interaction, as they are hydrophilic binding areas. It has also been speculated that these 
domains could help the pathogen to evade host immune system reeognition (Zhang et al., 
1987, Su et al., 1990a, Rodriguez-Maranon et a l, 2002).
The molecular genetic analysis of Ch. pneumoniae MOMP gene showed that this 
protein has seven cysteine residues located in the same positions as in other Chlamydia 
species (Zhang et al., 1989). Three cysteine residues are located in the N-terminus region 
before the VDl domain, two are located between VD2 and VD3 and another one is found 
in the C-terminus region after the VD4 domain (Figure 1.9). In addition, one cysteine
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residue is located in the conserved domain (Perez Melgosa Mercedes, 1991). These 
cysteine residues are responsible for the formation of intra- and inter-disulphide bonds or 
for cross linking with other membrane proteins (Newhall, 1988, Zhang et al., 1989, 
Findlay et al., 2005). Moreover, these structures are involved in the maintenance of 
structural integrity, the formation of ionic diffusion channels and Chlamydia 
differentiation (Haekstadt and Caldwell, 1985, Newhall, 1988).
Several studies have attempted to clarify the secondary and the tertiary structures 
of MOMP using in silico and algorithm analysis. These studies have suggested that 
MOMP is composed of 16 membrane spanning p-sheets that appear as a barrel-like 
structure with long external loops (Rodriguez-Maranon et al., 2002). This descriptive 
model is consistent with previous studies using enzymatic, biochemical and 
immunological tools confirming that the variable domains are extracellular structures 
(Sun et al., 2007, Wang et al., 2006). Previous researchers have also attempted to 
examine whether MOMP is a glycosylated protein or not. In 1981, Caldwell and his co­
workers concluded that MOMP protein is not glycosylated as it failed to stain positive for 
carbohydrate using periodic acid Schiff staining methods (Caldwell et al., 1981). 
However, other studies using enzymatic digestion, radio-labelling and carbohydrate 
staining techniques confirmed that MOMP is a glycosylated protein, and that this 
glycosylation mediates the adhesion function of the protein with the host cell (Swanson 
and Kuo, 1991, Swanson and Kuo, 1994, Campbell et al., 2006).
1.3.2. MOMP function
Accumulative studies have confirmed that MOMP is involved in several vital 
functions during the chlamydial life cycle. These vital functions are discussed in more 
detail in the following sections.
I.3.2.I. MOMP as a structural protein
The ability of Ch. pneumoniae to produce a peptidoglycan is a controversial issue 
(Hatch, 1996, Barbour et al., 1982, Stephens et al., 1998). Therefore, one of the 
hypotheses that have been suggested is that a peptidoglycan can be substituted by 
MOMP and other cysteine rich proteins to maintain the structural integrity of the cell 
membrane (Hatch, 1996). In 1983, Newhall and Jones proposed that MOMP has
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different forms in the EB’s cell membrane and that it could be identified in dimers, 
trimers and other multiple but structurally stable forms joined by disulfide cross linkages 
(Sun et al., 2007, Newhall and Jones, 1983). Despite some controversy regarding the 
trimeric structure of MOMP, several groups have confirmed the existence of trimeric 
forms of MOMP stabilised by disulphide bonds in the cell membrane (Newhall and 
Jones, 1983, Sun et al., 2007, McCafferty et al., 1995).
I.3.2.2. MOMP as a porin
In 1984, Bavoil and his group found that chlamydial MOMP can act as a porin 
(Bavoil et al., 1984). Porins are a family of membrane channels usually found in the 
outer membranes of Gram-negative bacteria, where they are involved in different vital 
functions such as diffusion pathways for nutrients, waste products, and antibiotics and 
can also be receptors for bacteriophages (Miot and Betton, 2004). The mechanism of 
opening and closing of pores is controlled by a reduction-oxidation (redox) mechanism. 
It has been proposed that MOMP porin is functional during the intracellular RB phase 
and acts to protect the bacterium from the host defence. A previous study confirmed this 
hypothesis, showing that the permeability of EBs is increased after treatment with 
reducing agents (Haekstadt et al., 1985). However, it is still unclear whether MOMP as 
porin is functionally active in extracellular EBs or not. Furthermore, it has been 
confirmed that the porin function of MOMP can be activated after reduction of 
disulphide bonds (Wang et al., 2006). This finding suggests that MOMP has an 
important role in protecting the organism from osmotic damage during the extracellular 
EB phase, but after internalisation the disulfide bonds are reduced by glutathione inside 
the inclusion vacuole. This would allow the organism to obtain nutrients and ATP 
molecules from the host cell through the pore (Bavoil et al., 1984).
Recently, the use of algorithms designed to produce a topological model of the 
Chlamydiae cell membrane has proposed that MOMP has 16 anti-parallel (3 sheets 
forming a barrel-like structure, which it is typically similar to other bacteria porins 
(Rodriguez-Maranon et al., 2002). Chlamydiae MOMP porin is distinct from other Gram 
negative porins in that they have a large number of cysteine residues (Stephens et al., 
1986). In 2000, Jones and his group generated the full length of C. trachomatis MOMP 
and then expressed it in E. coil. They showed that recombinant MOMP (rMOMP) 
facilitated the diffusion of solutes and thus confirmed that the function of MOMP was to
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serve as a general diffusion porin; this function is size-selective, but not ion-selective, in 
allowing the diffusion of solutes (Kol et al., 2000).
1.3.2.3. MOMP as a cytoadhesion molecule
The first step of chlamydial pathogencity is adhesion of EBs to the host cells 
followed by internalisation. Several studies have attempted to clarify this mechanism 
(Swanson and Kuo, 1994, Su et al., 1996) and have yielded functional information 
regarding the role of MOMP. Previous studies suggested that Chlamydophila MOMP is 
involved as a putative molecule for chlamydial cyto-adhesion to host cells (Su et al., 
1990b, Su et al., 1988). This suggestion has been confirmed by Caldwell and his group; 
as they observed that when EBs are treated with trypsin, which cleaves MOMP structure, 
reduced infectivity was observed (Caldwell and Judd, 1982). This observation has also 
been confirmed by other groups (Haekstadt et al., 1985, Su et al., 1990b). Furthermore, 
other studies have found that chlamydial infectivity is neutralised by antibodies directed 
against conformational MOMP epitopes (Fan and Stephens, 1997), however, the precise 
mechanisms remains unstudied. In 1990, Su and co-workers suggested that MOMP 
could act as a cyto-adhesion molecule by two different mechanisms: the first mechanism 
is the formation of electrostatic and hydrophilic interactions between MOMP and the 
host cell; the second mechanism is that MOMP can interact with the host cell via specific 
receptors like heparin sulphate. Moreover, this study and others found that the VD2 and 
VD4 domains can mediate cyto-adhesion via heparin sulphate (Su et al., 1988, Su et al., 
1996, Gordon et al., 2001). Other studies have revealed that MOMP acts as a cyto- 
adhesion molecule via N-linked high mannose type oligosaccharides (Swanson and Kuo, 
1991, Kuo et al., 1996). In addition to this, it has been recently reported that the 
internalisation mechanism is a multistep process mediated by a complicated network of 
molecules such as cellular receptors, adhesion molecules, transcription factors and 
receptors of endocytosis (Wang et al., 2010).
1.3.3. Immunogenicity of MOMP
The antigenic properties of MOMP are still controversial. Several studies have 
suggested that MOMP of Ch. pneumoniae is less immunogenic compared to that of other 
Chlamydia species (Campbell et al., 1990a, Jantos et al., 1997). Previous research 
reported that MOMP of Ch. pneumoniae is a surface exposed antigen eliciting a host 
antibody response that is mainly dependent on the conformational epitopes exposed 
(Wolf et al., 2001a). For more than 20 years, MOMP has been considered an attractive
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target molecule to develop a vaccine against chlamydial infection, although most of these 
studies have shown incomplete or short term protection against infection (Pal et al., 1999, 
Batteiger et al., 1993). Interestingly, recent evidence has suggested that MOMP induces 
the development of Th2 rather than Thl immune responses when DCs are pulsed ex vivo 
with rMOMP of C. trachomatis and then transferred into naïve mice (Shaw et al., 2002). 
Another finding, reported by our group (Oviedo Orta’s group. University of Surrey), 
suggests that rMOMP modulates innate immune responses by down-regulating MHC 
class-II, CD86 and CD40 expression on macrophages and by suppressing CD69 and 
CD40L (CD 154) expression on CD4^ T cells in vitro (Bermudez-Fajardo, 2011). In 
addition, evidences from several other studies report that MOMP from different 
Chlamydia species may induce a mixture of Thl and Th2 immune responses (Pal et al., 
2005, Pal et al., 2001, Zhang et al., 1999). These findings are discussed in detail in 
Chapter 4.
1.4. HYPOTHESIS
Our hypothesis is that rMOMP of Ch. pneumoniae may have anti-inflammatory 
properties capable of dampening down the host immune response, and that rMOMP 
could be used as a suppressive therapeutic antigen to halt the pathological inflammatory 
mechanism of atherosclerosis disease.
1.5. GENERAL AIM OF THE THESIS
The general aim of this thesis is to study the effect of rMOMP on immune
responses and the development of atherosclerosis in apoE" '^ mice.
1.6. SPECIFIC AIMS AND OBJECTIVES OF THE THESIS
The individual aims and objectives of this thesis are:
I. To prepare a surrogate host cell capable of expressing rMOMP to further 
investigate and characterise the immune responses induced by the protein in vitro 
and in vivo. Hence, truncated and un-truncated ompl genes encoding rMOMP, 
with and without signal peptide sequence respectively will be cloned into a 
mycobacterial expression vector to be transformed into Mycobacterium vaccae. 
These engineered bacteria will be used as an artificial expressing system instead 
of Ch. pneumoniae.
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IL To characterise the immune responses generated by rMOMP on T cell-mediated 
and humoral immune responses in vivo. To achieve this, C57B1/6J male mice 
will be immunised with rMOMP expressed by eukaryotic DNA plasmids and M. 
vaccae expression vectors using a short term immunisation protocol.
III. To examine the effect of rMOMP on selective markers expressed on APCs and T 
cells in order to determine its immuno-modulatory effects on the host immune 
réponse in vitro. These studies will be performed using mouse peritoneal 
macrophages as APCs and isolated syngeneic CD4^ T cells from splenocytes.
IV. To investigate the effect of intranasal immunisation with rMOMP expressed by 
different vectors on the immune response and the development of atherosclerosis 
in apoE"'^ ‘ mice. The effect of rMOMP on immune response will be examined by 
studying cell-mediated and humoral responses. Moreover, the effect of 
immunisation on CD4^ and CD8  ^ Treg populations will be measured by flow 
cytometry analysis. The effect of rMOMP immunisation on the plasma lipid 
profile (total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides) 
will also be examined. Finally, the effect of rMOMP on atherosclerotic plaque 
development and plaque stability (measured by plaque collagen and SMC 
content) in the aortic sinus and brachiocephalic artery will be examined by histo- 
chemical techniques and plaque morphometric analysis.
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CHAPTER 2
GENERAL MATERIALS AND METHODS
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2.1. GENERAL MATERIALS
2.1.1. Software and instruments
Ail centrifugations were performed using a Heraeus Megafuge l.OR, (Thermo 
Fisher Scientific Inc, UK), unless otherwise stated. Incubations at 37°C were carried out 
using a Heraeus Dry incubator (Fisher Scientific Inc, UK). Flow cytometry analyses 
were performed using a BD FACS Canto flow cytometer analyser and BD FACSDiva™ 
software version 5.03, 2007 (BD Biosciences, UK). ELISA analyses were performed 
using a Bio-Tek RLX800 plate reader and KC4 software version 3.4 (Bio-Tek 
Instruments Inc., Ontario, Canada).
2.1.2. Cell culture reagents
All cell culture reagents were purchased from Gibco Life Technologies 
(Invitrogen, UK) unless otherwise stated. RPMI 1640 media were certified for tissue 
culture use and contained (Invitrogen, GIBCO, UK). Plastic ware such as syringes, 
needles and tubes were purchased from BD Biosciences (UK), Terumo Europe 
(Belgium) or Barloworld Scientific (UK). All cell culture works were performed in 
tissue culture hoods (BioMAT, Class II Microbiological Safety Cabinet, Medical Air 
Technology Ltd, UK), which were regularly cleaned with Virkon® disinfectant (Antek 
International, A-DuPont Company, UK).
2.1.3. General reagents and buffers
The composition of buffers and reagents for general use are listed in the table below:
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Table 2.1. General use buffers, solutions and reagents
Name Composition
3,3\5,S'
T etramethylbenzidine 
dihydrochloride substrate
One Tablet in lOmL of 0.05M Phosphate citrate buffer, pH 5.0.
10% (v/v) neutral phosphate 
buffered formalin
lOOmL Formalin [40% (v/v) Formaldehyde solution], 4.5g Sodium di­
hydrogen orthophosphate (NaH2 FO4 2 H2O), 5.6g Anhydrous disodium 
hydrogen orthophosphate (Na2HP0 4 ) and up to IL with distilled water.
EDTA 0.5M stock solution made from ethlene-diaminetetreacetic acid disodium 
dehydrate solid, adjusted to pH 7.5 at RT.
ELISA blocking buffer 1% (w/v) BSA in PBS, pH 7.4.
ELISA coating buffer 0.05M carbonate-bicarbonate buffer pH 9.0.
ELISA diluent buffer 0.05% (v/v) Tween-20, 0.1% (w/v) BSA in PBS, pH 7.4.
ELISA substrate Ip-NPP tablet/4mL ultrapure water/ImL of diethanolamine (Pierce, UK).
ELISA washing buffer 0.05% (v/v) Tween-20 in PBS, pH 7.4.
FACS staining buffer 1% (v/v) BSA, 0.05% (v/v) NaN] in PBS, pH 7.4.
FACS fixative buffer 1% (v/v) Formaldehyde in PBS, pH 7.4.
FACS permeabilisation 
buffer
5ml of 10% (w/v) Saponin in PBS, pH 7.4.
FACS washing buffer 0.5% (w/v) BSA in PBS, pH 7.4.
Phosphate citrate buffer 
(0.05M)
One phosphate citrate buffer tablet (Sigma) dissolved in lOOmL of 
deionised water with stirring.
PBS Na2HP0 4  (O.OIM), KCl (0.0027M) and NaCl (0.137M), pH 7.4.
TBS 0.15M NaCl; O.IM Tris; HCl; pH 8.0.
2.2. GENERAL METHODS
2.2.1. Health and safety
The handling of all chemicals and reagents was carried out following the safety 
regulations supplied with each product and internal university COSHH regulations. In 
addition, biological waste was disposed following the university guidelines.
2.2.2. Immunisation of animals
All immunisations were carried out intranasally after light anaesthesia with 
isoflurane (ABBOTT, UK). Mice received lOpL of solution via each nostril, drop by 
drop and were allowed to inhale. The maximum volume of vaccine or control
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preparation given per animal was 20pL. Mice were euthanised by intra-peritoneal 
injection with sodium pentobarbital (lOOmg/kg) (VetTech, UK).
2.2.3. Flow cytometry analysis
2.2,3.1. Isolation o f  splenocytes
At termination, spleens were collected from the animals and splenocytes isolated 
separately as follows: The spleens were homogenised using a lOmL syringe plunger in a 
sterile petri dish and the homogenate was transferred to a 50mL tube (trying to avoid 
transferral of connective and fat tissues). Ten millilitres of sterile complete RPMI 1640 
[supplemented with 10% foetal calf serum (PCS) and lOOU/mL penicillin, 2mM 
glutamine and lOOpg/mL streptomycin (PGS)] was added followed by centrifugation at 
400 X g for 5 min to collect the cells. The pellet was resuspended in 3mL of IX red 
blood cell lysis buffer (R&D systems, UK) and incubated for 10 min on ice. lOmL of 
complete RPMI 1640 was then added followed by 5 min centrifugation at 400 x g 
followed by another wash step as described previously.
Cell viability was assessed using Trypan blue exclusion (Sigma, UK). Trypan 
blue dye was prepared in advance in a 1:1 ratio in PBS. The cells were suspended in 
ImL of complete RPMI 1640 medium and 2pL of cells suspension were mixed with 
Trypan blue solution to obtain a 1:10 dilution, and then transferred to both chambers of a 
haemocytometer for counting (Horsham, US). The cell concentration was calculated 
using the following formula:
(Cells/mL = the average count of cells per square x dilution factor x 10"^ ).
One millilitre of cell suspension containing 1.5x10^ cells from each spleen was 
transferred to a tube containing 3mL of complete RPMI 1640 and 500ng/mL ionomycin 
calcium salt from Streptomyces conglobatus (Sigma, UK) and lOng/mL phorbol 12- 
myristate-13-acetate (PMA) (Fluka, UK). The cells (5x10^ cells/well) were cultured in 
24-well plates in triplicate at 37°C; 5% CO2 in the presence of PMA and ionomycin for 
72 hrs. After incubation, the cells were collected by centrifugation at 400 x g for 5 min 
and the supernatant was separated from the cells and stored at -80°C until further 
analysis.
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2.2.3.2. Direct immunofluorescence staining for flow cytometry analysis.
After 72 hrs incubation, the cell pellet was resuspended in ImL of flow cytometry 
staining buffer. The remaining cells were then resuspended in FACS staining buffer to 
obtain a cell suspension of 1x10^ cells/mL, and O.lmL of this suspension was transferred 
to 5mL of polypropylene tubes (BD Bioscience, UK) and incubated with 1 pg of mouse 
seroblock (rat anti-mouse CD16/CD32 monoclonal antibodies, Serotec, UK) for 15 min 
on ice. After this, fluorescently labelled antibodies (rat anti-mouse monoclonal 
antibodies, Serotec, UK) against CD4 or CDS and CD25 were added to each tube 
according to the combinations listed in Table 2.2, using the recommended concentration 
suggested by the manufacturers.
T ab le  2 .2 . C o m b in a tio n  o f  a n t ib o d ie s  u s e d  fo r  f lo w  cy to m e tr y  a n a ly s is  o f  T reg p o p u la t io n s
Combination FITC RPE Alexa Fluor 647
Detection o f CD4^ Treg 
population Rat-anti-mouse CD4
Rat-anti-mouse
CD25 Rat-anti-mouse FoxPS
Detection o f CD8^ Treg 
population Rat-anti-mouse CDS
Rat-anti-mouse
CD25
Mouse-anti-mouse
FoxP3
General isotype control Rat IgG2a Rat IgGl Mouse IgGl
Unstained control - - -
Fluorescence minus one 
(FMO)- CD4 Isotype 
control
Rat IgG2a Rat-anti-mouseCD25 mouse-anti-mouse FoxPS
FMO- CD25 Isotype 
control Rat-anti-mouse CD4 Rat IgGl mouse-anti-mouse FoxPS
FMO- FoxP3 Isotype 
control Rat-anti-mouse CD4
Rat-anti-mouse
CD25 Mouse IgG 1
FMO- CDS Isotype control Rat IgG2a Rat-anti-mouseCD25
Mouse-anti-mouse
FoxPS
(Appendix 2, Tablai).
Cells and antibodies were mixed and incubated on ice in the dark for 30 min and
then washed by centrifugation using 2mL of FACS washing buffer. The cell pellet was
resuspended in O.lmL of 1% (v/v) formaldehyde (Sigma, UK) in freshly prepared
phosphate buffered saline (PBS) and incubated in the dark for 20 min. The cells were
washed twice by centrifugation with ImL FACS permeabilisation buffer, and then
resuspended in O.lmL permeabilisation buffer and incubated at room temperature (RT) in
the dark for 15 min. After a further wash with permeabilisation buffer, cells were
resuspended in O.lmL of permeabilisation buffer and an appropriate amount of mouse
anti-mouse FoxP3 monoclonal antibody conjugated to Alexa 647 (eBioscience, UK) or
54
its isotype control (eBioscience, UK) were added to the corresponding tubes at the 
concentrations recommended by the manufacturer. Tubes were kept in the dark for 30 
min, followed by two washes with FACS staining buffer. The cell pellet was 
resuspended in 0.3mL of 1% (v/v) formaldehyde in PBS and kept in the dark at 4°C until 
flow cytometry analysis.
2.2.S.3. Analysis o f  splenocytes by flow  cytometry
Samples were analyzed after setting the parameters as described in Table 2.3.
T ab le  2 .3 . P a r a m e te r s  u s e d  to  s e t  up  th e  f lo w  c y to m e te r  so f tw a r e .
Voltage Mode Fluorochrome Excitation Emission
FSC 25 Lin None None None
SSC 295 Lin None None None
FITC 385 Log FITC 488nm 525nm
PE 365 Log RPE 488nm 578nm
APC 520 Log Alexa Fluor 647
633nm 660nm
The following list of compensation controls (compensation beads, BD 
Biosciences, UK) were used to set up the instrument before running the samples:
• Un-stained cells
• Rat anti-mouse CD4-FITC
• Rat anti-mouse CD8-FITC
• Rat anti-mouse CD25-RPE
• Mouse anti mouse FoxP3-Alexa 647
The purpose of using the compensation beads, stained with each fluorescently 
labelled antibody, was to correct for the spectral overlap of each fluorochrome on other 
emission channels. 500.000 events were acquired per sample. Parameters for the 
analysis of triple stained samples (i.e. for CD4^CD25^FoxP3^ Treg or 
CD8^CD25^FoxP3^ Treg) were set up as described in Figure 2.1.
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A. 1®* step. T cell populations were 
gated depending on the 
morphmetric characters using 
forward scatter vs side scatter.
1
B. 2"C step. CD4+ or 
CD8+ population was 
gated
C. 3'‘‘‘ step. The gated CD4* or 
CD8*T-cell populations were 
plotted against the other two 
fluorchrome channels PE (RPE) 
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F igu re  2.1. G a ting  s tra te g y  used  to  id e n tify  th e  tr ip le  s ta in e d  CD4^ and CDS"^ T reg  p o p u la tio n s  
in m ouse  s p le n o c y te  sam p les .
2.2.4. Cytokine analysis by ELISA
Plasma samples and supernatants derived from splenocyte cultures were used to 
determine the levels of IL-4, lL-10, IFN-y, using commercially available ELISA kits 
(PeproTech Inc., UK). TGF-p was measured using a human/mouse TGF-p, ELISA Kit, 
‘Ready-SET-Go’ (eBioscience, UK). Plasma samples were diluted 1:50 in ELISA 
diluent buffer (as deseribed in Table 2.1). Supernatants were used undiluted.
Briefly, Nunc Immuno MaxiSorp 96 well flat bottom plates (Fisher, UK) were 
coated with either lL-4, lL-10 or IFN-y speeific rabbit-anti-mouse antibodies at a 
eoncentration of Ijug/mL and the plates were sealed and incubated overnight at 4°C.
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Plates were then washed four times with 300pL of ELISA washing buffer and then 
‘blocked’ with 300|iL of ELISA blocking buffer for 1 hr, to reduce non-specific binding. 
After blocking, the solution was discarded and the plates were washed four times with 
washing buffer. A cytokine standard curve was set up by performing serial dilutions of 
the provided standards in ELISA diluent buffer. The standard curve ranged between 
Ong/mL and 2ng/mL for IL-4 and IFN-y, and between Ong/mL to 3ng/mL for IL-10. 100 
pL of standards and samples was added to each well in duplicate and the plates were 
incubated at 4°C overnight. The plates were then washed four times with washing buffer 
and lOOpL of biotinylated antigen specific rabbit-anti-mouse monoclonal antibody was 
added at a concentration of 0.5pg/mL for IL-4 and IL-10, and 0.25pg/mL for IFN-y. The 
plates were incubated for 2 hrs at RT.
Secretion of TGF-j3 was measured using a commercial kit, following 
manufacturer’s instructions. Briefly, plasma samples were diluted 1:5 in PBS and culture 
supernatants were .used undiluted. Samples were first activated with IM HCL for 10 min 
at RT and then neutralised with IM NaOH immediately before adding to flat bottomed 
ELISA plates pre-coated with Ipg/mL of TGF-p anti-mouse antibody. Plates were then 
incubated overnight at 4°C followed by washing 5 times with 250pL of 0.05% (v/v) 
Tween-20 in PBS. After washing, plates were blocked for 1 hr at RT with diluent buffer 
supplied in the kit. A cytokine standard curve was set up by performing serial dilutions 
of standards, provided in the kit, in diluent buffer to achieve a standard curve ranging 
from 0.06ng/mL to 8ng/mL. Experimental samples were then added and incubated 
overnight at 4°C. The plates were then washed four times with 0.05% (v/v) Tween-20 in 
PBS and lOOpL of biotinylated antigen specific anti-mouse antibody was added at a 
dilution recommended by manufacture. The plates were incubated for I hr at RT.
After washing the plates for all cytokines (IL-4, IL-10, TGF-p and IFN-y) as 
described before, Extravidin-horseradish peroxidase (HRP) conjugate diluted 1:2000 in 
diluent buffer was added to the IL-4, IL-10 and IFN-y plates. For TGF-p, detection 
Extravidin-HRP conjugate was diluted 1:250 in diluent buffer. All plates were then 
incubated for 30 min at RT and then washed. The reaction was developed by adding 
lOOpL of 3,3’,5,5’-tetramethylbenzidine di-hydrochloride (TMB) substrate (Sigma, UK) 
in phosphate citrate buffer (Sigma, UK) to each well and the plates were incubated at RT 
for 5 to 10 min to allow a colour change to occur. The reaction was stopped using 2M 
H2SO4 (Sigma, UK) and the absorbance measured using an automatic plate reader at a 
wavelength of 450nm.
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2.2.5. Detection of antigen-specific antibodies by ELISA
Antigen-specific IgM, IgA, IgGl and lgG2a were detected in plasma collected 
pre-immunisation and at termination in order to evaluate the humoral immune response 
indueed by treatment using an in-house developed ELISA (Bermudez-Fajardo 2011). 
Briefly, Nunc Immuno MaxiSorp 96 well flat bottom plates were washed once with 
200pL carbonate-bicarbonate buffer, pH 9.0 (Sigma, UK) per well. Plates were then 
eoated with SOpL of Spg/mL rMOMP in 0.05M carbonate-bicarbonate buffer, pH 9.0 
(Sigma, UK) and incubated overnight at 4°C. The plates were then washed four times 
with 0.05% (v/v) Tween-20 in TBS. Non-specific binding sites were blocked by adding 
200pL Superblock blocking buffer in TBS (Pierce, UK) followed by immediate removal 
of the buffer. The blocking step was repeated twiee. For detection of anti-rMOMP 
specific antibodies, individual serum samples were diluted 1:50 in diluent buffer 
[Superblock buffer diluted 1:10 in TBS and 0.1% (v/v) Tween-20]. lOOpL of diluted 
sample was added to each well and the plates were incubated overnight at 4°C. After 
incubation, samples were aspirated from the plates and the wells were washed four times 
with 0.05% (v/v) Tween-20 in TBS. Deteetion antibodies were diluted in diluent buffer 
(see Table 2.4) and lOOpL was added to each well followed by a 2 hr incubation at 37°C.
T ab le  2 .4 . D e ta ils  o f  b io tin y la ted  a n t ib o d ie s  u s e d  in th e  ELISA.
Antibody Source
Initial
concentration
Final
concentration
Rat anti-mouse IgGl heavy 
chain-biotin monoclonal Serotec, UK Img/mL 0.5pg/mL
Rat anti-mouse IgG2a heavy 
chain-biotin monoclonal Serotec, UK Img/mU 0.5pg/mL
Rat anti-mouse IgM heavy 
chain-biotin monoclonal Serotec, UK 1 mg/mL O.Spg/mL
Goat anti-mouse IgA (a-chain)- 
biotin polyclonal Sigma, UK 0.4mg/mL 0.2pg/mL
(Appendix 2, Tablai).
After ineubation with the biotin-eonjugated antibodies, the plates were washed 
four times with 0.05% (v/v) Tween-20 in TBS. Extravidin conjugated to alkaline 
phosphatase (AP) (Sigma, UK) was then diluted 1:2000 in diluent solution and lOOpL 
were added to each well. The plates were then incubated for 1 hr at 37°C. Finally, the 
plates were washed four times with 0.05% (v/v) Tween-20 in TBS and the substrate was 
prepared immediately as follows: one p-nitrophenyl phosphate disodium salt (p-NPP)
58
tablet (Pierce, UK) was dissolved in lOmL of diethanolamine (Pierce, UK), previously 
diluted 1:5 in distilled water. lOOpL of the substrate was added to each well followed by
1 hr incubation at 37°C. Once the colour developed, the reaction was stopped by adding 
50pL of 2M NaOH (Sigma, UK) and the absorbance was measured using an automatic 
ELISA plate reader at a wavelength of 405nm.
2.2.6. Statistical analysis
Statistical analysis in this study was performed to compare treatment groups with 
controls using GraphPad Prism software (version 5.02, GraphPad Software Inc., La Jolla, 
CA,USA). For in vitro study, each experiment was repeated at least three times. Values 
herein are expressed as mean ± SD. To compare groups of means (in this case more than
2 groups), an F-test was firstly performed to test for similarity between variances; if 
variances were similar, a one-way ANOVA was performed followed by a Bonferroni’s 
multiple comparison post-hoc test, to determine which groups were significantly 
different. If the variances were significantly different, a Kruskal-Wallis test was used. In 
all cases, statistical significance was attained if the 2-tailed probability was: *p < 0.05 or
< 0.01 or ***p < 0.001.
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CHAPTERS
CLONING AND EXPRESSION OF RECOMBINANT MAJOR 
OUTER MEMBRANE PROTEIN (rMOMP) IN 
MYCOBACTERIUM VACCAE AND ESCHERICHIA COLI
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3.1. INTRODUCTION
MOMP is the predominant surface protein of Ch. pneumoniae. It contributes to 
several important biological functions, and maintains the structural rigidity of the bacterial 
cell (Stephens, Mullenbach et al. 1986). Genetic analysis using in silica predictions has 
revealed that the sequence of the Ch. pneumoniae MOMP is taxonomically distinct from 
orthologues in other Chlamydia species (Carter, al-Mahdawi et al. 1991) as the nucleotide 
sequence of the Ch. pneumoniae MOMP shows only 68% and 71% similarity to C. 
trachomatis and C. psittaci, respectively. Nucleotide sequence analysis shows that the ompl 
gene encoding MOMP is composed of an 1167 base pair (bp) open reading frame encoding a 
mature protein of 366 amino acids, plus a 23 amino acid leader peptide (signal peptide 
sequence) that is identical in all Chlamydia species, and includes a Leu-Glu-Ala protease 
cleavage site. MOMP mRNA has a ribosomal binding entry site located in the 5’ upstream 
region of the N-terminus and two stop codons followed by a stable stem loop structure (Perez 
Melgosa Mercedes 1991).
Understanding MOMP function has been hampered by two technical difficulties. 
Firstly, it has been difficult to purify MOMP protein, retaining the same functional form as it 
is found in its natural state expressed by Chlamydiae. Researchers have attempted to obtain 
MOMP protein from the EB cell membrane or have cloned and expressed the entire protein 
or specific fragments or domains in a heterologous system but with limited success (Bavoil, 
Ohlin et al. 1984; Dascher, Roll et al. 1993; Wyllie, Longbottom et al. 1999). Additionally, 
the literature reasoned that genetic manipulation of Ch. pneumoniae by homologous 
recombination or transposon mutagenesis to knock out targeted genes, specifically ompl gene 
encoding MOMP, is not possible because of its important structural and functional roles in 
the complex life cycle, the potential role of this protein as cellular adhesion (Su, Zhang et al. 
1988), its biological function as a porin (Bavoil, Ohlin et al. 1984), its immunogenicity 
related to specific variable domains (Stephens, Mullenbach et al. 1986; Baehr, Zhang et al. 
1988) and the effect of conformational structure on its antigenic properties (Fan and Stephens 
1997). Therefore, the classic method to analyse the function and to characterise the antigenic 
properties of MOMP is not available.
The need for a reliable source of MOMP has prompted the development of a range of 
experimental techniques to purify this protein, but their results have been mixed (Taylor, 
Whittum-Hudson et al. 1988). Such purified MOMP has been used to study its structural and
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functional properties, to develop vaccines against chlamydial infection and to set up new 
serological tests to detect chlamydial infection in clinical trials (Batteiger, Newhall et al. 
1986; Baehr, Zhang et al. 1988; Baud, Regan et al. 2010; Lu, Wang et al. 2010). There have 
been several reports about the successful purification of MOMP from EBs from several 
Chlamydia species using different methodologies including the use of high performance 
liquid chromatography (HPLC) to separate proteins from extracts obtained using sodium 
dodecyl sulphate (Taylor, Whittum-Hudson et al. 1988). The protein obtained using this 
method has been used to develop a vaccine and to study the molecular structure of MOMP. 
Unfortunately, this purification method had a deleterious effect on MOMP epitopes as it 
employed strongly denaturing conditions. This led to poor immuno-protection against 
chlamydial infection due to failure to induce antibody immune response caused by 
misinterpretation of three-dimensional MOMP structures (Taylor, Whittum-Hudson et al. 
1988). Furthermore, it has been reported that the use of this method has resulted in 
contamination of the MOMP extract with other Chlamydiae cell membrane proteins 
(Batteiger, Rank et al. 1993).
The ionic detergent, sodium lauroyl sarcosinate (sarkosyl) and the non-ionic detergent 
octyl-(3 glucopyonoside are alternative buffers used to purify MOMP (Bavoil, Ohlin et al. 
1984). Compared to the SDS method, these detergents do not affect the conformational 
structure of MOMP’s epitopes (Bavoil, Ohlin et al. 1984). However, extracting and purifying 
MOMP from EBs is still a daunting and challenging task due to factors such as: difficulties in 
growing Chlamydia on a large scale (Hoelzle, Hoelzle et al. 2003); insufficient protein yields 
from the purification process, and the high cost of purification and reconstitution whilst 
maintaining MOMP’s natural folding form (Pal, Theodor et al. 2001; Pal, Davis et al. 2002).
An alternative experimental approach that has been used to produce MOMP protein is 
to clone the gene that encodes it and express it in different vectors. The use of E. coli has 
been the most common heterologous system used for this purpose. Cloning in E. coli has 
facilitated the characterisation of the antigenic and biological properties of this protein 
(Stephens, Wagar et al. 1988; Kaul, Duncan et al. 1990; Koehler, Birkelund et al. 1992; 
Dascher, Roll et al. 1993; Manning and Stewart 1993; Su, Raymond et al. 1996; Wyllie, 
Longbottom et al. 1999; Jones, Kubo et al. 2000; Hoelzle, Hoelzle et al. 2003). Different 
forms of rMOMP have also been expressed in E. coli to study specific experimental questions 
regarding MOMP function. For example, the whole MOMP molecule or its truncated form 
lacking the signal peptide sequence have been cloned to investigate MOMP’s localisation on
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the cell membrane of Chlamydiae and the mechanism of interaction with other cell 
membrane proteins (Hoelzle, Hoelzle et al. 2003; Findlay, McClafferty et al. 2005). rMOMP 
expressed in E. coli has been used to search for T and B cell epitopes for vaccine 
development (Su, Morrison et al. 1990; Ortiz, Demick et al. 1996; Kim, Angevine et al. 
1999). In addition, it has been found that using rMOMP fusion proteins or a cocktail of 
different MOMP epitopes expressed in E. coli simultaneously has enhanced its 
immunogenicity in experimental vaccination studies (Toye, Zhong et al. 1990; Hayes, Conlan 
et al. 1991). However, the expression of rMOMP in E. coli has a major drawback due to the 
contamination of the culture system with E. coli derived LPS, which interferes with the 
biological effect of rMOMP and thus the interpretation of results (Tuffrey, Alexander et al. 
1992; Pal, Theodor et al. 1997).
Other groups have tried to overcome the LPS contamination issue by using cell 
culture expression systems such as C0S7 cells and other eukaryotic cells that involve cloning 
the ompl gene encoding MOMP in a suitable eukaryotic expression vector (Vanrompay, Cox 
et al. 1998; Penttila, Vuola et al. 2000). However, these eukaryotic cell expression systems 
have shown poor efficiency, resulting in a very low protein expression and recovery rate 
(Penttila, Tammiruusu et al. 2004). In order to overcome these difficulties, scientists have 
also used LPS-cleaned MOMP DNA to directly immunise animals (Zhang, Yang et al. 1997; 
Zhang, Yang et al. 1999). This method has been used by different groups to characterise the 
immunogenicity of MOMP or for use as a vaccine because this system (MOMP DNA) 
guarantees a constant and rapid source of protein production (Pal, Barnhart et al. 1999; 
Penttila, Vuola et al. 2000; Penttila, Tammiruusu et al. 2004).
There is also a considerable amount of literature in relation to the expression of 
rMOMP, or specific domains of rMOMP in other heterologous vectors including Vibrio 
cholerae ghost (VCG) (Eko, He et al. 2004), Salmonella typhimurium (Hayes, Conlan et al. 
1991) and poliovirus (Murdin, Dunn et al. 2000). These heterologous vectors have been also 
used as adjuvants to enhance the immunogenicity of MOMP in order to protect against 
chlamydial infection. However, most of these studies failed to induce short or long term 
protection against infection due to in adequate cellular immune responses or failure antibody 
immune responses induction.
The purpose of the research presented in this chapter was to express the MOMP of 
Ch. pneumoniae in a different surrogate bacterium with the ultimate goal of characterising the
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immune response induced by this recombinant protein in vivo and in vitro. Immune-response 
characterisation is addressed in the following chapters, with the particular emphasis to 
examining the effect of this protein on atherosclerosis development. However, before 
moving into this aim, we first needed to find a suitable technique to produce MOMP without 
interference from other antigenic components of the Chlamydophila cell wall. We therefore 
decided to clone and express MOMP in Mycobacterium vaccae, chosen as a non-pathogenic 
heterologous system that acts as a surrogate for protein expression.
M. vaccae is a Gram positive, soil-dwelling, non-pathogenic bacterium which have 
been used in clinical studies to enhance immunity against tuberculosis as an adjuvant 
(Stanford, Bahr et al. 1990; Stanford, Rook et al. 1990; Vuorio, Andersson et al. 1999). This 
bacterium was approved by the WHO as a clinical immunisation agent in the 1990s (WHO 
1991). The bacterium has thus been used in patients with pulmonary tuberculosis and 
melanoma (Maraveyas, Baban et al. 1999; Johnson, Kamya et al. 2000), prostate cancer 
(Hrouda, Baban et al. 1998) and lung cancer (Assersohn, Souberbielle et al. 2002). 
Moreover, in Tanzania, these non-pathogenic bacteria have been used clinically to intra- 
dermally immunise HIV positive people against tuberculosis, instead of using the more 
traditional Bacille Calmette-Guerin (BCG). Results of these immunisation have been good, 
showing safety and stability after immunisation (Lahey, Arbeit et al. 2010; Yang, Chen et al. 
2010). The genetic system of M. vaccae is versatile and has the ability to express a wide 
range of recombinant antigens including M. tuberculosis and other heterologous antigens 
(Garbe, Barathi et al. 1994). Thus, M. vaccae was considered a suitable expression system in 
which to express the MOMP of Ch. pneumoniae.
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3.2. SPECIFIC AIM
The main aim of this chapter was to clone and express the Ch. pneumoniae MOMP in 
M. vaccae, for its subsequent use in other chapters to immunise animals in order to 
characterise the immune response induced by this protein.
3.3. OBJECTIVES
The aim of this chapter will be achieved by:
• Amplifying the ompl gene encoding MOMP using two different sets of primers 
in order to express the entire MOMP gene or the truncated form; missing the 
signal peptide sequence.
• Cloning both MOMP versions into the pSMT176 mycobacterial expression 
vector.
• Transforming M. vaccae with the constructed vectors and expressing functional 
proteins to provide a flexible model to study the immune response induced by 
rMOMP.
• Cloning and expressing the ompl gene in E. coli to purify the rMOMP needed for 
further studies (as an antigen for antibody detection using ELISA).
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3.4. MATERIALS AND METHODS
3.4.1. Materials
3.4.1.1. Bacterial strains and culture conditions
For gene cloning, E. coli strain DH5a (Invitrogen, UK) was grown in LB agar or 
broth at 37°C and supplemented with lOOpg/mL ampicillin (Sigma, UK), SOpg/mL 
hygromycin B (Roche, UK) or 50pg/mL kanamycine (Roche, UK), as appropriate. M 
vaccae (University of Surrey bacteria collection) was grown on Nutrient Broth 2 (NB2) and 
NB2 agar supplemented with 50pg/mL hygromycin B. For protein purification, One Shot ® 
BL21 (DE3) pLysS eompetent E. coli eells (Invitrogen, UK) were also eultured in LB media 
supplemented with lOOpg/mL ampicillin (Sigma, UK). All media recipes were listed in 
Appendix 1, Table 1.
T ab le  3 .1 . P la sm id s  u s e d  in th is  s tu d y .
Name Supplier Size
pcDNA3.1 Invitrogen, UK 3.4Kb
pcDNA-MOMP Kindly provided by Dr. Puolakkainen, Department of Virology, Haartman Institute, University of Helsinki, Finland* 5.3 Kb
psMT176 Kindly provided by Dr Graham Stewart, FHMS, University o f Surrey, UK** 4.6Kb
pCR-Bluntll-TOPO® Invitrogen, UK 3.5Kb
pETlOl/D-TOPO® Invitrogen, UK 5.75Kb
^Department of Virology, Haartman Institute, University of Helsinki, Finland; **FHMS, University of Surrey, UK. (Appendix 1, 
Figure 1)
T ab le  3 .2 . R estr ic tio n  e n d o n u c le a s e  e n z y m e s  u s e d  In th is  s tu d y
Enzyme Supplier Cutting sequence
Spel New England, Biolab, US 5 A T C T A G T 3
Bam\{\ Promega, UK 5 G T G A T C C 3 ’
Xbal New England, Biolab, US 5T T C T A G A 3’
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3.4.2. Methods
3.4.2.1. Cloning and expression o f MOMP in M. vaccae
3.4.2.1.1. Amplification of the MOMP gene (ompl) by PCR
The Ch. pneumoniae MOMP gene, ompl (Genbank accession no. M69217) (Perez 
Melgosa Mercedes 1991) was amplified by PCR from the mammalian expression vector 
pcDNA-MOMP (Saiki, Scharf et al. 1985; Saiki, Gelfand et al. 1988). All PCR reactions 
were performed using a GeneAmp PCR system 9700 Thermocycler (ABI, Foster city, US). 
Two sets of oligonueleotide primers were designed based on the DNA sequences acquired 
from GenBank in order to amplify the MOMP DNA. Primers were constructed with terminal 
Spel endonuclease restriction sites (Rosch and Bothe 2005), see Table 3.3. The 
oligonucleotide primers were designed using Vector NTI 9.0TM PAI software (Invitrogen, 
UK). The first set of primers was used to amplify full-length MOMP; designated 
MOMP+SPS to show the inclusion of the signal peptide sequenee. The reaction was set up 
by using 0.5pM forward primer, MOMP-1 (sense) and an equal amount of reverse primer, 
MOMP-3 (anti-sense). The MOMP-3 primer included a histidine tag (His-Tag) sequenee. 
The second set of primers was used to amplify MOMP, excluding the DNA coding for the 
signal peptide sequenee (MOMP-SPS). These primers were both used at concentrations of 
0.5 pM.
In addition to the primers and the DNA template, the reaetion mixture contained 2.25mM 
deoxynucleotide triphosphates (dNTPs), 4mM MgCb, 2mM Tris-HCl buffer pH 8.0, 5mM 
KCl and 0.5U of high fidelity PCR system thermostable DNA polymerase (Roche, UK), 
Cyeling parameters were adjusted as follows:
- Initialisation step: samples were heated at 95°C for 1 min.
- Dénaturation step: DNA melted by disrupting the hydrogen bonds between
complementary bases, yielding single-stranded DNA molecules by heating at 95°C
(30 sec).
- Annealing: the temperature of the reaction lowered to 50°C (30 sec).
- Extension/elongation step: the reaction sample heated at 72°C (1 min). These three
previous steps were repeated 30 cycles.
- Termination with a final extension step at 72°C for 7 min for elongation.
- Cooling at 4°C.
Reaction products were visualised on a 0.8% agarose gel using eleetrophoresis. Fresh PCR 
products were used directly in the TOPO® cloning reaction.
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Table 3.3. Primer sequence and restriction endonuclease (REN) sites of fragments used to
Construct Prime Sequences Restrictionsite Description
Size of 
PCR 
product
MOMP+SPS
MOMP-1
SENSE
MOMP-3
ANTI-SENSE
GGACTAGTGGAGGATTCAC 
CAT GAAAAAACTCT TAAAG
TC
Spel
U ntruncated 
w ith His-tag
1217 bp
GGACTAGTTTAGTGGTGAT
GGTGATGATGGAATCTGAA
CTGACCAGATA
Spel
MOMP-SPS
MOMP-2
SENSE
GGAC TAGTGGAGGAT T CAC
CATGTGCCTGTAGGGAACC
CTTC
Spel
T runcated with 
His-tag
1148 bp
MOMP-3 
ANTI SENSE
GGACTAGTTTAGTGGTGAT
GGTGATGATGGAATCTGAA
CTGACCAGATA
Spel
3.4.2.I.2. Agarose gel electrophoresis
Visualisation and analysis of DNA fragments was carried out using agarose gels at a 
concentration 0.8% (w/v). Then, O.lpg/mL of ethidium bromide was added to the agarose 
solution and it was placed in the gel caster until set and ran it in IX TAE (Tris-acetate 
EDTA) buffer using an electrophoresis tank (EMBL-tec, UK). PCR samples were mixed 
with Blue/Orange 6X Loading dye (Promega, UK) and carefully loaded into the gel. Ikb 
DNA ladder (Promega, UK) was used as a reference against which fragment size was 
determined. Electrophoresis was carried out at 120V until the blue/orange loading dye was 
sufficiently separated to distinguish individual bands.
The DNA was visualized under UV light using a UV transilluminator and a digital 
image was acquired using Syngene software (Syngene, UK). DNA fragments were then 
excised from the gel using a sharp blade under UV light and purified using a Qiagen Gel 
Extraction Kit (Qiagen, UK) following manufacturer’s instructions. The kit used is designed 
to extract and purify DNA fragments between 70bp to lOkb from standard or low-melt 
agarose gels, which is within the range of the fragments to be purified.
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3.4.2.1.3. Construction of pMOMP+SPS and pMOMP-SPS expression vectors
A  1.1 kb DNA fragment encoding the Ch. pneumoniae MOMP was amplified from 
pcDNA-MOMP plasmid by PCR as deseribed above using primers containing the Spel 
endonuclease enzyme restriction site. MOMP-1 and MOMP-2 sense primers contained an 
ATG start codon. MOMP-3 antisense primer introduced a His-Tag sequence at the C- 
terminal end and a TAA stop codon. The MOMP gene was then directly cloned into a 3.5kb 
pCR-TOPO™ vector encoding a kanamycin resistant gene (Invitrogen, UK). Subsequently, 
the pCR-Blunt II-TOPO constructs were transformed into eompetent E. coli cells (Invitrogen, 
UK). The transformation was carried out following the kit’s instructions, briefly IpL of 
reaction mix [fresh PCR fragments (MOMP-SPS or MOMP-SPS), salt solution, H2O and 
pCR-Blunt II-TOPO plasmid] with 50pL of eompetent E. coli and incubation on ice for 30 
min. Cells were then heat shocked at 42°C for 1 min and brought back immediately to ice for 
2 min. 450pL of pre-warmed Super optimum catobolite repression medium (SOC), at 37°C, 
were added to the mixture before a further incubation at 37°C with constant shaking for 1.5 
hr. 100 |iL of the mixture was then plated out on pre-warmed LB agar plates eontaining 
50jig/mL kanamycin. Transformants were checked for inserts by inoculation of colonies into 
5mL LB broth supplemented with 50pg/mL of kanamycin and incubated at 37°C with 
shaking overnight. The plasmid DNA was then purified using a Qiagen miniprep 250 kit 
(Qiagen, UK) following the manufacturer’s instructions.
3.4.2.1.4. Ligation of sub-cionedfragments
The target gene was excised from the TOPO vector using Spel restriction 
endonuclease. In parallel, the plasmid vector pSMT176 encoding a hygromycin-B resistant 
gene (Stewart, Robertson et al. 2004) was restrieted using the same enzyme and treated with 
O.OlU/pmol of calf intestinal alkaline phosphatase (CLAP) (Promega, UK) at 37°C for 40 min 
to remove 5 phosphate groups from the veetor to prevent re-circularization (self-ligation) 
(Sambrook 2001). The gene fragments and plasmids were separated using 0.8% (w/v) 
agarose gel eleetrophoresis and isolated using a gel extraction kit (Qiagen, UK) according to 
manufacturer’s instructions. The MOMP DNA fragments (MOMP+SPS and MOMP-SPS) 
were ligated separately into the pSMT176 vector using a 3:1 insert gene: veetor molar ratio. 
The concentration of the digested fragments was determined by eomparing to a Ikb DNA 
ladder on a gel (Promega, UK), (Appendix 1, Figure 2 & Table 2). The following equation 
was used to calculate the appropriate amount of product (insert) to veetor:
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ng o f vector x kb size o f insert  y  Insert: vector m olar ratio = ng o f insert
kb size o f vector
The ligation reaction was performed using a T4 DNA ligase enzyme (Roche, UK) and 
incubated overnight at 16°C. Suecessful ligation products were screened by gel 
electrophoresis and then Ing of ligated plasmid (pMOMP+SPS and pMOMP-SPS) was used 
to transform competent E. coli (DH5a) as described previously.
3.4.2.1.5. Screening colonies for the presence of inserts
Briefly, ten colonies from each transformation were picked and inoculated into 5mL 
fresh LB broth with 50|xg/mL hygromycin and incubated overnight at 37°C with shaking. 
Following incubation, plasmid DNA was purified using a QIAprep Spin Miniprep kit 
(Qiagen, UK), following the manufacturer’s instructions. Orientation of the inserted 
fragments was assessed by restriction endonuclease digestion with BamHl (Promega, UK). 
The restrietion products were visualised by agarose gel electrophoresis.
3.4.2.1.6. Transformation of M. vaccae by electroporation
M. vaccae was prepared by inoculating 80mL of NB2 broth (OXOID, UK) 
supplemented with 0.05% (v/v) Tween-80 and 0.2% (v/v) glyeerol with 5mL of late 
exponential phase culture in a sterile conical flask. The culture was grown for 7 days with 
constant shaking (225 rpm) at 30°C until it became turbid, then the culture was transferred to 
50mL centrifuge tubes for eentrifugation (1500 x g, 15 min). The supernatant was removed 
and the pellet was resuspended and washed twice in 40mL of 10% (v/v) sterile glycerol. 
Subsequently, the pellet was resuspended in ImL of 10% of glyeerol and stored at -80°C. 
Approximately, 200ng of each plasmid were transferred to pre-chilled 0.2cm electroporation 
cuvettes (Thistle Scientific, UK). The transformation control (negative control) was prepared 
using 5pL of nuelease free water instead of plasmid. A 200pL aliquot of M. vaccae was 
added to each cuvette. The mixture was pipetted up and down several times to mix and the 
cuvettes were incubated at 30°C for 10 min. The Bio-Rad Gene Puiser electroporator (Bio- 
Rad, US) was connected and the pulse controller was set to a resistanee of 1000 ohms, a 
eapacitanee of 25pF and a voltage of 2.5kv. Eaeh cuvette was electroporated individually. 
After eleetroporation, ImL of NB2 broth media was added to eaeh electroporated mixture 
and mixed by pipetting up and down. The mixture was transferred into bijous and ineubated 
overnight at 30°C with constant shaking. Following the incubation, the transformed cultures
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from each reaction were plated out onto NB2 media supplemented with 50pg/mL 
hygromycin. Plates were incubated at 30°C for 7 days.
3.4.2.1.7. Detection of MOMP expression by M. vaccae
In order to determine if the target protein had been expressed by M. vaccae, the two 
groups of transformed M. vaccae colonies were analysed by sodium dodecyl sulphate- 
polyacrylamide gel electrophoresis (SDS-PAGE) and stained with Coomassie brilliant blue 
(Laemmli 1970).
Sample preparation
Several colonies were pieked from each reaction culture and inoculated into 5mL 
NB2 broth containing 50pg/mL hygromycin then incubated for 7 days at 30°C with shaking. 
Following the incubation, cultures were spun down at 4000 x g for 10 min at 20°C. The cell 
pellets were washed twice with PBS and resuspended in 300pL of IX sample buffer [40% 
(v/v) glyeerol, 4% (w/v) SDS, 0.05% (w/v) bromophenol blue, 50% (v/v) stacking gel buffer,
19 mL of deionised H2O, 1% (v/v) p-mercaptoethanol]. Cells were lysed in the presenee of 
50mg of glass beads (0.1mm diameter) using pulses at 6000 x g, three times every 30 sec in a 
mini-bead beater (FAST Prep FP 120-biolOl; Thermo Savant, UK) with intervals of 30 sec 
rest on ice. The mixture was then boiled for 10 min and subsequently centrifuged at the 6000 
X g for another 10 min (Hurley, Splitter et al. 1987).
SDS PAGE
Acrylamide gels containing 12% (v/v) acrylamide and 0.1% (w/v) SDS were prepared 
as follows: a resolving gel was firstly prepared by adding 3mL of 40% bis-acrylamide 
(Sigma, UK) in a 20mL tube with 2.5mL resolving gel buffer [1.5M Tris-HCl, 0.4% SDS 
(w/v), pH 8.8] and 4.5mL distilled water. Then, lOOpL of 10% (w/v) ammonium persulphate 
(Sigma, UK) in distilled water was added followed by lOpL of tetramethylethelinediamine 
(TEMED) (Sigma, UK). The gel was poured using a 1mm spacer plate. Butanol, ImL, was 
added on the top of the resolving gel to remove air bubbles and the gel was allowed to set for
20 min. Stacking gel was prepared by adding 750pL of 40% bis-acrylamide followed by 
1.5mL stacking gel buffer (0.5M Tris-HCl; pH 6.8) and 3.75mL distilled water. 60pL of 10% 
(w/v) ammonium persulphate was added together with 6pL of TEMED. After removing the 
butanol solution from the top of resolving gel the stacking gel [0.5M Tris-HCl, 0.4% (w/v) 
SDS; pH 6.8] was poured on the top. A comb of 10 wells (Bio-Rad, UK) was inserted gently
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and the gel was left to set for another 20 min at RT. SDS running buffer was prepared by 
diluting 10 X pre-prepared SDS running buffer [0.5 M glycine, 0.25M Tris, 1% (w/v) SDS] 
(Bio-Rad, UK). For running the gel, the electrophoresis tank was toped up with IL of 
running buffer. The combs were removed from the gels and before loading samples, the 
wells were washed with distilled water. The gels were placed in the tank and submerged 
completely in the running buffer. 15pL of samples were loaded into each well eareftilly. The 
same volume of rainbow markers (GE Healtheare, UK) was loaded in parallel to determine 
the relative molecular weight of each protein. Electrophoresis was carried out at 120 V at RT 
until the bromophenol blue entered the running buffer.
Detection of MOMP expression by Coomassie® Blue staining
Following SDS-PAGE, the gels were stained with Coomassie® Blue (Bio-Rad, UK) 
for one hour (Reisner 1975). The gels were washed several times with de-staining solution 
[10% (v/v) methanol (Fischer Scientifle, UK); 5% (v/v) acetic acid (Fisher Scientifie, UK) in 
distilled water] overnight with in order to remove excess stain so that the protein bands eould 
be clearly seen.
Detection protein expression bv Western blot
After protein samples were resolved by SDS-PAGE, proteins were blotted onto a 
polyvinylidene fluoride (PVDF) membrane (HyBond, Amersham Biosciences, UK). PVDF 
membrane was pre-equilibrated with 100% (v/v) methanol for 5 min then immersed in 
transfer buffer with the protein gel [0.25M Tris base; 0.187M glycine in 20% (v/v) methanol] 
for 15 min. The acrylamide gel was placed in a blotting unit (Bio-Rad, Trans-blot SD semi­
dry transfer cells, UK) that had been covered with filter paper (Bio-Rad, UK) pre-soaked with 
transfer buffer on both sides. The membrane was kept wet all times and plaeed on top of the 
gel. Transfer was undertaken at lOV for 3 hrs. The membrane was then removed from the 
blotting unit and stained with Ponceau’s Red (Fluka, UK) to visualise the protein bands and 
to confirm that the transfer was performed successfully. The Ponceau’s red stain was 
removed by washing the membrane several times with distilled water.
Blocking of non-specific binding sites on the membrane was carried out by incubating 
with blocking buffer [1% (w/v) BSA (Fluka, UK); 5% (w/v) skimmed milk powder in PBS] 
and incubated on a roller overnight at 4°C. Blocking buffer was then removed and the 
membrane was incubated in PBS buffer containing 50pg/mL of primary anti-His-Tag
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antibody (Abeam, UK) diluted in blocking buffer for one hour. The primary antibody was 
then discarded and the membrane washed three times for 10 min each using 0.01% (v/v) 
Tween-20 in PBS. The membrane was then incubated with 2.5pg/mL of secondary antibody 
(goat anti-mouse IgG conjugated horseradish peroxidase antibody (Abeam, UK) for one hour 
at RT in PBS and then washed as described above.
Immuno-reactivity was visualised using the enhanced chemiluminescence substrate 
(ECL) detection system (Amersham, GE healthcare, UK). The membrane was processed and 
exposed to a film in a dark room as follows: The membrane was soaked first with the 
prepared solution of ECL following the manufacturer’s instructions, and was then placed into 
a photographic cassette and exposed to X-ray film (Amersham, GE healthcare, UK) for 3-10 
min. during the exposure time, trays were prepared with Polyeon manual X-ray developer, 
another with Amfix manual X-ray Fixer (Champion Photochemistry, UK) and the other tray 
was filled with distilled water for a washing stage. The film was then transferred 
immediately into the developing solution for 1 min and washed briefly with distilled water 
before it was placed fixative solution for at least five min or until the film baekground was 
completely clear. The film was then rinsed under running tap water and placed on a raek to 
dry.
3.4.2.2. Preparation ofM. vaccae expressing MOMP for animal immunisation
Colonies of wild-type M. vaccae and M. vaccae expressing MOMP with and without 
signal peptide sequenee were inoculated separately into lOOmL of NB2 broth media 
supplemented with SOpg/mL hygromycin and incubated at 30°C for 7 days. Cells were 
colleeted by centrifugation at 4000 x g for 10 min at 20°C. Cell pellets were subsequently 
washed twice with 0.05% (v/v) Tween-80 in PBS. Cells were then resuspended in 50mL of 
10% glycerol for storage at -80°C until use. The viable count of M. vaccae inoculation was 
assessed by plating thawed aliquots on NB2 agar and counting colony forming units (CPU). 
These values were used to adjust baeterial load in the inocula.
3.4.2.3. Cloning and expression MOMP in E. coli
DNA was amplified from pcDNA-MOMP using two different sets of primers, as 
shown in table 3.4. The sequenee of the ompl gene from Ch. pneumoniae (Genbank 
M69230) was used to design the primers noted as Topol, TopoII and TopoIII, see Table 3.4. 
PCR amplifieation was carried out as mentioned in section 3.4.2.1.1 using the same 
conditions. PCR products were visualised using gel electrophoresis as described above.
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T ab le  3 .4 . S e q u e n c e s  o f  p r im ers u s e d  to  c lo n e  MOMP DNA in p E T 1 0 1 -T o p o  v e c to r . CAC CA  
s e q u e n c e s  fo r  s e n s e  p r im ers w e r e  a d d e d  at th e  5 ’ e n d  fo llo w in g  m a n u fa c tu rer ’s  
r e c o m m e n d a tio n .
C onstruct Prim er S e q u e n c e s S ta te
S ize o f  
PCR 
p rod u cts
Topo
MOMP+SPS
Topol
Sense
5 " -CACCATGAAAAAAACTCTAAAGTC-3"
Un­
trunca ted
1199 bp
TopoIII
A nti-
Sense
5 " -GAATCTGAACTGACCAGATA-3'
Topo
MOMP-SPS
TopoII
sense
5 ' -CACCATGTTGCCTGTAGGGAACCCTTC-3'
T runcated 1130 bpTopoIII
A nti­
sense
5 ' -GAATCTGAACTGACCAGATA-3'
3.4.2.3.I. Construction of pET-TopoMOMP+SPS and pET-TopoMOMP-SPS
Blunt end PCR products (TopoMOMP+SPS and TopoMOMP-SPS) were cloned 
directly into a pETlOl/D-TOPO vector provided with His-tag sequence using the 
Champion™ PET Directional TOPO® expression kit (Invitrogen, UK) following 
manufacturer’s instructions. pET-TopoMOMP+SPS and pET-TopoMOMP-SPS were 
transformed into Top 10 competent E. coli cells provided with the kit and cells were plated on 
LB agar supplemented with lOOpg/mL ampicillin. The s success of the transformation was 
checked by inoculation of 5mL of LB broth medium supplemented with lOOpg/mL 
ampicillin with several colonies from each transformation reaction. Subsequently, the 
resulting plasmids were screened and checked for correct orientation of the inserted gene 
using Xba\ restriction endonuclease (New England Biolabs, US). The restricted fragments 
were visualised using agarose gel electrophoresis.
3.4.23.2. Detection of MOMP protein expression in E. coil
The BL21 Star E. coli strain provided with the Zero blunt Topo PCR cloning kit 
(Invitrogen, UK) was used to express MOMP protein. Bacteria were transformed with pET- 
TopoMOMP+SPS and pET-TopoMOMP-SPS plasmids separately as described above. 
Transformed bacteria were plated on LB agar supplemented with lOOpg/mL ampicillin
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overnight at 37°C. Expression conditions were optimized by inoculating lOmL of LB 
containing lOOpg/mL ampicillin with transformed cells and incubated overnight at 37°C. 
Protein expression was induced using 0.5mM of Dioxane-free Isopropyl p-D-1- 
thiogalactopyranoside (IPTG) (Promega, UK), once the optical density of the baeterial 
culture reached the exponential phase (0.6 - 0.8 OD at 600nm). Aliquots (500pL) of indueed 
culture were taken at time 0 (time of induetion) and at 1 hr intervals thereafter up to 4 hrs 
post induction, in parallel with un-induced bacteria cultures. The bacterial cultures were then 
centrifuged (4000 x g; for 15 min at 4°C) and bacterial pellets were frozen at -20°C for 
subsequent protein detection and purification. The expression level of MOMP protein was 
analysed by Coomassie® Blue staining and Western blot analysis as described above.
3.4.2.4. Endotoxin-free plasmid purification for immunisation
pcDNA-MOMP plasmids and pcDNA3.1 (empty) plasmids were purified under 
endotoxin-free conditions using a Qiagen Endotoxin Free Plasmid kit (Qiagen, UK), 
following manufacturer’s instructions prior to animal immunisation.
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3.5. RESULTS
3.5.1. Cloning and expression MOMP in M, vaccae
3.5.1.1. Construction pMOMP+SPS andpMOMP-SPSplasmids
Ompl, Ch. pneumoniae MOMP gene, was amplified from peDNA-MOMP by using 
two different sets of oligonucleotide primers, forming two different fragments of MOMP 
gene one with and the other one without signal peptide sequence. Two different sizes of 
MOMP fragments had been visualised by ethidium bromide using 0.8% of agaros gel. The 
fragment detected at 1217 bp corresponds to the full length of MOMP gene with signal 
peptide sequence (MOMP+SPS) and the other fragment deteeted at 1148 bp eorresponds to 
MOMP gene without N terminal signal peptide sequence, see Figure 3.2 A.
An intermediate sub-cloning step was used to improve the effieiency of cloning into 
the mycobacterial expression vector, pSMT176. In this step, the freshly amplified versions of 
the ompl gene were inserted into the pCR-Blunt II-TOPO vector and the inserted fragment 
was then excised from the TOPO vector using Spel restriction endonuclease digestion, see 
Figure 3.2 B. The fragments were then sub-eloned into the E. co//-mycobacterium shuttle 
expression plasmid pSMT176, which was also linearised by digestion with a Spel restriction 
enzyme. Subsequently, two plasmids were generated: pMOMP+SPS and pMOMP-SPS, 
whieh were used to express MOMP protein in M. vaccae.
In order to check the eorreet orientation of the MOMP inserts, plasmids were digested 
with restriction endonuclease enzyme BamHl. The two bands expected after BamRl digestion 
were (4845 bp, 906 bp) and (4776 bp, 906 bp) for pMOMP+SPS and pMOMP-SPS, 
respectively had been deteeted, see Figure 3.2 C. Myeobaeterium shuttle plasmid psMT176 
expressing MOMP, (pMOMP+SPS and pMOMP-SPS), was constructed as described in 
Figure 3.1.
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Ompl (MOMP)
PCR amplification
pcDNA-MOMP 
6521bp
SPS O m p l (MOMP) ^
0 .p „ M 0 M P )
SPS O m pf (MOMP)
pMOMP
+SPS
5780bp
His
O m pf (MOMP)
pCR-Blunt
ll-Topo
3519
PSM T176
4563
Digested by Spef
O m p l (MOMP) Spel
Om pf(M O M P)
pCR-Blunt
ll-Topo
3519
pMOMP-
SPS
5711bp
F igu re 3 .1 . D ia g ra m m a tic  su m m a ry  o f  th e  s t e p s  fo r  th e  g e n e r a t io n  o f  pM O M P +SP S an d  pM OM P- 
S P S  p la s m id s . (A) The omp1 gene from the eukaryotic expression vector pcDNA-M O M P (6521 bp) was 
amplified using two d ifferent sets o f primers, leading to two d ifferent fragm ents of MOMP; one including 
the 23 amino acid signal peptide sequence (1217 bp) and the other lacking this signal peptide (1148 bp). 
Both amplified sequences had a 6x His sequence at the C -term inal end and Spel restriction sites at both 
ends. (B) Each fragm ent was cloned separately into the pC R -B luntll-TO PO  plasmid to enhance the 
ligation with the shuttle plasmid. (C) MOMP fragm ents were excised by Spel restriction digestion from 
pGR-BLUNT II-TOPO and the pSMT176 plasmid was linearised with the sam e digestion and treated with 
CIAP enzyme. (D) The excised fragm ents were sub-cloned into pSMT176 (4563 bp) generating two 
different plasmids; pMOMP+SPS and pM OM P-SPS o f 5780 bp and 5711 bp, respectively.
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DNA ladder MOMP+SPS MOMP-SPS
M W o f lOObp
(D MOMP+SPS M O M P-SPS
1 2 3 4 5 6 7 8  9 10 11 12 13 14 15 18
M W of 1Kb
pMOMP+SPS pMOMP-SPS
1 2 3 4 5  6 7 8 9 10  11 12 13 14 15 16 17  18
MW o f  1 Kb
F igu re 3 .2 . T h e MOMP g e n e  fr a g m e n ts  am p lified  by PC R  an d  c lo n e d  in to  th e  M y co b a c ter iu m  
sh u t t le  p la sm id  p sM T 176. (A). The omp1 gene (lane 1: the entire MOMP gene; lane 2: MOMP gene 
w ithout signal peptide sequence) amplified from pcDNA-M O M P plasm id using two d ifferent sets of 
primers. (B). Lanes 2, 4, 5, 6, 8 and 10 refer to MOMP gene fragm ents containing signal sequence 
(M OMP+SPS) excised from pC R-B luntll-TO PO  using an Spel restriction endonuclease enzyme; 
whereas lanes 1 , 3 , 7  and 9 show pC R -B luntll-TO PO  plasm ids containing the full length MOMP gene 
extracted from different E. coli colonies. Lanes 11-15 show the MOMP gene w ithout signal peptide 
sequence, excised from pC R-B luntll-TO PO  using the sam e restriction endonuclease enzyme, w hereas 
lanes 11 and 14 show two bands corresponding to pC R -B luntll-TO PO  plasm ids cloned w ith a 
truncated form of the MOMP gene before restriction digestion w ith Spel. (C). The correct orientation o f 
MOMP fragm ents cloned in psMT176 were checked by using BamHl endonuclease restriction 
digestion; giving two bands of different sizes (4845 bp, 906 bp, lanes 3, 5, 7 and 9) running in parallel 
to un-cut pMOMP+SPS plasm ids with the full length o f MOMP gene (lanes 4, 6, 8 and 10). The 
orientation o f the truncated form o f MOMP gene inserted in psM T176 was checked by using the sam e 
restriction endonuclease enzym e leading to two fragm ents w ith sizes 4776 bp and 906 bp, (lanes 11, 
13, 15,and 17), whereas lanes 12, 14, 16 and 18 correspond to un-cut pMOMP-SPS. Lanes 1 and 2 
show one o f the colonies transform ed with pM OM P+SPS plasmid with the w rong orientation o f gene 
inserted.
3.5.1.2. Detection o f Ch. pneumoniae MOMP protein expression in M. vaccae
The expression of Ch. pneumoniae MOMP protein in M. vaccae was achieved after 
electroporation with the newly constructed plasmids (pMOMP+SPS and pMOMP-SPS). The 
number of transformed M. v<3cc*<5re-rMOMP-SPS was approximately 72 colonies; the number
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of M voccûre-rMOMP+SPS was 21 colonies, whereas the negative control gave no colonies. 
The expression of rMOMP was assessed by Western blot, see Figure 3.3. Two forms of 
rMOMP were detected in the SDS-PAGE. The lower molecular weight band was 
approximately 40kDa, corresponding to the mature form of the protein. The second form of 
MOMP was approximately 42kDa corresponding to rMOMP containing the additional 23 
amino acids of the signal peptide sequence. Coomassie staining did not show a clear 
detection of rMOMP expression as several bands of M vaccae proteins were of the same 
molecular weight, data not shown.
M. vaccae M. vaccae-rMOMP-SPS
M. vaccae- 
rMOMP+SPS
. . * * * • - .
40 kDa
F igu re  3 .3 . W estern  b lo t a n a ly s is  s h o w in g  rMOMP e x p r e s s e d  by M. vaccae. The first lane 
corresponds to w ild-type M vaccae lysate, lanes 2-7 show the protein expressed by different 
colonies o f M vaccae transform ed with pM O M P-SPS plasmid w ithout signal peptide sequence with 
a m olecular w eight o f 40kD a (M. vaccae-rM OM P-SPS). Lane 8 shows a higher band of 
approxim ately 42kDa, corresponding to rMOMP expressed by M. vaccae-rM OM P+SPS. The 
detection was performed by using a m ouse anti-H is-Tag monoclonal antibody.
3.5.2. rMOMP expressed by E. coli
3.5.2.1. C o n s tru c tio n  o f  M O M P  express ing  p la sm id s
Two different fragments of MOMP gene were amplified by PCR from pcDNA- 
MOMP using two different combinations of primers, see Figure 3.4 A . The size of the first 
fragment is approximately 1199 bp corresponding to the full length of ompl gene in addition 
to an upstream CACCA sequence recommended by the plasmid kit, denoted as Topo- 
MOMP+SPS. The size of the other fragment is 1130 bp corresponding to MOMP lacking the 
first 23 amino acids of the N-terminal coding for the signal peptide following the CACC 
sequence denoted as Topo-MOMP-SPS, see Figure 3.5 A. Both PCR fragments 
(TopoMOMP+SPS and TopoMOMP-SPS) were then inserted into the expression vector, 
pETlOl/D-TOPO used to control the expression of MOMP induced by IPTG in E. coli, see 
Figure 3.4 C. The plasmid also contained a His-Tag sequence at the C-terminal end to 
facilitate the detection and purification of MOMP, see Figure 3.4. Stable transformants were 
obtained when pET-TopoMOMP+SPS and pET-TopoMOMP-SPS were introduced into
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TOP 10 E. coll. The orientation of the gene was assessed by restriction endonuclease 
digestion using enzyme, see Figure 3.5 B.
Omp1 (MOMP) 1199bp
Omp1 (MOMP) 1130 bp
Omp1 (MOMP)
PCR amplification
pcDNA-MOMP 
6521b p
pET101d-
/Topo
Utx>a(3«50)
©
Omp1 (MOMP) 1199bp
pET-
TopoM OM +
S P S
6952b p
Omp1 (MOMP) 1130 bp
pET-
TopoM OM -
S P S
6883b p
F igu re 3 .4 . D ia g ra m m a tic  su m m a r y  o fth e  c o n s tr u c t io n  s t e p s  fo r  th e  e x p r e s s io n  p la s m id s  
pE T -T opoM O M P +SP S an d  pE T -T opoM O M P -SP S. (A) The omp1 gene encoding MOMP in the 
mammalian expression vector pcDNA-M O M P (6521 bp) was amplified by two sets o f prim ers in 
order to generate two fragm ents of MOMP protein,; one with signal peptide sequence called 
TopoM OM P+SPS (1199 bp) and the other w ithout it, called TopoM O M P-SPS (1130 bp). (B ) The 
PCR fragm ents were cloned into the E. coli expression vector pET101d/-Topo (5653 bp), which 
carries the ampicillin resistance gene, the high level IPTG inducible promoter, a C -term inal V5 
epitope and the C-term inal 6x His Tag sequence. (C) Two different constructed plasm ids w ere 
generated fo r expression of MOMP with and w ithout signal peptide in E. coli; pET-TopoM O M P+SPS 
and pET-TopoM OM P-SPS, respectively.
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DNA Ladder
isodwwww TopoMOMP-SPS TopoMOMP+SPS
MW of 1Kb
pET-TopoMOMP-SPS pET-TopoMOMP+SPS
1500
1000
7 50 R 1 2 3 4 5 6 7
MW of 1 Kb
F igu re 3 .5 . MOMP g e n e s  a m p lified  by PC R  an d  in se r te d  in pE T -101D -T O PO  to  e x p r e s s  rMOMP 
in £. coli. (A). MOMP gene w ithout signal peptide sequence (TopoM O M P-SPS) lanes: 1 & 2 and 
MOMP gene with signal peptide sequence (TopoM O M P+SPS) lanes: 3 & 4. (B ). The orientation of 
the MOMP gene either with or w ithout signal peptide sequence cloned into pET-101D-TO PO  plasmid 
was checked by restriction digestion using Xba\ endonuclease enzyme. Lanes 1 and 3 show  pET- 
TopoM OM P-SPS plasmid digested with Xba\ endonuclease enzyme, leading to two fragm ents o f the 
following sizes: 1018 bp and 5836 bp, whereas lanes 2 and 4 represent un-cut pET-TopoM OM P-SPS; 
approxim ately 6883bp. The orientation o f the untruncated form of MOMP inserted into the same 
plasmid was also exam ined using the sam e endonuclease enzyme, generating two bands at 
expecting sizes 1087 bp and 5836 bp, as shown in lanes 5 and 7. Lanes 6 and 8 show un-cut pET- 
TopoM OM P+SPS detected at an expecting size o f 6952bp.
3.5.2.2. Detection o f  MOMP expression in E. coli
For MOMP expression, the constructed plasmids were transformed into the BL21 
bacterial strain. Selected colonies were broth cultured and induced with IPTG to express the 
protein. Upon induction with IPTG, transformation with pET-TopoMOMP+SPS produced 
two bands after I hr, corresponding to pre-MOMP and a mature form of MOMP, from which 
the signal peptide was cleaved (Figure 3.6 A). However, at 3 hrs post-induction, a single band 
was produced at approximately 40kDa, corresponding to the mature MOMP protein only, see 
Figure 3.6 A. The BL21 bacterial strain transformed with pET-TopoMOMP-SPS and 
induced by IPTG showed a faint single band at 40kDa corresponding to mature form of
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MOMP protein; the intensity of this band was increased after 3 hrs induction, see Figure 3.6 
B.
® ®
(42kDa) Pre-MOMP 
(40kDa)MOMP
rMOMP + SPS rMOMP - SPS
F igu re 3 .6 . S D S -P A G E  a n a ly s is  o f  s a m p le s  from  an  in d u c t io n  s tu d y  o f  rMOMP p ro te in  in BL21
£. coli. BL21 E. co //ce lls  w ere transform ed with pET-TopoM OM P+SPS and pET-TopoM O M P-SPS 
constructs, cultured into 5m L o f LB broth, grown at 37°C with shaking until an ODeoo 0.5-1.0 was 
reached and then induced with 0.5mM IPTG. 500 pL sam ples were taken after 1 and 3 hrs post 
induction and were prepared as described in the m aterials and methods section. (A). rM OMP 
expression from cells transform ed with pET-TopoM O M P+SPS (with signal peptide sequence). Lane 
1: rMOMP induced after Ih r  and detected as two bands, the highest band detected at 42kD a 
corresponds to the pre-rMOMP form, while the lowest band detected at 40kDa corresponds to 
mature rMOMP. Lane 2; MOMP induced after 3 hrs, a single band at 40kDa is detected referring to 
the cleavage of signal peptide sequence. (B). rMOMP expression from cells transform ed with pET- 
TopoM OM P-SPS (w ithout signal peptide sequence). Lane 1: MOMP induced after 1 hr o f adding 
IPTG. Lane 2; MOMP induced after 3 hrs o f adding IPTG, the m olecular w eight fo r both bands was 
approxim ately 40kDa.
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3.6. DISCUSION
MOMP is a 40kDa protein localised in the cell membranes of EBs and RBs of 
Chamydophila (Caldwell, Kromhout et al. 1981). This protein plays a significant role as a 
structural protein (Hatch 1996), in eyto-adhesion (Su, Zhang et al. 1988) and as a porin 
(Bavoil, Ohlin et al. 1984; Wyllie, Ashley et al. 1998). The cloning and genetic manipulation 
of the ompl gene encoding the Ch. pneumoniae MOMP has been one of the biggest 
challenges for experimental attempts to evaluate the different functions and immunogenicity 
of this protein. To date, a mutant Chlamydia strain lacking this protein has been impossible 
to create (Montigiani, Falugi et al. 2002; Heuer, Kneip et al. 2007). Here, we successfully 
clone and express MOMP in E. coli and M. vaccae to provide a means to study the immune 
response to, and immuno-modulation by MOMP.
A considerable amount of literature has suggested that the signal peptide sequence of 
rMOMP is toxic and can therefore affect the viability of the surrogate bacteria and that the 
intracellular expression level of rMOMP without the sequence is higher than that achieved 
when the signal peptide sequence is present (Puohiniemi, Butcher et al. 1991; Daseher, Roll 
et al. 1993). Therefore, we decided to clone and express two different forms of MOMP (un­
truncated and truncated) in M. vaccae and E. coli. In order to engineer M. vaccae expressing 
MOMP, two forms of MOMP were amplified from pcDNA-MOMP by PCR and cloned into 
a commercial pCR-Blunt II-TOPO vector. This strategy was undertaken in order to enhance 
PCR fragment ligation with plasmids, as it is known that the extra Adenosin bases overhang 
at the 3’ of PCR fragment end of each strand can prevent the insertion of gene into the vector 
(Brown 2006. fourth edition). The pCR-Blunt II-TOPO vector is a linearised vector 
containing the Vaccinia virus DNA topoisomerase I. This vector has a tyrosyl residue (Tyr- 
274) at both ends that binds to the 3’ end of each DNA strand by a covalent bond using the 
energy that is released from the broken phosphodiester backbone. Subsequently, the 
phospho-tyrosyl bond formed between the DNA and the enzyme is attacked by the 5’ 
hydroxyl of the original cleaved strand, leading to the release of the topoisomerase enzyme 
(Shuman 1994).
The MOMP genes were then sub-eloned into the shuttle plasmid, pSMT176 for 
expression in M. vaccae. This plasmid is designed for replication within different host 
species {E. coli and Mycobacterium) (Stewart, Robertson et al. 2004). This heterologous 
model of MOMP expression represents a novel approach that has never been reported before.
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These vectors will serve as reagents to allow the study of the immune response and immuno- 
modulation of MOMP when delivered by M. vaccae, which is itself a powerful immunogenic 
and immuno-modulator.
For protein production and purification, MOMP open reading frames (ORFs) with and 
without signal sequence were obtained by PCR amplification from pcDNA-MOMP and were 
cloned and expressed in E. coli (BL21) under the control of the T7 promoter. Upon induction 
by IPTG, BL21 transformed cells with the entire ompl gene, expressed MOMP at detectable 
levels. Expression of MOMP was detected by Western blot, showing two bands 1 hr post­
induction. The lower molecular weight band (approximately 40kDa) represents a form of 
protein from which the signal peptide sequence had been cleaved. The second band was 
approximately 2 kDa larger and represents the precursor protein containing the signal peptide 
sequence as previously reported (Kaul, Duncan et al. 1990; Koehler, Birkelund et al. 1992; 
Daseher, Roll et al. 1993; Manning and Stewart 1993). The expression of MOMP in this 
form has been shown to cause a reduction in cell viability compared with truncated forms 
(Hoelzle, Hoelzle et al. 2003). A potential explanation for reduced viability may be that the 
translocation of MOMP in the cell membrane leads to destabilization and lysis of the outer 
membrane of E. coli as it had been found previously in experiments were the entire C. 
trachomatis MOMP gene was expressed in E. coli (Manning and Stewart 1993). However, 
we did not investigate the effect of the signal peptide sequence on the viability of bacteria, so 
cannot substantiate this hypothesis.
Finally, two different forms of rMOMP were successfully expressed by M. vaccae. 
Both froms of rMOMP will be used to characterise the immune responses induced by 
rMOMP and to investigate their effect on atherosclerosis development in the following 
chapters.
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CHAPTER 4
CHARACTERISATION OF IMMUNE RESPONSES ELICITED 
BY M  VACCAE EXPRESSING MOMP AND DNA VECTOR 
ENCODING MOMP IN  VIVO
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4.1. INTRODUCTION
The antigenic properties of MOMP from Ch. pneumoniae remain controversial 
(lijima, Miyashita et al. 1994; Jantos, Heek et al. 1997). Several studies have suggested that 
the Ch. pneumoniae MOMP is less immunogenic than that from other Chlamydia species as 
it is not a surface exposed antigen (Campbell, Kuo et al. 1990). Conversely, other studies 
have found that MOMP of Ch. pneumoniae is surface expressed and its immunogenicity 
depends mainly on the conformational epitopes exposed (Conlan, Kajbaf et al. 1989; Wolf, 
Fischer et al. 2001). Most studies have focused on using this protein in vaccine development 
and have concentrated their observations on protective efficacy, providing a limited view of 
the responses triggered and the immuno-regulatory properties of this protein.
MOMP has been considered an attractive molecule to produce vaccines against 
chlamydial infection, although most studies have found that it elicits very week immune 
responses (Newhall 1988; Taylor, Whittum-Hudson et al. 1988) in addition to incomplete 
and/or short term protection against infection (Batteiger, Newhall et al. 1986; Su and 
Caldwell 1992; Batteiger, Rank et al. 1993; Zhang, Yang et al. 1997; Pal, Barnhart et al. 
1999; Zhang, Yang et al. 1999). These effects have been attributed to an inadequate 
induction of the protective Thl immune response. Several attempts have been made to 
enhance the immunogenicity of MOMP, for example, by selecting specific T helper cell 
peptide epitopes or B cell epitopes (Hayes, Conlan et al. 1991; Zhu, Shi et al. 2008) or by 
combining both approaches (Su, Morrison et al. 1990; Ishizaki, Allen et al. 1992; Su and 
Caldwell 1992; Kim and DeMars 2001). However, some of these studies have still only 
shown partial protection against infection (Su, Parnell et al. 1995). Studies in which 
adjuvants have been used have not shown an increase in antibody-mediated response against 
MOMP (Pal, Davis et al. 2002; Pal, Luke et al. 2003; Eko, He et al. 2004; Igietseme, Eko et 
al. 2004; Hansen, Jensen et al. 2008), or in T cell-mediated protective immune responses 
(Igietseme, Eko et al. 2005; Pal, Peterson et al. 2006).
Conversely, several reports have shown that MOMP induces a Th2-mediated immune 
response rather than a Thl-mediated one. In a study carried out by Zhang and co-workers, it 
was found that BALB/c mice immunised intramuscularly with an eukaryotic expression 
vector encoding the MOMP gene from C. trachomatis, induced not only IFN-y but also 
significant levels of IL-10 (Zhang, Yang et al. 1999). The expression of this cytokine may 
well counterbalance the effect of IFN-y on the induction of T cell-mediated immune
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responses, whieh are eritieal for protection against this intracellular bacterium. In another 
study, sonicated MOMP purified from C. trachomatis induced a weaker IgG2a than IgGl 
immune response in BALB/c mice, referring to Th2 immune response (Pal, Theodor et al. 
2001). Splénocytes from these mice produced low levels of IFN-y but elevated IL-4, 
suggesting induction of the Th2 immune response. Despite this immune-modulatory effect, 
there was no evidence of protection against C. trachomatis, as the fertility of these animals 
did not improve compared with control group.
In 2002, Shaw and co-workers carried out a study using DCs pulsed with 
recombinant C. trachomatis MOMP that were adoptively transferred to naïve C57B1/6J mice, 
known to have a predominant Thl phenotype with high basal levels of IFN-y expression. In 
this study, MOMP induced a predominant IgGl response and secretion of IL-4 and IL-10 
(Shaw, Grund et al. 2002). In an alternative approach, Zhu and his group found that 
immunisation of BALB/c mice with eukaryotic expression vectors expressing multi-epitopes 
of the C. trachomatis MOMP had no affect on the levels of CDSVlL-lO, and CD3^/IL-4 cells 
compared with the control groups, but an increased number of IFN-y producing CD3^ T cells 
was observed (Zhu, Shi et al. 2009). In contrast to the above finding. Champion and 
colleagues found that mice immunised intranasally with rMOMP of C. muridarum 
encapsulated in vault nano-capsules, induced a specific immune response to MOMP that 
protected against infection and at the same time increased the level of IL-10 in the plasma 
(Champion, Kiekhoefer et al. 2009). Although there are inconsistencies in the above results, 
these observations collectively suggest that MOMP may induce an anti-inflammatory (Th2) 
immune response and may play a role in potentiating persistent chlamydial infection. Most 
recently, our group has also shown that in addition to suppressing T and B cell responses, 
MOMP can also affect innate immunity by suppressing the capacity of macrophages to 
activate cell-mediated immune responses. This is achieved via damping down MHC elass-II, 
CD86 and CD40 expression and down-regulating CD69 and CD 154 (CD40L) expression on 
CD4^ T cells in vitro (Bermudez-Fajardo 2011).
To further investigate the immunological role of the Ch. pneumoniae MOMP, we 
performed experiments to examine the immune responses induced by rMOMP expressed by 
M. vaccae and by a eukaryotic DNA expression vector. As far as we are aware, this study is 
the first study that has attempted to evaluate the effect of rMOMP expressed by different 
vectors on Treg cell populations and to link these effects to the anti-inflammatory properties 
ofMOMP.
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4.2. SPECIFIC AIM
The main aim of this chapter was to characterise the effect of vectors expressing 
rMOMP on cellular and humoral immune responses.
4.3. OBJECTIVES
In order to achieve our aim, C57B1/6J male mice were immunised intranasally with 
rMOMP expressed either by M. vaccae or a eukaryotic expression vector using a short term 
immunisation protocol. The objectives were as follows:
• To measure the effect of the treatment on Treg cells by collecting spleens and
assessing total spleneytes for Treg markers using flow cytometry analysis.
• To assess cytokine production in immunised animals by measuring IFN-y, IL-4 and
IL-10 levels in the supernatants of ex vivo splenocytes and in plasma by ELISA.
• To determine the specific humoral immune response in immunised animals by
detecting anti-rMOMP IgGl, IgG2a, IgA and IgM antibodies by ELISA.
4.4. MATERIALS AND METHODS
4.4.1. Animals
Eight week old, male, speeifie pathogen-free (SPF) certified C56B1/6J mice (D and K, 
UK) were used in this study.
4.4.2. Immunisation
To characterise the immune responses induced by rMOMP, seven groups of male 
C57B1/6J mice (n = 5) received immunogens (or control solution; PBS/PBS-Tween80) by the 
intranasal route as described in Chapter 2; section 2.2.2, see Table 4.1.
T a b le  4 .1 . E x p er im en ta l g r o u p s  u s e d  in th e  p ilo t s tu d y .
Group Group ; Immunogens
rMOMP with and P* group 0.05% (v/v)Tween-80 in PBS
without signal peptide 
sequence expressed by 2"^* group 2.5x10  ^CPU ofM vaccae
M. vaccae
3"^  group 2.5x1 O^CFU ofM vflccae-rMOMP+SPS
n= 5 / group 4* group 2.5x10  ^CFU ofM  vûfccae-rMGMP-SPS
rMOMP expressed P‘group PBS
pcDNA-MOMP plasmid 2”'^  group lOOpg pcDNA3.1 (empty plasmid)
n= 5 / group 3"^  group lOOpg pcDNA-MOMP
A 30 day immunization protocol was used, see Figure 4.1. Pre-immunisation blood 
was collected from the tail vein at day 0 and before the booster dose at day 15. On day 30, 
mice were euthanized and blood was collected from the abdominal aorta. Spleens were also 
collected for cellular analysis as described in Chapter 2, section 2.2.3.1. Plasma was obtained 
to measure the level of cytokines (IL-10, IL-4 and IFN-y) and to measure antigen specific 
antibody levels (IgGl, IgG2a, IgA and IgM), see Chapter 2, section 2.2.4 and 2.2.5, 
respectively. Splenocytes were isolated and labelled for the analysis of CD4^ or CD8^, 
CD25^ and FoxP3^ cell sub-populations by flow cytometry as previously described in 
Chapter 2, section 2.2.3.3.
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B leed
d o s e
Day 15
Bleed 
2"“ dose
Day 30
Collect:
• Plasma.  
♦Spleen.
F igu re 4 .1 . Im m u n isa tio n  p r o to c o l u s e d  in th is  s tu d y . C57BI/6J m ice were im m unised in tranasally 
with immunogens (rMOMP expressed either by M. vaccae or eukaryotic expression vector pcDNA- 
MOMP in parallel with control groups). Blood was collected from the tail vein at day 0 and day 15 of 
immunisation and from the aorta at term ination on day 30 in order to study the effect on hum oral and 
cellular immune responses. The spleens w ere also collected upon term ination fo r T cell response 
analysis. Each treatm ent group contained 5 animals.
4.4.3. Detection of Treg markers using flow cytometry analysis
Splenocytes were isolated and stained with fluorescently labelled antibodies for the 
analysis of CD4^CD25^FoxP3 Treg and CD8 CD25^FoxP3 Treg phenotypes by flow 
cytometry, as described in Chapter 2, section 2.2.3.
4.4.4. Detection of cytokines in culture supernatants and plasma samples by 
ELISA
Cytokines; IL-4, IL-10 and IFN-y were detected in the supernatants of cultured 
splenocytes previously re-challenged with PMA and lonomycin, and in plasma samples using 
commercially available ELISA kits, as described in Chapter 2, section 2.2.4.
4.4.5. Detection of antigen-specific antibodies in plasma using ELISA
Humoral immune responses were monitored by measuring anti-rMOMP IgGl, IgG2a, 
IgA and IgM specific antibody levels in plasma samples, as previously described in Chapter 
2; section 2.2.5.
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4.5. RESULTS
To characterise cellular and humoral immune responses covering the four phases of 
antibody production (lag, log, plateau and decline of antibody response) against Ch. 
pneumoniae MOMP (Abbas 2004), mice were immunised with rMOMP expressed by 
different vectors (as described in Table 4.1), applying a short term immunisation protocol for 
30 days. T cell-mediated immune response was assessed through determination of IFN-y, IL- 
10 and IL-4 cytokine concentration; whereas humoral immune response was examined by 
measuring the levels of plasma anti-rMOMP specific IgGl, IgG2a, IgM and IgA antibodies. 
The effect of rMOMP immunisation on the proliferation of Treg populations was also 
measured.
4.5.1. Immunisation with recombinant vectors expressing rMOMP induced a 
predominant anti-inflammatory response
Secretion of IFN-y is known to be linked to the Thl-mediated immune response, 
which plays a critical role in pro-inflammatory responses against bacterial infections 
(Barouch, Santra et al. 1998). On the other hand, synthesis of IL-10 and IL-4, whieh were 
classically associated with Th2-mediated T cell responses, are now more specifically known 
for their anti-inflammatory actions and their involvement in the synthesis of antibodies, 
respectively (Abbas, Murphy et al. 1996). We measured the concentration of cytokines in the 
plasma. Unfortunately, the values of all cytokine concentrations detected in the plasma were 
below the detection limit of the assays, but the concentrations of these cytokines were 
detectable in the supernatant which were secreted by splenocytes ex vivo using ELISA.
The groups treated with M. vaccae expressing either version of rMOMP (M vaccae- 
rMOMP+SPS or M. vufccufe-rMGMP-SPS) showed no statistically significant difference in 
the levels of IFN-y and IL-4 produced by splenocytes in culture compared to the PBS- 
Tween80 and wild type M. vaccae control groups. Conversely, treatment with M. vaccae- 
rMOMP-SPS significantly increased the levels of IL-10 compared to control groups; PBS- 
Tween-80 and wild-type M. vaccae (2491 ± 401pg/mL vs 1554 ± 727pg/mL, < 0.05; and
2491 ± 401pg/mL vs 1315±401 pg/mL,*p < 0.01, respectively). Additionally, the group 
treated with M. vnrucure-rMOMP+SPS significantly demonstrated an increase in the 
concentration of IL-10 compared with wild M  vaccae only (2159 ± 251pg/mL vs 1315 ± 
95pg/mL, < 0.05), see Figure 4.2 A.
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Immunisation with DNA encoding MOMP (pcDNA-MOMP), significantly reduced 
levels of IFN-y secreted by splenocytes compared to the empty plasmid pcDNA3.1 control 
group (1791 ± 163pg/mL v.s' 2125 ± 140 pg/mL, < 0.05). The same treatment induced a 
significant increase in the levels of IL-4 (194 ± 37pg/mL vs 24.3 ±  19pg/mL, **p< 0.01) and 
IL-10 (2792 ± 844pg/mL vs 1282 ±414 pg/mL, < 0.05) compared to PBS control group, 
see Figure 4.2 B.
rMOMP expressed by M. 
vaccae
1  1000
PBS- M. vaccae M. vaccae- M. vaccae- 
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rMOMP*SPS rMOMPSPS
PB S PCDNA3.1 pcDNA-MOMP
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PB S PCDNA3.1 pcDNA-MOMP
PB S pcDNA3.1 pcDNA-MOMP
F igu re 4 .2 . E ffec t o f  r e c o m b in a n t MOMP e x p r e s s e d  by M. vaccae o r  e n c o d e d  by  a  e u k a r y o tic  
e x p r e s s io n  v e c to r  on  th e  le v e ls  o f  IFN-y, IL-10 an d  IL-4 s e c r e t e d  by  s p le n o c y t e s  ex-vivo.
Splenocytes were Isolated from mice upon term ination and then cultured fo r 72 hrs in the presence of 
10ng/mL of PMA and 500ng/m L o f lonomycin. Supernatants w ere collected from  each group and the 
concentrations of IFN-y, IL-10 and IL-4 were measured using com m ercially available ELISA kits. (A). 
The immunisation with M. vaccae expressing MOMP with and w ithout signal peptide sequence had no 
effect on IFN-y and IL-4 levels secreted but significantly increased the concentration o f IL-10 
compared with control groups. (B). Treatm ent w ith pcDNA-M O M P significantly inhibited the level o f 
IFN-y secreted compared with the pcDNA 3.1 control group. The sam e treatm ent sign ificantly 
increased the levels o f IL-10 and IL-4 compared w ith PBS control group. The data is presented as 
mean (n=5) ± SD, *p<0.05, **p<0.01; n=5.
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4.5.2. Vaccination with M  vaccae expressing rMOMP and DNA plasmid 
encoding rMOMP had no effect on the synthesis of anti-rMOMP-specific 
antibodies
In order to characterise the specific humoral immune response induced by treatment, 
plasma anti-rMOMP specific IgGl, IgG2a, IgA and IgM antibodies were assessed by an 
ELISA, developed in our laboratory by Dr Alexandra Bermudez-Fajardo, with purified 
rMOMP as the antigen. Classically, IgGl is induced under control of Th2 immune response, 
whereas IgG2a is induced under control of a Thl immune response (Reiner and Locksley 
1992; Abbas, Murphy et al. 1996). However, the levels of the antibodies induced by 
immunisation were below the detection limit of the assay, therefore we were unable to detect 
the production of any rMOMP specific antibodies of any isotypes.
4.5.3. Intranasal administration with recombinant vectors expressing rMOMP 
modulates the proliferation of CD4^ and CDS T cells and Treg cells
The effect of rMOMP immunisation on the number of total CD4^ and CD8  ^T cells 
and both CD4^ and CD8  ^ Treg populations was measured by flow cytometry, using total 
splenocytes isolated from the spleen of immunised animals. Results showed that vaccination 
with M  vaccae-rMOMP-SPS significantly enhanced the percentage of CD4^ T cells 
compared to PBS-Tween80 and wild-type M. vaccae control groups (54.2 ± 1.6% vs 44 ± 
1.2%, < 0.05; and 54.2 ± 1.6% vs 39.7 ± .9%, ***p< 0.001; respectively). Moreover, the
group treated with M. vacc«e-rMOMP+SPS significantly increased the percentage of CD4^ T 
cells compared to wild-type M. vaccae (50.4 ± 1.1% vs 39.7 ± 0.9%, < 0.05), see Figure
4.3 A. On the other hand, treatment with rMOMP encoded by the eukaryotic expression 
vector significantly decreased the number of CD4^ T cells compared with the empty 
pcDNA3.1 plasmid (23.3 ± 0.6% vs 74.6 ±0.5%, **p < 0.01), see Figure 4.4 A. The effect of 
the treatment on CD8  ^ T cells was also studied. Wild-type M  vaccae immunisation 
significantly increased the percentage of CD8  ^ T cells compared with the PBS-Tween80 
control group (48.1 ± 1.4% 31.3 ± 1.6%, < 0.001). Similarly, M  vaccae expressing
rMOMP with signal peptide sequence significantly increased the CD8  ^ T-cell numbers 
compared with PBS-Tween80 control (46.7 ±0.5% vn 31.3 ± 1.6%, < 0.05), see Figure 4.3
B. The group treated with pcDNA-MOMP significantly increased the proliferation of CD8  ^
T cells compared with control PBS (60.7 ± 1.6% vs 54.7 ± 1.7%, < 0.05), see Figure 4.4
B.
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F igu re 4 .3 . E ffec t o f  rMOMP e x p r e s s e d  by M. vaccae on  th e  n u m b er  o f  CD4^ an d  CDB^ T c e lls .  
(A). Representative dot plots from the flow  cytom etry analysis showing the num ber o f CD4^ T cells 
w ithin the P2 region. Data from this analysis have been plotted as a bar graph. (B ). Representative 
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The effect o f  the treatments on CD4^CD25^FoxP3^ and the CD8"^CD25"^FoxP3^ Treg 
populations was studied. Our results show that M  vaccae  vectors expressing MOMP with 
signal peptide sequence had a greater inductive effect on the numbers o f  CD4^CD25^FoxP3^ 
and CD8^CD25^FoxP3^ Tregs., see Figure 4.5. The group o f  animals immunised with M  
vaccae  vectors expressing rMOMP with signal peptide sequence significantly induced the 
number o f  CD4^ Treg cells compared to the group treated with wild-type M. vaccae  (1.8 ±  
0.1% vs 0.7 ±  0.1%, ***p < 0.001), see Figure 4.5 A. The same treatment had a similar 
effect on the CD8^ Treg population when compared to PBS-Tween 80 and wild-type M. 
vaccae  control groups (0.67 ± 0.1% vs 0.2 ±0.1% , *p< 0.0,5; for both), see Figure 4.5 B.
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effect o f rMOMP expressed by M. vaccae on the proliferation o f CD8^CD25''FoxP3‘" Treg in vivo. Each 
dot plot showed the percentage of parent cells, as previously described in C hapter 2, section 2.2.2.5 
The results from the flow  cytom etry analysis are displayed in bar graphs as mean (n=5) ± SD; *p < 
0.05, ***p < 0.001; n=5.
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The effect of immunisation using pcDNA-MOMP on the numbers of the above- 
mentioned Treg populations was analysed in parallel using the same methodology. The 
results showed that the group treated with pcDNA-MOMP significantly increased the 
percentage of CD4^ Treg compared with PBS and pcDNAS.l control groups (3.7 ± 0.08% vs 
0.3 ± 0.05%, ***/? < 0.001; and 3.7 ±0.17% vs 1.3 ± 0.1%, ***/? < 0.001, respectively), see 
Figure 4.6 A. The results also showed that treatment with either pcDNA-MOMP or 
pcDNA3.1 significantly increased the percentage of CD8  ^ Treg compared to PBS control 
group (1.5 ± 0.1% V5 0.2 ± 0.3%, < 0.05 and 1.1 ± 0.1% vs 0.2 ± 0.3%, *p < 0.05,
respectively), see Figure 4.6 B.
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*p<0.05, **p<0.01; n=5.
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4.6. DISCUSSION
There is a considerable body of work examining the immune response to ehlamydial 
MOMP. However, as we mentioned before mueh of these studies focused on assessing the 
effectiveness of MOMP as a vaceine eandidate against chlamydial infection rather than the 
immune response and the immuno-modulatory meehanisms involved in sueh a response. In 
order to further these observations, we deeided to investigate the effeet of rMOMP on 
immune responses in vivo using C57B1/6J mice. Our study focused on measuring specific 
parameters that elassieally serve as surrogates to assess immuno-suppressive reaetions.
In this study, we have used mycobacterial and eukaryotie DNA expression veetors 
generated and deseribed in Chapter 3. The pcDNA3.1 eukaryotic expression vector allows 
intracellular synthesis of a native protein. As a vaceine delivery system, DNA expression 
veetors have some attractive qualities as they are safe, stable at different temperatures and 
guarantee the long-term expression of antigens within tissues (Doria-Rose and Haigwood
2003). The major disadvantage of this system is that the amount of protein expressed by 
plasmids is variable and unpredictable as the DNA is suseeptible to degradation by several 
factors (Donnelly, Ulmer et al. 1997; Doria-Rose and Haigwood 2003). The other system 
used in this study was to express and deliver Ch. pneumoniae MOMP in M. vaccae. These 
bacteria, chosen depending on the eriteria mentioned in the previous chapter, are non- 
pathogenie and have been used clinically as therapeutic agents, and most importantly these 
baeteria are resistant to enzymatic degradation in the respiratory tract, they are suitable for 
intranasal administration (Hrouda, Baban et al. 1998; Shirteliffe, Goldkom et al. 2003; 
Hadley, Smillie et al. 2005). Additionally, the genetic system of these bacteria is very 
flexible and is capable of expressing high levels of heterologous proteins, making it a good 
source of produetion of reprodueible immunogens (Garbe, Barathi et al. 1994; Christine abou- 
zeid 1997).
C57B1/6J miee were inoculated intranasally, in order to mimie the main portal entry 
of Ch. pneumoniae infeetion, with either lOOpg of naked DNA plasmid eneoding rMOMP or 
2.5 X 10  ^ CFU of M. vaccae expressing MOMP (with or without signal peptide sequenee). 
Splenocytes from immunised animals were isolated and eultured for 2 days with PMA and 
lonomycin to amplify the in vivo induced immune response. Our results showed that the 
groups treated with M. vaccae expressing MOMP with or without signal sequenee induced 
relatively high levels of IL-10 compared to controls but they did not affect levels of IFN-y
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and IL-4. The DNA plasmid eneoding MOMP decreased the levels of IFN-y seeretion. This 
profile of eytokines suggests that immune responses indueed by MOMP shift towards a Th2- 
mediated effeet, whieh is un-proteetive against chlamydial infection (Mosmann, Cherwinski 
et al. 1986; Romagnani 1996). This finding is in agreement with that of Shaw and 
colleagues, who earlier reported that when naïve mice were immunised with DCs pulsed with 
rMOMP of C trachomatis ex vivo, the immune response was driven towards a Th2 type 
response (Shaw, Grund et al. 2002). Shaw’s observations were followed by a nother study 
designed to assess the effeet of intramuseular administration of C. trachomatis rMOMP using 
a eukaryotic DNA expression vector, where it was found that rMOMP DNA induced IL-10 
seeretion compared with control group (empty plasmid), as was seen in our study (Zhang, 
Yang et al. 1999). Another signifieant finding in our study was the reduction of IFNy 
concentrations in the culture of splenocytes colleeted from the animals immunised with 
peDNA-MOMP. This is a pertinent finding as the C57B1/6J mouse strain is characterised by 
high basal expression levels of this eytokine (Heinzel, Sadiek et al. 1989; Jawien, Nastalek et 
al. 2004).
Conversely, M  vaccae expressing both forms of rMOMP had no effect on the 
expression levels of IFN-y. This could be due to the inability of rMOMP to inhibit the affect 
of M  vaccae, which is known to trigger a potent Thl-mediated immune response in itself 
(Dlugovitzky, Bottasso et al. 1999), alongside the dominant effeet of IFN-y produeed 
naturally by the C57B1/6J mice. Despite this, M. vacc^e-rMOMP+SPS and -rMOMP-SPS 
induced changes in IL-10 secretion (a potent anti-inflammatory cytokine), suggesting an anti­
inflammatory response to rMOMP. Secretion of IL-10 may be from a variety of sources 
ineluding Th2 cells and Treg eells (Moore, de Waal Malefyt et al. 2001). This cytokine 
inhibits the eonversion of naïve T eells in to Thl eells and also has direet effects on APC-T 
cell stimulatory functions (Fiorentino, Bond et al. 1989; MacNeil, Suda et al. 1990; 
Fiorentino, Zlotnik et al. 1991; Nakagome, Dohi et al. 2005; Okunishi, Dohi et al. 2005). IL- 
10 also impairs antigen presentation by APCs via down-regulation of the expression of MHC 
class-II (Bogdan, Vodovotz et al. 1991; Fiorentino, Zlotnik et al. 1991; Gazzinelli, Oswald et 
al. 1992; Yamakami, Akao et al. 2002). IL-10 also down-regulates the expression of
important eo-stimulatory moleeules sueh as CD80 and CD86 required for T eell activation 
and differentiation (Bogdan, Vodovotz et al. 1991; Gazzinelli, Oswald et al. 1992; Ding, 
Linsley et al. 1993). This inhibitory effect of IL-10 suppresses host protective immune 
responses to infeetion and to deereases the ability of eells to kill engulfed miero-organisms
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(Bogdan, Vodovotz et al. 1991; Gazzinelli, Oswald et al. 1992; Yamakami, Akao et al. 2002). 
Furthermore, IL-10 has also been shown to prevent complete parasite elimination even in the 
presence of a strong Thl-mediated proteetive immune response and induees bacterial 
replieation inside infeeted cells (Belkaid, Hoffmann et al. 2001). Collectively, this suggests 
that MOMP may be involved in the pathological mechanism of Ch. pneumoniae infection by 
damping down the host immune response.
The humoral immune response refers to speeifie antibodies produced against the 
antigen. The effeet of MOMP on the humoral immune response is still controversial 
(Beagley and Timms 2000; Penttila, Vuola et al. 2000; Pal, Peterson et al. 2005). This study 
investigated the antibody response generated against rMOMP in the plasma of immunised 
animals. For this purpose, levels of anti-rMOMP speeifie IgGl, IgG2a, IgM, and IgA were 
measured by ELISA. It has been doeumented that the major antibody detected during the 
primary immune response is IgM, as indicative of primary or immature immune response. 
IgM is then switched to high titres of IgG during the secondary immune response (Abbas
2004). IgA, on the other hand, is the main antibody seereted in mucosal surfaces and it is 
important in the pathology of chlamydial infection (Beagley and Timms 2000; Christiansen 
and Birkelund 2002). Characterisation of the antibody class and IgG isotype profile is also 
indieative of the type of eellular immune response initiated. IgGl synthesis is indueed by the 
secretion of Th2-derived eytokines sueh as IL-4 and IL-5, while IgG2a is a produet of the 
maturation of B cells under the influence of a Thl immune response (Reiner and Locksley 
1992; Feltquate, Heaney et al. 1997). Unfortunately, our study revealed that the levels of 
induced antibodies were below the detection limit of the assays used. The failure of antibody 
detection is consistent with previous observations from different groups (Taylor, Whittum- 
Hudson et al. 1988; Zhang, Yang et al. 1997; Pal, Barnhart et al. 1999; Zhang, Yang et al. 
1999; Penttila, Vuola et al. 2000; Vanrompay, Vanlooek et al. 2001). One potential 
explanation for the low antibody response to rMOMP, is that rMOMP from peDNA vector or 
M. vaccae was degraded inside the host cells, limiting the level of antigens exposed to 
eirculating antibodies (Penttila, Vuola et al. 2000; Christiansen and Birkelund 2002; Pal, 
Peterson et al. 2006). Another explanation for the undeteetable humoral immune response 
may be a result of the modulatory effect of MOMP on co-stimulatory molecules involved in 
the direct interaction between B and T cells.
It is well known that B eell activation is augmented by signalling from different co­
stimulatory molecules in order to exchange information, leading to induetion, proliferation
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and differentiation into antibody forming eells (Abbas 2004). The interaction between B 
cells and T cells is aehieved through two main signals. The first signal involves presenting 
antigens to T eells, which is mediated mainly by MHC elass-II and the TCR complex (TCR- 
CD3). The second signal is mediated via molecules such as CD80 (B7.1) and CD86 (B7.2), 
expressed on the membrane of B eells and interaets with CD28 and CTLA4 on T cells. 
Another molecule that transmits the most potent aetivation signal to B eells is CD40. This 
moleeule interaets with CD40L expressed on the surfaee of aetivated T cells. The interaction 
between these two molecules induees B cells into an aetivation cyele (Stavnezer and 
Amemiya 2004). In the light of these facts, an inhibitory effect ofMOMP on one of these eo- 
stimulatory molecules may be a possible explanation for the low antibody response. 
Therefore, in the following chapter (Chapter 5) we investigated the effect of rMOMP on the 
expression of these markers to examine this hypothesis.
While most studies of Ch. pneumoniae have demonstrated the importanee of eellular 
immune responses; specifically T cell populations in immuno-proteetion and immuno- 
pathology (Rottenberg, Gigliotti Rothfuchs et al. 1999; Vuola, Puurula et al. 2000; 
Rodriguez-Maranon, Bush et al. 2002), little is known about the direet effeet of MOMP on T 
cell populations (CD4^ and CD8  ^ T eells). The results deseribed above eneouraged us to 
investigate the effect of rMOMP on T cells and Treg populations and to investigate whether 
rMOMP could ultimately play a role in the pathogenieity of Ch. pneumoniae or not. 
Interestingly, the present study showed a significant decrease in the number of CD4^ T cells 
in mice treated with rMOMP encoded by the eukaryotie expression vector (pcDNA-MOMP), 
which is an effect that has not been previously described. CD4^ T eells have wide ranging 
and magnanimous effeets on other cells of immune system in order to prompt various aspeets 
of the immune response, including immunoglobulin isotype switching and maturation of 
antibody response, maerophage aetivation and stimulation of NK cells and CD8  ^T eells. The 
protective effect of CD4^ T cells against chlamydial infection has been confirmed in several 
studies (Cohen, Nguti et al. 2000; Kelly 2003). Taken together, the suppression of the CD4^ 
T cell population suggests that MOMP has a negative regulatory effect on the host immune 
system.
Another major finding of the present study was that regulatory T cell proliferation 
increased upon treatment with rMOMP expressed by different vectors. Treg eells are a 
subelass of T cells that express unique markers, ineluding not only CD25 (IL-2 alpha ehain 
reeeptor) but also the intracellular marker FoxP3 (also known as fork head box P3)
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(Annacker, Pimenta-Araujo et al. 2001; Brunkow, Jeffery et al. 2001; Loser, Hansen et al.
2005). These cells were firstly deseribed by Gershon in 1972 (Gershon, Cohen et al. 1972), 
but the effeet of MOMP on Treg eells has not been previously investigated. CD4^ Treg eells 
represent approximately 5-10% of the total T cell population and have suppressive effects on 
naïve and memory T cell proliferation in vivo and in vitro (Sakaguehi, Sakaguehi et al. 1995; 
Pieeirillo and Shevach 2001; Sakaguehi, Sakaguehi et al. 2001). CD4^ Treg eells mediate 
their suppressive function via secretion of IL-10 and TGF-p (Weiner, Gonnella et al. 1997; 
Annacker, Pimenta-Araujo et al. 2001). Induetion of this population of Treg cells has been 
reported for several pathogens such as Mycobacteria spp. and Listeria monocytogenes and 
may represent a pathogenic mechanism needed to survive and replieate inside the host cells 
(Redpath, Ghazal et al. 2001; Sakaguehi 2003; Couper, Blount et al. 2008) Sueh a 
suppressive effeet on the T cell population may have been observed in this study, as peDNA- 
MOMP immunised mice showed a decrease in CD4^ T cell numbers that correlated with an 
increase in the pereentage of proliferating CD4^ Treg cells. However, whereas M. vaccae 
expressing rMOMP demonstrated an increasing percentage of CD4^ Treg cells, there was no 
corresponding deerease in overall CD4^ T eell numbers. A possible explanation for the latter 
finding may be eorrelated to the effect of M. vaccae, which is capable of inducing CD4^ T 
cells itself, thereby masking the suppressive effect of rMOMP expressed by these baeteria.
As obligate intracellular baeteria, CD8  ^ T cells are critical in the protection against 
chlamydial infection (Penttila, Anttila et al. 1999; Rottenberg, Gigliotti Rothfuchs et al. 
1999). The effeetive meehanism of this population of T cells is mediated by eytokine 
secretion or the release of exoeytose lytie granules (Russell 2002). Therefore, we also 
investigated the effect of rMOMP on another population of regulatory T cells; CD8  ^ Treg 
eells (subpopulation of CD8  ^ T cells). These represent less than 1% of the total T eell 
population residing in the lymph nodes and the spleen (Rocha, Vassalli et al. 1991). These 
Treg eells have a suppressive effeet on aetivated T cells, espeeially Thl cells (Jiang, 
Braunstein et al. 2001; Tang, Smith et al. 2005; Correale and Villa 2008). This suppressive 
effect modulates different mechanisms including the induetion of apoptosis, via the Fas-Fas 
ligand mechanism or via the perforin pathway (Badovinae, Tvinnereim et al. 2000; Correale 
and Villa 2008). Our analysis revealed that rMOMP expressed by M. vaccae with signal 
peptide sequenee increased CD8  ^Treg numbers compared with other control groups, whereas 
the effeet of rMOMP expressed by the eukaryotic expression vector induced the same 
number of CD8  ^Treg as the empty plasmid. This result eonfirms a previous finding by our
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group that when maerophages were treated with rMOMP and eo-cultured with CD8  ^T cells 
inereased expression of CD25 in a dose-dependent manner (Bermudez-Fajardo 2011). The 
findings from this part of the study suggest that MOMP down-regulates host immune 
response by inducing both CD4^ and CD8  ^Treg populations.
In eonelusion, the results obtained confirmed the hypothesis that rMOMP can induce 
anti-inflammatory immune responses. Putting this in context with the Ch. pneumoniae life- 
cyele and its ehronic survival within tissues, we can speculate that MOMP plays a key role in 
the immune evasion mechanisms used by the baeterium to survive for long periods within the 
host by dampening-down effective adaptive immune responses. These findings therefore 
eneouraged us to carry out additional experiments to further elucidate the mechanisms of 
immune-modulation elicited by MOMP. Thus it was deeided to investigate the effect of 
rMOMP on the expression of key suppressive markers on T cells, sueh as CTLA-4 and Fas- 
ligands on APCs and on the proliferation of T cell populations. The aim of these further 
investigations is to identify and elarify the effects of MOMP treatment on immune responses 
and in particular, the induetion of Treg populations.
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CHAPTER 5
THE EFEECT OF RECOMBINANT MOMP ON 
MACROPHAGES AND CD4^ T CELLS IN  VITRO
103
5.1. INTRODUCTION
Ch. pneumoniae is a highly successful intracellular pathogen known for its 
evasion mechanisms from the host protective immune response and for causing several 
chronic diseases in humans. As discussed in the previous chapter, although MOMP is 
considered a very attractive vaccine candidate to protect against chlamydial infection, it 
has demonstrated short-lived or incomplete protection against this pathogen. To date, the 
literature in relation to the detailed effects of MOMP on the mechanisms of activation or 
inhibition of host immune responses has been scarce. This prompted us to examine the 
effect of rMOMP on selective markers expressed by lymphocytes and macrophages that 
have a crucial role, not only in the modulation of immune responses but also in the 
development of atherosclerosis. Previous observations have shown that Ch. Pneumoniae 
MOMP may have immuno-suppressive function of indeterminet pathways. This may 
explain the potential immune-protective response to Ch. Pneumoniae described above 
and may also explain the experimental findings described in the previous chapter. 
Therefore, the main aim of this chapter was to investigate the effect of MOMP on 
selective markers linking innate immune responses with adaptive immune responses 
(Figure 5.1).
This study used peritoneal macrophages acting as APCs and CD4^ T cells 
extracted from C57B1/6J mice, a scenario used in further chapters to assess the effect on 
atherosclerotic plaque development. The markers examined were PRRs, specifically 
(TLR2, TLR4) and CD 14, and other activation molecules such as MHC class-II, CD80, 
CD86 and CD40 that are either expressed on peritoneal macrophages and/or have been 
found to play key roles in atherogenesis. In addition, this chapter aimed to examine the 
effect of rMOMP on the expression level of CD28 and CD3 molecules on T 
lymphocytes. Most importantly, we also evaluate how rMOMP affects the proliferation 
of Treg cells through the expression of the CTLA-4 molecule by naïve CD4^ T cells in 
vitro. This will allow us to understand how MOMP can potentially modulate the 
biological function of T cells during the immune response. Moreover, these selective 
markers were not chosen randomly, but they were selected due to their particular roles in 
atherosclerosis development, as previously discussed in Chapter 1, section 1.1.1.3.3. 
Below, a brief introduction to each of the selected markers under investigation in this 
study is given.
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F igu re  5 .1 . C ell s u r fa c e  m o le c u le s  th a t p a r tic ip a te  in th e  in tera ctio n  b e tw e e n  A P C s an d  T c e l l s .
The dynam ic Interaction established between APC s and T cells during im m une responses is 
mediated by a w ide range o f receptors, and is believed to be initiated by PRRs that recognise 
pathogen-associated m olecular patterns (PAMPs). Interaction between these m olecules stim ulates 
the expression o f o ther co-stim ulatory receptors on APC s and activates I  cells by enhancing antigen 
presentation and in turn activating adaptive immune responses. [Modified from  (Carreno and Collins 
2002)].
5.1.1. Pattern Recognition Receptors (PRRs)
Innate immunity is a non-specific response and is considered the first line of 
defence that is rapid and short-lived. Innate immunity largely depends on a wide range 
of moleeular receptors including PRRs that recognise PAMPs (Janeway and Medzhitov 
2002). PRRs have been divided into different families depending on their functions and 
the ligands that bind to them, such as mannose receptors, TLRs and cytoplasmic 
receptors (Abbas 2004).
TLRs, a type of PRR, were first described in Drosophila in 1988 (Hashimoto, 
Hudson et al. 1988). Sinee then, around 10 members of the TLR family have been 
described in mammals, and have been shown to recognise spécifié structures present on 
invading microorganisms (Medzhitov, Preston-Hurlburt et al. 1997; Rock, Hardiman et 
al. 1998; Chuang and Ulevitch 2000). TLRs are type I trans-membrane receptors, 
composed of two distinct domains. The first domain is an extracellular leucine domain 
and the other one is an intracellular domain (Gay and Keith 1991; O'Neill and Greene
1998). The aetivation and expression of these receptors is modulated by several factors
105
such as microbial invasion, interaction with complement molecules or cytokine secretion 
(Takeda, Kaisho et al. 2003). These receptors play a crucial role in enhancing innate 
immune responses, not only by increasing the production of pro-inflammatory cytokines, 
but also by up-regulating the expression of other activator markers (Akira and Takeda 
2004; Palm and Medzhitov 2009; Takeuchi and Akira 2010).
Several studies have suggested that TLRs seem to control the stimulation of Thl- 
driven immune responses rather than Th2-immune responses (Schnare, Barton et al. 
2001). Upon pathogen recognition, TLRs induce host defence immune responses via 
several mechanisms, such as secretion of inflammatory cytokines and production of 
chemokines, triggering the expression of co-stimulatory molecules such as CD80, CD86 
and CD40. TLRs also enhance antigen presentation via stimulation of the production of 
MHC class-I and II molecules and increase the production of antimicrobial products such 
as nitric oxide (Kawai and Akira 2010). Therefore, through these actions, TLRs act as a 
bridge between the innate immune and adaptive immune responses (Schnare, Barton et 
al. 2001; Valen 2010). In this chapter, we investigated the effect of rMOMP on the 
expression levels of TLR2, TLR4 and CD 14 as these have all been linked to the 
development of atherosclerosis (Curtiss and Tobias 2009).
TLR4 is essential for the recognition of LPS, a major component of Gram 
negative bacteria. To date, the exact recognition mechanism is unclear, but it seems to be 
mediated by other molecules such as CD 14 and MD2 (Lien, Means et al. 2000; Poltorak, 
Ricciardi-Castagnoli et al. 2000). Once TLR4 recognises its ligand, it induces the 
secretion of inflammatory cytokines and the expression of other co-stimulatory 
molecules, especially CD80 (Medzhitov, Preston-Hurlburt et al. 1997). In addition, 
TLR2 recognises a large number of other ligands such as peptidoglycan and lipoproteins 
on Gram negative bacteria (Takeuchi, Hoshino et al. 1999). It also recognises HSP70, 
produced by mycobacterial cell wall (Hajjar, OMahony et al. 2001), and Zymosan; a 
component of yeast cell walls (Underhill, Ozinsky et al. 1999; Underhill, Ozinsky et al.
1999). It has been reported that each class of TLR stimulates specific responses, 
suggesting that each class of TLR has a distinct signalling pathway that elicits different 
actions, or that these receptors, when stimulated by pathogens, react differently 
depending on the nature of the pathogen. For example, TLR4 ligation on DCs induces a 
cocktail of pro-inflammatory cytokines such as IFN-y and IL-12, but also of anti­
inflammatory cytokines including IL-10. Conversely, TLR2 engagement on DCs leads
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to the secretion of an alternative profile of cytokines, including IL-8 , IL-12 and IL-23 
(Re and Strominger 2001; Harari, Alcaide et al. 2006).
An additional molecule, which cooperates with TLRs to aid recognition of a 
pathogen, is CD 14. CD 14 is a member of the PRR family, although it was initially 
thought to be the exclusive receptor for LPS (Wright, Ramos et al. 1990). However, it 
was later found that CD 14 recognises a wide range of microbial antigens such as 
peptidoglycan, lipoteichoic acid, lipoproteins, lipo-arabinomannan and apoptotic cells 
(Aderem and Underhill 1999; Dziarski, Ulmer et al. 2000; Dziarski, Viriyakosol et al.
2000). There are two forms of CD 14, a membrane-bound form and a secreted form that 
is shed from the membrane or secreted directly from intracellular vesicles under 
inflammatory conditions (Kirkland and Viriyakosol 1998). CD 14 is also involved in 
many different functions, such as intracellular adhesion, trans-cytosis, potocytosis and 
trans-membrane signalling (Anas, Hovius et al. 1983; Anderson, Kamen et al. 1992). In 
addition, CD 14 co-operates with other members of the TLR family, such as TLR3, TLR7 
and TLR8 in order to amplify the inflammatory immune responses triggered by 
pathogens (Lee, Dunzendorfer et al. 2006). CD 14 is also involved in macrophage 
phagocytosis (Gregory, Devitt et al. 1998) and contributes to the extracellular 
metabolism of phosphatidylinositol by monocytes (Gregory, Devitt et al. 1998; Wang 
and Munford 1999).
5.1.2. Major histocompatibility complex (MHC)
Upon antigen interaction with PRRs, other molecules such as the MHC- 
complexes are consequently activated. MHC molecules present antigens to T cells and 
act as the first signal to stimulate adaptive immune responses (Abbas, Lohr et al. 2007). 
In this study, we examined the effect of rMOMP on the levels of MHC class-II expressed 
on peritoneal macrophages, which presents peptides (antigens) to CD4^ T cells. This 
molecule was chosen due to its activation role on CD4^ T cells that contribute to the 
pathogenic immune response of atherogenesis. MHC class-II is a heteromeric molecule 
made of a and p chains and is expressed mainly on phagocytic APCs such as 
macrophages, DCs and B lymphoeytes. Each chain has two extracellular globular 
domains denoted as al/a2  and pl/p2. The a l and pi domains form a polymorphic 
peptide binding cleft, which able to accommodate peptides ranging between 10 to 30 
amino acids in length in order to present this peptide to CD4^ T cells (Abbas, Lohr et al. 
2007).
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Peptides presented by the MHC class-II complex are derived from exogenous 
antigens that are phagocytosed, processed inside endosomes and presented to CD4^ T 
cells. These chains of MHC class-II, a and p, are also synthesised in the endoplasmic 
reticulum (ER) but are bound to a polypeptide called Invariant chain (li). These are then 
transported through the Golgi complex to the acidic endosomal compartment. The li 
chain is cleaved into a smaller fragment called class Il-associated invariant chain peptide 
(CLIP) that blocks the MHC class-II antigen groove (cleft) and protects it from 
degradation. CLIP is then displaced by the appropriate peptide and the complex is then 
transported to the plasma membrane where is ready to interact with CD4^ T cells (Abbas, 
Lohr et al. 2007).
5.1.3. Co-stimulatory molecules
Generally, antigen presentation through MHC complex molecules and 
recognition via the TCR complex is not sufficient to activate and induce proliferation of 
T cells. Crucially, a second signal is required, otherwise T cells become unresponsive. 
This second signal is mediated by co-stimulatory molecules that present simultaneously 
on the same APC, with antigen specific signals (Jenkins, Chen et al. 1990; Schwartz, 
Valente et al. 1993). Co-stimulatory signalling plays an essential role in the initiation 
and termination of immune responses by regulating T cell priming, growth, maturation, 
and tolerance (T cell tolerance and auto-immunity) (Greenwald, Freeman et al. 2005). 
The most potent co-stimulatory molecules expressed on APCs are B7 and TNF-receptor 
super family molecules, which are discussed in further detail below.
5.L3.L CD80/CD86
The B7 family of proteins can be classified into activator or inhibitor co­
stimulatory molecules that up or down-regulate the immune responses, respectively 
(Greenwald, Latchman et al. 2002; Greenwald, Freeman et al. 2005). The B7 family 
contains 7 members namely: CD80 (B7.I), CD86 (B7.2), B7-DC (PDL-2 or CD273), 
B7-H1 (PDL-1 or CD274), B7-H2 (ICOSL), B7-H3 (CD276) and B7-H4 (B751 or B7X) 
(Sharpe and Freeman 2002; Chen 2004). In this study, we assessed the effect of rMOMP 
on the expression of CD80 (B7.1) and CD86 (B7.2) that modulate T cell activation via 
binding to either CD28 or CTLA-4 on T-cells (Chang, Kuchroo et al. 2002). CD80 and 
CD86 are not activation or inhibitor molecules by themselves, but acquire their activity 
by binding with inhibitory CTLA-4 or activator CD28 co-receptors expressed on T cells 
(Waterhouse, Penninger et al. 1995; Greenwald, Latchman et al. 2002).
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These molecules (CD80 and CD86) can also be expressed on the surface of T 
cells but the function of these molecules on T cells is still controversial (Azuma, Yssel et 
al. 1993; Abe, Takasaki et al. 1999; Greenwald, Freeman et al. 2005). Although a 
previous study suggested that expression of these molecules on T cells correlated with 
clinical complications such as systemic lupus erythematosus (Abe, Takasaki et al. 1999), 
another study reported that under normal conditions, resting T cells constitutively express 
CD86 , whereas CD80 is not present (Taylor, Lees et al. 2004).
5.I.3.2. CD28/CTLA-4
CD28 and CTLA-4 are trans-membrane protein members of the immunoglobulin 
gene super-family, having a single extracellular membrane (V-like) domain (Aruffo and 
Seed 1987; Brunet, Denizot et al. 1987). CD28 is constitutively expressed on the surface 
of T cells while the expression of CTLA-4 is limited to the first 48-72 hrs of T cell post­
activation (Freeman, Lombard et al. 1992; Linsley and Ledbetter 1993; Alegre, Noel et 
al. 1996). CTLA-4 is expressed intra-cellularly and upon activation trans-locates from 
the cytoplasm into the cell membrane. CTLA-4 stabilises on the surface of the cell 
membrane after phosphorylation of the cytoplasmic domain (Linsley and Golstein 1996; 
Shiratori, Miyatake et al. 1997). .
CTLA-4 is an inhibitory receptor limiting T cell activation leading to a decrease 
in the amount of IL-2 produced and regulation of peripheral T cell tolerance (Linsley, 
Brady et al. 1991; Carreno and Collins 2002; Abbas 2003). The CTLA-4 molecules bind 
more competitively with B7-1/B7-2 molecules than CD28 molecules (Greenwald, 
Freeman et al. 2005). The CD28 molecule interacts with B7 family receptors leading to 
augmentation of IL-1 production and secretion of other cytokines. Although the 
interaction of B7:CD28 initiates T cell activation, recently, it has been found that this 
interaction has a role in promoting T cell tolerance via its effect on the homeostasis of 
CD4^CD25^ Treg cells via secreting IL-2 from conventional T cells and enhanced 
expression of CD25 on Treg (Salomon, Lenschow et al. 2000; Lohr, Knoechel et al. 
2003; Tang, Henriksen et al. 2003).
5.L3.3. CD40
CD40 is a member of the TNF-receptor super-family, first identified during 1985- 
1986 (Paulie, Ehlin-Henriksson et al. 1985; Clark and Ledbetter 1986). This co-
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stimulatory molecule is expressed on APCs within 6-12 hrs of stimulation (Schonbeck 
and Libby 2001). This molecule is activated by interaction with its co-receptor molecule, 
CD40L (CD 145), expressed mainly by CD4^ T cells and some CD8  ^ T cells, basophils 
and mast cells (Grammer and Lipsky 2000). CD40L is crucial for the activation and 
maturation of adaptive immunity, including antibody class-switching and induction of 
memory cells (Banchereau, Blanchard et al. 1994; Lenschow, Herold et al. 1996; 
Lenschow, Walunas et al. 1996). It is expressed on a wide range of cells including DCs, 
B cells, macrophages, ECs and SMCs.
CD40 also has specific effects on different cells, for example, macrophages need 
two signals from ThI cells in order to be activated: The first signal is provided by IFN-y 
and the second is the interaction of CD40L on Thl cells with the CD40 molecule 
expressed on macrophages. This interaction up-regulates the expression of CD40 on the 
surface of macrophages and the production of TNF-a to amplify the immune response by 
increasing reactive oxygen species and nitric oxide to destroy the engulfed microbe 
(Andrade, Portillo et al. 2005; Suttles and Stout 2009). Another scenario occurs when B 
cells act as APCs for T-helper cells; T-helper cells recognise the antigen presented by B 
cells, which triggers the expression of CD40L. The interaction of CD40L on T-helper 
cells with CD40 on B cells causes B cell activation, differentiation into plasma cells and 
antibody class-switching (Lenschow, Walunas et al. 1996). The expression of CD40 
molecule on B cells can be also induced by IFN-y, IL-4, anti-IgM and anti-CD20 
(Ledbetter, Shu et al. 1987; Valle, Zuber et al. 1989).
5.L3.4. CD3
When T cells encounter an antigen via the TCR, they are incapable of 
transmitting the intracellular signals as the TCR lacks an intracellular domain. Instead, 
this function is mediated by another molecule with a negatively charged intracellular 
domain, called CD3. CD3 is a macromolecular complex of glycol-proteins associated 
with the positively charged TCR and is involved in the proliferation, maturation and 
selection of T lymphocytes during their development (Alarcon, Gil et al. 2003; Abbas, 
Lohr et al. 2007). CD3 polypeptides are physically associated with either a/p or y/8  T 
cell receptor and two  ^ polypeptides subunits in the plasma membrane as it plays an 
important role in signal transduction following antigen recognition (Abbas 2004). CD3 
is composed of 4 distinct chains: one y, one 5, two ^ (Samelson, Harford et al. 1985). 
These polypeptides are members of the immunoglobulin super-family, with each one
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composed of an external domain followed by a trans-membrane domain and a conserved 
cytoplasmic domain of 40 or more amino acids (Rojo, Bello et al. 2008).
5.2. SPECIFIC AIM
The aim of this chapter was to investigate the effect of rMOMP on selective 
markers expressed on APCs (macrophages) and T cells in order to understand the 
immuno-modulatory effects of this protein on the host immune system. This task was 
undertaken in order to understand how MOMP can modulate the pathological immune 
mechanisms of atherosclerosis development.
5.3. OBJECTIVES
To achieve our aim, it was necessary to complete the objectives listed below
• To examine the effect of rMOMP on the expression levels of macrophage 
activation markers using isolated peritoneal macrophages incubated with 
different vectors encoding rMOMP. Changes in cell surface marker 
expression will be evaluated using flow cytometry analysis.
• To investigate the effect of rMOMP on the expression of markers related to 
CD4^ T cell function focusing on those involved in Treg cell differentiation 
and suppressive functions. Changes in cell surface marker expression will 
also be evaluated using flow cytometry analysis.
To study the effect of rMOMP on the activation of adaptive immune responses 
by measuring T cells proliferation. Naive CD4^ T cells will be co-cultured 
with peritoneal macrophages pre-treated with rMOMP. CD4^ T cell 
proliferation will be detected by measuring the quantity of DNA using a 
CyQuant fluorescent kit.
I l l
5.4. MATERIALS AND METHODS
5.4.1. Cell preparation
Peritoneal macrophages and CD4^ T cells were obtained from C57B1/6J male 
mice as described below.
5.4.1.1. Peritoneal macrophage isolation
Macrophages were obtained by intraperitoneal injection of mice with ImL of 
sterile 3% thioglycolate (Sigma, UK) 7 days prior to harvest. Mice were killed by 
cervical dislocation; cells were harvested by peritoneal lavage with lOmL of 4°C RPMI- 
1640 media supplemented with PSG. Cells were collected by centrifugation at 400 x g 
for 10 min at 4°C and the cell pellet was resuspended in 3mL of IX red blood cell lysis 
buffer (R&D systems, UK) and incubated for 10 min at RT. Then 30mL of RPMI-1640 
was added and the cell suspension was washed twice for 5 min at 400 x g. The 
supernatant was discarded and the cells resuspended again in ImL of RPMI-1640 
supplemented with 10% PCS and 10% PGS. Cells were stained and counted using the 
Trypan blue (Sigma, UK) exclusion method. Cells were then cultured in 24 well plates 
at a density of 1x10^ cells/well in triplicate at 37°C, 5% CO2 for 48 hrs. Non-adherent 
cells were washed out of the cultures twice using RPMI-1640 with 10% PCS and PGS, 
while adherent macrophages were left in culture.
5.4.1.2. Isolation of CD4  ^T cells from splenocytes by negative selection
Spleens were collected from euthanised C57B1/6J mice. Splenocytes were 
isolated as described before in Chapter 2, section 2.2.3.1. Cells were counted using the 
Trypan blue (Sigma, UK) exclusion method and the number of cells adjusted to achieve a 
final concentration of 5x10^ live cells/mL in RPMI-1640 with 10% PCS and PGS. Cells 
were transferred into tissue culture flasks (25cm^) and incubated at 37°C, 5% CO2 for 2 
hrs in order to deplete the cultures of adherent cells. Non-adherent cells were collected 
into 50mL centrifuge tubes by centrifugation at 400 x g for 10 min. After the supernatant 
was discarded, the cells were resuspended in ImL of complete media. Cell number was 
counted and adjusted to 1x10^ cell/mL. A negative selection method was used to isolate 
CD4^ T cells. A suspension of magnetic beads; BioMag goat anti-rat IgG (Qiagen, UK), 
was washed 5 times to remove the sodium azide used as preservative, with complete 
media using a ‘20 megaoersted 15/50mL tube magnet’ (Qiagen, UK).
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In parallel, cells were labelled using Ipg/pL rat anti-mouse CDS, C D llb and 
CD 19, and 0.5pg/pL of CD 16/32 monoclonal antibody (Serotec, UK) and incubated for 
30 min at 4°C. Unbound antibodies were washed from cells by centrifugation at 400 x g 
for 10 min and cells were resuspended in ImL of complete media. Each, 1x10^ cell 
suspension, was treated with Img/mL of BioMag (magnetic beads) and incubated for 30 
min at 4°C with swirling every 2 min. Tubes were then applied to a magnetic separator 
for 10 min. Once the separation was complete, as shown by a clear supernatant, the 
supernatant was removed carefully without disturbing the magnetic beads; this step was 
repeated twice to increase the yield of CD4^ T cells. Isolated cells were collected by 
centrifugation at 400 x g for 10 min at 4°C and the pellet was resuspended finally in ImL 
of fresh complete RPMI-1640 media and cells were counted.
5.4.2. Cell treatment
5.4.2.1. Treatment o f Peritoneal macrophages
Peritoneal macrophages were treated with rMOMP expressed either by M  vaccae 
or by pcDNA-MOMP plasmid. For the latter, cells were treated with 20pg/mL of 
pcDNA-MOMP plasmid in parallel with a control group of cells treated with an equal 
concentration of empty plasmid (pcDNA3.1); each group was prepared in triplicate. The 
cells treated with rMOMP expressed by M  vaccae were divided into 3 groups. Each 
group was treated with 1:20 MOI of wild-type M  vaccae, M. vaccag-rMOMP+SPS or M  
vaccae-rMOMP-SPS in triplicate. Macrophages treated with bacteria were cultured in 
RPMI-1640 media containing 10% PCS without antibiotics. A separate group of cells 
was treated with PBS only as a negative control. All groups of cells were incubated at 
37°C, with 5% CO2 for another 48 hrs.
5.4.2.2. Co-culture o f CD4^T cells with peritoneal macrophages
After 48 hrs of incubation (above section) the media from treated peritoneal 
macrophages was carefully removed and replaced with fresh complete RPMI-1640. Cells 
were then co-cultured with CD4^ T cells (prepared as in section 5.4.1.2.) at a ratio 1:1 
CD4^T cells: macrophages and incubated at 37°C, with 5% CO2 for 5 days.
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5.4.3. Flow cytometry analysis for markers expressed on peritoneal 
macrophages and CD4  ^T cells
5.4.3.1. Cell labelling
After 5 days of incubation, flow cytometry analysis was used to investigate the 
effect of the treatments on the expression of activation and inhibitor markers on 
peritoneal macrophages and CD4^ T cells. Briefly, negatively isolated CD4^ T cells 
were collected gently from co-cultures without disturbing the peritoneal macrophages 
attached to the plastic surface of the well. Cells were counted as described above and 
were then resuspended in an appropriate volume of flow cytometry staining buffer, to a 
final concentration of 1x10^ cell/mL. The peritoneal macrophages were scraped from the 
bottom of each well and collected by centrifugation at 400 x g for 10 min and the 
supernatant discarded. Cells were resuspended in ImL of staining buffer and counted, 
adjusting the final concentration of macrophages to Ix 10  ^cell/mL.
To prevent non-specific binding of antibodies to peritoneal macrophages and 
CD4^ T cells, cells were first incubated with Ipg/lxlO^ cells of Seroblock (rat anti­
mouse CD16/CD32 monoclonal antibodies, Serotec, UK, to block Fey receptors II and 
III) for 10 min. lOOpL containing IxlO^ macrophages or CD4^ T cells was used for each 
label and mixed with the corresponding antibodies. For peritoneal macrophages, the 
extracellular activation markers, TLR2, TLR4, CD 14, MHC class-II, CD80, CD86 and 
CD40, were used, see Table 5.1, and for CD4^ T cells, extracellular markers, CD4, 
CD25, CTLA-4, CD28 and CD3 were used, see Table 5.2.
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Table 5.1. Combination of antibodies used to detect surface markers on peritoneal
Detection Staining combination Isotype
FITC or FITC or
PE Alexa488/647 PE Alexa488/647
CD40 CDllb-RPE CD40-FITC Rat IgG2b-RPE Rat lgG2a-FITC
CD80 CDllb-RPE CD80-FITC Rat IgG2b-RPE Rat IgG2a-FITC
CD86 CDllb-RPE CD86-F1TC Rat lgG2b-RPE Rat lgG2a-FlTC
MHC class-II CDllb-RPE MHC II-FITC Rat IgG2b-RPE Mouse IgM-FlTC
CD14 CDllb-RPE CD14-F1TC Rat IgG2b-RPE Rat TgGl-FITC
TLR4 CDllb-RPE TLR4-alexa 488 Rat lgG2b-RPE Mouse IgGl- Alexa 488.
TLR2 CDllb-RPE TLR2-alexa 647 Rat IgG2b-RPE Mouse IgGl- Alexa647
Negative control Unstained Unstained Unstained unstained
All antibodies used to detect surface markers on peritoneal macrophages were monoclonal 
antibodies used to detect MHC class-II, TLR2 and TLR4, which were monoclonal mouse 
(Appendix 2, Tab le l).
rat anti-mouse, except 
anti-mouse antibodies
T ab le  5 .2 . C o m b in a tio n  o f  a n t ib o d ie s  u s e d  to  d e te c t  s u r fa c e  m ark ers o n  C D 4+ T c e l l s  by
Description Staining combination Isotype
CD25 CD4-Alexa 647 CD25-F1TC Rat IgG2b-Alexa 647 Rat IgG 1-FITC
CTLA-4 CTLA-4-RPE CD4- Alexa 647 Hamster IgG-RPE Rat lgG2b-Alexa 647
CD28 CD28-Alexa 647 CD4-FITC
Mouse IgGl- 
Alexa 647 Rat lgG2a-FlTC
CD3 CD4-Alexa 647 CD3-FITC Rat lgG2b-Alexa 647 Rat IgG2a-FlTC
Negative control Unstained Unstained Unstained unstained
All antibodies used to detect surface markers on CD4 T cells were monoclonal rat anti-mouse, except the antibody used 
to detect CD28, which was a monoclonal mouse anti-mouse and the antibody used to detect CTLA-4, which was a 
monoclonal hamster anti-mouse antibody (Appendix 2, Tablel).
Cells and antibodies were mixed gently, followed by incubation at 4°C in 
darkness for 30 min. Cells were then washed twice by centrifugation using 2mL o f  flow  
cytometry washing buffer. Cell pellets were resuspended in 0.3mL o f  1% (v/v) 
formaldehyde (Sigma, UK) PBS and kept at 4°C until flow  cytometry analysis.
5.4.3.2. Detection surface markers expressed either on peritoneal macrophages or on 
CD4^ T cells by flow cytometry
Samples were analysed for fluorescein isothiocyanate (FITC; excitation X at 
488nm and emission X at 525nm), A lexa Fluor 488 (excitation X at 488 nm and em ission  
X at 519 nm), phycoerythrin (PE; excitation X at 488nm and emission X at 578nm), 
allophycocyanin (APC; excitation X at 633 nm and emission 1 at 661 nm), and A lexa 647 
(excitation X at 633nm and emission X at 668nm) using BD FACS Canto and BD
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FACSDiva Software v 5.03, 2007 (Becton Dickinson). Data were generated using 5x10"^  
cells for each sample and analysed. Appropriate negative controls (unstained cells and 
cells stained with isotype controls) were used to set up the gating and quadrants for each 
fluorochrome.
To investigate the effect of treatments on specific markers expressed on 
peritoneal macrophages (TLR2, TLR4, CD 14, CD80, CD86 and CD40) or on activation 
and inhibitory markers expressed on CD4^ T cells (CD25 CTLA-4, CD28 and CD3), 
double labelled cells with fluorochrome-conjugated antibodies were analysed by flow 
cytometry. Each experiment was repeated in triplicate. For peritoneal macrophages, the 
analysis was performed using the following strategy: cells were first gated depending on 
their morphological properties (size and complexity) using forward versus side scatter 
(FSC-H vs SSC-A) and aggregated cells and debris were excluded from the analysis. 
Then, the cell population of interest (selected above) was displayed as contour maps or as 
dot plots for binary analysis depending on the fluorescent marker of interest. Quadrants 
were applied to these binary plots to allow selection of double positive cells expressing 
the phenotypic and the specific activation/inhibition markers. These quadrants were 
adjusted based on the staining given by the isotype control and unstained cells (negative 
control), see Figure 5.2. A similar strategy was used for CD4^ T cells analysis, see 
Figure 5.3.
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5.4.4. Analysis of CD4 T cell proliferation using the CyQuant kit
In order to evaluate the effect o f  rMOMP on CD4^ T cell proliferation, 1x10^ 
eells/mL peritoneal macrophages were treated with 20pg/m L o f  pcD N A S.l or pcD NA - 
MOMP, 1:20 MOI o f  wild-type M. vaccae, M. vaccr/e-rMOMP+SPS or M  vaccae-vM O M ?- 
SPS. Treated cells were incubated at 37°C with 5% CO2 for 48 hrs. After incubation, media 
was replaced with complete RPMI-1640 containing IxlO^cells/mL naïve CD4^ T cells and 
plates were incubated at 37°C with 5 % CO2 for 7 days. A separate group o f  freshly isolated 
CD4^ T cells (IxlO^cells/mL) were immediately frozen at -80°C to be used in the standard
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curve for the CyQuant assay. After 7 days of incubation, CD4^ T cells were gently collected 
into micro-centrifuge tubes and frozen at -80°C until CyQuant analysis.
The CyQuant cell proliferation kit (Invitrogen, UK) is a convenient and a sensitive 
procedure for determining the number of cells in culture. The assay works within linear 
detection range extending from 50 or fewer to at least 50,000 cells. By increasing the dye 
concentration, the linear range can be extended up to approximately 250,000 cells (Jones, 
Gray et al. 2001). The basic principle of this kit depends mainly on the green fluorescent 
dye, CyQUANT GR, which exhibits strong fluorescence enhancement when bound to 
cellular nucleic acids. Samples were prepared according to manufacturer’s instructions. 
Briefly, cells were thawed at room temperature and lysed by addition of ImL of buffer 
containing the CyQUANT GR dye/cell-lysis buffer and vortexing. For the standard curve, a 
serial dilution of CD4^ T cells was generated in the wells of a micro-plate using CyQUANT 
GR dye/cell-lysis buffer to obtain dilutions ranging from 3100 -  200 000 cells in a total 
200pL volume; including a 200pL sample with no cells as a negative control. At the same 
time, cell samples were diluted 1:2 in CyQUANT GR dye/cell-lysis buffer, to give a final 
volume of 200pL. Plates were incubated for 5 min at RT in dark. Fluorescence of the 
samples was measured using a fluorescence Bio-Tek RLX800 plate reader coupled with KC4 
software version 3.4 (Bio-Tek Instruments Inc., Ontario, Canada). The excitation maximum 
was approximately 485nm; the emission maximum was approximately 535nm.
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5.5. RESULTS
The effect of rMOMP on the expression level of specific markers expressed on 
peritoneal macrophages and CD4^ T cells was studied by flow cytometry in order to 
understand the mechanistic effect of this protein on APC and CD4^ T cell activity (APC-T 
cell cross talk).
5.5.1. rMOMP has a differential effect on the percentage of peritoneal 
macrophage expressing selective markers
The analysis revealed that cells treated with pcDNAS.l significantly increased the 
percentage of macrophage expressing TLR2 molecule compared with PBS control (93.5 ± 
1.6% vs 74.3 ± 0.4%, *p < 0.05); whereas, cells treated with pcDNA-MOMP plasmid showed 
no change with regard to expression of this molecule, see Figure 5.4 A. On the other hand, 
cells treated with M. vacc^re-rMOMP+SPS showed a significant decrease in the percentage of 
macrophage expressing TLR2 molecule compared to that of the PBS control (22.8 ± 4.2% vj 
74.3 ± 0.4%, < 0.05); while no other treatments had any effect on this marker, see Figure
5.5 A. Moreover, the flow cytometry analysis showed no effect on the number of 
macrophages expressing TLR4 or CD 14 molecules upon treated with rMOMP expressed by 
either eukaryotic expression vector (Figure 5.4 B & C), or M  vaccae (Figure 5.5 B & C).
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rMOMP on the percentage o f cells expressing the above mentioned markers are presented as mean 
± SD o f three independent experiments. A sterisks indicate s ignificant differences com pared to PBS 
and w ild-type M. vaccae treated control cells (*p < 0.05).
The effect of rMOMP on the percentage of macrophage expressing MHC class-II had 
also been investigated in this study. The analysis showed that the percentage of peritoneal 
macrophages expressing MHC class-II significantly increased upon treatment with pcDNA- 
MOMP compared to PBS control (5.6 ±  \% v s  2.4 ± 0.7%; *p  <  0.05), see Figure 5.6 A. The 
same finding was observed with cells treated with M. vaccr/e-rMOMP+SPS compared to the 
PBS control group (10.6 ± 5.3% vs 2.4 ± 0.7%; *p  <  0.05), see Figure 5.7 A. All other
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treatments showed no significant alteration to the number of macrophages expressing MHC 
class-II molecule when compared to control groups. Moreover, the analysis revealed that 
vectors carrying rMOMP had no effect on the percentage of peritoneal macrophages 
expressing either CD80 or CD86 molecules; see Figure 5.6 B & C and Figure 5.7 B & C, 
respectively.
Interestingly, the most striking results were seen when the percentage of peritoneal 
macrophages expressing CD40 molecule significantly increased upon empty DNA plasmids 
treatments compared with that treated with PBS (9.4 ± 3.7% v^ ' 0.2 ± 0.1%, ***/> < 0.001) 
and this percentage was in turn significantly decrease upon pcDNA-MOMP (2.5 ± 0.4% V5 
9.4 ± 3.7%, ***p < 0.001), see Figure 5.6 D. Moreover, the percentage of cells expressing 
CD40 molecule significantly decreased upon treated with M  vaccae-MOMP-SPS compared 
to the percentage of cells treated with wild-type M  vaccae (0.05 ± 0.0.05% vs 1.75 ± 0.6%, 
**/> < 0.01), see Figure 5.7 D. However, treatment with M  vaccae-MOMP+SPS showed no 
effect on the percentage of cells expressing this molecule.
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125
5.5.2. rMOMP expressed by M. vaccae and pcDNA-MOMP plasmid increased 
the percentage of Treg cells and CD4^ T cells expressing other suppressive 
markers
In this study we investigated whether rMOMP expressed by different veetors eould 
affect the percentage of CD4^ T cells expressing suppressive markers using flow cytometry. 
To this effect, we investigated the effect of rMOMP on the percentage of CD4^CD25^ T 
cells. pcDNAS.l and pcDNA-MOMP treatments had no significant effect on CD4^CD25^ T 
cell numbers; see Figure 5.8 A. On the contrary, the percentage of CD4^CD25^ T cells in the 
total population significantly increased when naïve CD4^ T cells were co-cultured with 
peritoneal macrophage treated with M  voccoe-rMOMP+SPS compared with the PBS and 
wild-type M  vaccae positive controls (7.6 ± 1% vs 2.1 ± 0.3%,***p < 0.001 and 7.6 ± 1% vs 
2.7 ± 0.8%, <0.01, respectively). The same observation was found in cells treated with
M. vflccae-rMOMP-SPS compared with PBS and wild-type M  vaccae control groups (4.8 ± 
0.2% vs 2.1 ± 0.3%, **p < 0.01 and 4.8 ± 0.2% vs 2.7 ± 0 . 8 % , <  0.05, respectively), see 
Figure 5.9 A.
The analysis revealed that rMOMP encoded by the pcDNA-MOMP plasmid did not 
have an effect on the number of CD4^ T cells expressing CTLA-4 molecule, see Figure 5.8 
B. In contrast, the percentage of cells expressing CTLA-4 molecule was approximately 3- 
fold higher in the group treated with M. v«ccae-rMOMP-SPS compared to PBS controls and 
the wild-type M. vaccae positive control (6.1 ± 0.4% V5 2 ± 1.5% and 2 ± 0.8%, < 0.05;
respectively). A similar increase was observed in the group treated with M  vaccae- 
rMOMP+SPS, where the percentage of cells expressing CTLA-4 was also higher than in the 
populations of cells treated with PBS and wild M. vaccae controls (7.2 ± 1.6% v.s' 2 ± 1.5% 
and 2 ± 0.8%, **p < 0.01; respectively); see Figure 5.9 B. The percentage of CD4^ T cells 
expressing CD28 was also assessed in this study. Flow cytometry analysis illustrated that 
none of the treatments had an effect on the percentage of CD4^ T cells expressing CD28 
molecule; see Figure 5.8 C and Figure 5.9 C.
The percentage of CD4"^  T cells expressing CD3 molecule was studied using 
splenocytes following depletion of CD8  ^T cells. The number of cells expressing CD3 were 
significantly reduced by treatment with pcDNA-MOMP compared to the peDNA3.1 control 
group (45.3 ± 3% vs 53.7 ± 3%, < 0.05); see Figure 5.8 D. Conversely, the number of
cells expressing CD3 increased significantly after treatment with wild-type M. vaccae, M.
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vaccûre-rMOMP+SPS and M. vaccnf^-rMOMP-SPS compared to the PBS control group (81.3 
± 4.9%, 77.8 ± 8.9% and 77.4 ± 3.4% 5.1 ± 1.3%, ***j9 < O.OOl; **p < O.Ol and **;? <
0.01, respectively); see Figure 5.9 D. However, there were no differences in the percentage 
of CD4^ T cells expressing this marker on the eells treated with either M. vaccae- 
rMOMP+SPS or M. vnrcc<2e-rM0MP-SPS compared to the wild-type M. vaccae control 
group, see Figure 5.9 D.
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***p <0.001).
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5.5.3. rMOMP expressed by pcDNA-MOMP inhibits the proliferation of CD4 T 
ceils
The effect of rMOMP on CD4^ T cell proliferation was also assessed in this study. 
Interestingly, results showed that pcDNA-MOMP had a significant inhibitory effect on CD4^ 
T cell proliferation compared with the effect of treatment with the pcDNAS.l empty vector 
(28702 ± 286 46502 ± 633, < 0.05), see Figure 5.10 A. In contrast, the results also
demonstrated that cells treated with M. vaccae, M. vr/ccag-rMOMP+SPS and M. vaccae- 
rMOMP-SPS showed significantly enhanced CD4’*’ T cell proliferation compared with PBS 
controls (61695 ± 779, 60219 ± 514 and 6100 ± 479 37901 ± 5 2 3 , <  0.05, **p < 0.01,
<0.01, respectively), see Figure 5.10 B.
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5.6. DISCUSSION
Although the Ch. pneumoniae MOMP was considered one of the most important 
vaccine candidates against this pathogen, the effect of MOMP on innate immune parameters 
has not as yet been fully investigated. In fact, innate and adaptive immune responses are 
linked by communication channels that allow innate signals to influence the quality of the 
adaptive response and vice versa. In order to fill the knowledge gap and to extend the 
characterisation of MOMP’s involvement in the immune response, this study aimed to 
determine the effect of rMOMP expressed either by M. vaccae or by eukaryotic expression 
vectors on selective markers expressed by APCs involved in the induction of both innate and 
adaptive immune responses. We also aimed to understand how the effects on APCs could be 
translated into downstream effects on T lymphocytes markers, which would further elucidate 
the nature of MOMP-mediated immune responses. The cell-surface markers studied were 
also chosen because of their involvement in the pathological immune response of 
atherogenesis, which is the main research area of this thesis. To analyse the effect of 
rMOMP on these markers, peritoneal macrophages were used as a model of APCs using 
C D llb as a phenotypic marker (Shaw and Griffin 1982; Leenen, de Bruijn et al. 1994).
Herein, we investigated for the first time the effect of rMOMP on the percentage of 
peritoneal macrophages expressing PRRs such as TLR2 and TLR4, in addition to the CD 14 
co-receptor molecule. Our results showed that only rMOMP expressed by M. vaccae 
significantly decreased the number of macrophages expressing TLR2 compared to that 
treated by the PBS control group, without affecting percentage of cells expressing TLR4 or 
CD 14. The other recombinant vectors had no effect on number of cells expressing TLR or 
CD 14 expression, suggesting a vector-related effect. However, the treatment with wild-type 
M  vaccae had no effect on the percentage of macrophages expressing TLRs or CD 14. This 
latter observation was unexpected as previous works have shown that wild-type M  vaccae 
can up-regulate the expression of TLRs and CD 14 on APCs in vitro and in vivo (Martinelli
2004). Moreover, these bacteria have been used as adjuvant in pharmacological preparations, 
to treat diseases such as asthma, tuberculosis and cancer due to their ability to induce TLRs 
using specific mycobacterial-derived molecules such as lipoarabinomannan (Means, Wang et 
al. 1999).
A potential explanation for the contrary observations in our study could be due to the 
cell-type (peritoneal macrophage) and pre-treatment (thioglycolate effect) involved in the
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study design. Herein, peritoneal macrophages obtained from thioglycolate-treated animals 
were used with the objective of enhancing the number of recruited peritoneal macrophages 
(Cohn 1978; Eichner and Smeaton 1983). Previous studies have shown that thioglycolate- 
induced peritoneal macrophages can express high levels of TLR2 and low levels of TLR4, 
therefore showing a different phenotype and immunological response pattern than those 
obtained from untreated animals (Renshaw, Rockwell et al. 2002). Furthermore, previous 
studies have reported that thioglycolate-induced peritoneal macrophages are less phagocytic 
compared to resident macrophages (Miake, Takeya et al. 1980; Leijh, van Zwet et al. 1984). 
This evidence may explain why the peritoneal macrophages used in this study did not 
demonstrate induced TLR expression upon treatment with wild-type M. vaccae (potent 
activation for these markers). However, to be certain of this hypothesis, further studies to 
elucidate the effect of M. vaccae using resident macrophages or un-induced macrophages 
under the same experimental conditions would need to be conducted.
One of the most interesting findings in relation to the expression of specific markers 
of inflammation was the effect of rMOMP on the percentage of macrophages expressing 
CD40 molecule. Our results revealed that the number of cells expressing CD40, the only 
investigated co-stimulatory marker expressed by AFC, is inhibited by rMOMP. The 
percentage of cells expressing this molecule was significantly reduced upon pcDNA-MOMP 
treatment compared to those that were treated with empty plasmid. This effect was similar to 
the one observed in macrophages treated with M. voccog-rMOMP-SPS compared with cells 
treated with M. vaccae. This finding is significant since we know that MOMP molecule 
plays a significant role in both stimulation of host immune responses against pathogen 
infection and also in the pathological mechanisms leading to atherogenesis (Hayashi, Rao et 
al. 1999; Schonbeck, Sukhova et al. 2000; Suttles and Stout 2009; Martin, Agarwal et al. 
2010). Previous studies have reported that a decreased expression of CD40 by immune cells 
contributes to Treg cell differentiation, which can in turn suppress protective pro- 
inflammatory immune responses, indicating a potential immune suppressor effect of MOMP 
(Martin, Agarwal et al. 2010).
MOMP could also contribute to the down-regulation of immune responses by 
inhibiting B cell maturation and isotype class-switching, suppression of T cell proliferation, 
macrophage activation and secretion of pro-inflammatory cytokines such as IFN-y and TNF- 
a; all of which are known to be mediated by CD40 (Banchereau, Blanchard et al. 1994; 
Andrade, Portillo et al. 2005; Suttles and Stout 2009). Therefore, our results support the
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hypothesis that MOMP could act during chlamydial infection as a suppressor of immune 
responses using the above mentioned mechanisms. However, further experiments are 
required to firmly demonstrate this hypothesis and identify the exact mechanism of action. 
An important piece of data that is consistent with the above mentioned effects is that anti- 
MOMP specific IgM, IgA, IgGl and IgG2a antibodies were not at high enough titres to be 
detected in the plasma of animals immunised with rMOMP in the previous chapter. In the 
context of atherosclerosis, it has been shown in animal studies that by blocking the 
interaction of CD40 with CD40L using antibodies, atherosclerosis development can be 
reduced (Mach, Schonbeck et al. 1998; Lutgens, Cleutjens et al. 2000; Schonbeck and Libby 
2001). It has been also reported that genetic mutations in the gene encoding CD40L can 
decrease the size of atherosclerotic lesions (Lutgens, Gorelik et al. 1999). Furthermore, the 
pro-atherogenic role of CD40 molecules seems to be mediated by an increased production of 
pro-inflammatory cytokines, chemokines, adhesion molecules, metalloproteinases, and tissue 
factor pro-coagulants (Karmann, Hughes et al. 1995; Schonbeck and Libby 2001). 
Additionally, platelets can be activated by CD40/CD40L interactions leading to thrombosis 
following plaque rupture (Henn, Slupsky et al. 1998; Inwald, McDowall et al. 2003). These 
previous findings suggest that the inhibitory effect of MOMP on CD40 expression could have 
significant therapeutic implications for the treatment of atherosclerosis.
Other cell surface molecules involved in APC-lymphocyte crosstalk also play a key 
role in atherosclerosis. We focused on investigating the effect of MOMP on the percentage 
of cells expressing CD28/CTLA-4 receptors by CD4^ T cells, which provide the second 
signals required for the activation/suppression of lymphocytes upon TOR engagement. 
During physiological conditions, CTLA-4 and CD28 expressed on the surface of CD4^ T 
cells are in constant competition to ligate with CD80/CD86 co-stimulatory molecules 
expressed by the APCs. Engagement of CD28 with CD80/CD86 triggers T cell proliferation 
and differentiation, whereas ligation of CTLA-4 with CD80/CD86 suppresses T cell 
activation (Waterhouse, Penninger et al. 1995). Interestingly, M  vaccae-rMOMP+SPS and 
M. vaccoe-rMOMP-SPS enhanced the percentage of CD4^ T cells expressing CTLA-4. This 
finding further supports our hypothesis that MOMP has a suppressor effect on immune 
responses via inhibition of T cells and induction of apoptosis, although the latter requires 
further experimental evidence. This is another interesting finding that could have 
implications in the selection of immuno-modulatory strategies to treat atherosclerosis. 
Studies using animal models of the disease have shown that CTLA-4; now considered as a
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classical marker of Treg cells with an ‘athero-protective role’, is a major negative regulator of 
T cell-mediated immune functions in the process of atherosclerosis, leading to a significant 
reduction in lesion size (Paust, Lu et al. 2004; Jacobson and Tomer 2007; Sier 2010).
The effect of rMOMP on T cells can also be assessed by measuring the expression of 
molecules such as CD25; the alpha chain of the lL-2 receptor. The other potential suppressor 
evidence, that may point out MOMP’s suppressor properties, was an increase in the 
percentage of CD4^CD25^ T cell upon treatment with rMOMP expressed by M  vaccae- 
rMOMP+SPS and M. vaccae-rMOMP-SPS. It is known that CD25 is highly expressed by 
Treg cells, which are capable of suppressing the immune response via cell-cell contact 
mechanisms or via the secretion of anti-inflammatory cytokines such as lL-10 and TGF-p, 
both of which inhibit adaptive and innate immune responses (Taams, van Amelsfort et al.
2005). However, further studies are required to ascertain whether these CD25^ cells are truly 
Treg cells or conventional T cells. Analysis of the expression of FoxP3 (a transcription factor 
known to be selectively expressed by Treg cells), the secretion of lL-10 and TGF-p and 
functional inhibitory assays are some of the methods that could be employed to help us 
validate this hypothesis.
The idea to study the effect of MOMP on the expression of CD3 on T cells was 
prompted by a previous study reporting that human lymphocyte Molt-4 cells infected with 
Ch. pneumoniae could alter the expression of CD3, whereas heat denatured bacteria or lysate 
bacteria did not have this effect (Yamaguchi, Matsuo et al. 2008). Based on this evidence, 
we decided to examine whether MOMP was involved in regulation of CD3 or not. 
Interestingly, cells treated with pcDNA-MOMP showed significant inhibition of the CD4+ T 
cell percentage expressing CD3 molecule compared with that treated with empty plasmid. 
The same treatment showed a significant inhibition of CD4^ T cells proliferation. These 
findings are consistent with published literature showing that blocking of CD3 
expression/signalling using anti-CD3 antibodies leads to a dramatic inhibition of T cell 
functions including cyto-toxicity and cell proliferation. In these previous experiments, the 
authors showed that T lymphocytes lost their ability to recognise antigens by inhibition of 
CD3 expression/signalling, which may also be involved in the delivery of inhibitory signals 
leading to induction of immunosuppressive responses (Reinherz, Hussey et al. 1980). 
Recently, biochemical studies revealed that down-regulation of the CD3 molecule mediated 
by anti-CD90 antibody treatment, inhibited T cell activation and proliferation by impairing 
lL-2 secretion (Nishida, Chen et al. 2011). Furthermore, others have found that anti-CD3
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antibodies can have a crucial role in induction of tolerance by stimulation of the CD4^CD25^ 
T cell population (Belghith, Bluestone et al. 2003; Fallarino, Grohmann et al. 2003). This 
finding further supports our hypothesis for the anti-inflammatory role of MOMP, which in 
our case could be acting via the inhibition of CD3 expression, leading to an increase of Treg 
cell numbers (Plain, Chen et al. 1999; Bisikirska, Colgan et al. 2005; Steffens, Burger et al.
2006).
Our findings, especially the effect of rMOMP on CD3 expression may suggest a 
potential role for MOMP in the pathogenesis of Ch. pneumoniae infection. Indeed it has 
been reported that anti-CD3 antibodies can suppress Thl immune responses; a protective 
response in terms of chlamydial infection, and also stimulate the Th2 un-protective immune 
response (Smith, Tang et al. 1998; Plain, Chen et al. 1999). In contrast, rMOMP expressed 
by M. vaccae-rMOMP+SPS and M. vaccag-rMOMP-SPS showed no effect either on CD3 
molecule expression or on the proliferation of CD4^ T cells compared to cells treated with 
wild-type M  vaccae. These results could be due to the fact that M  vaccae alone can 
potentially enhance Thl immune responses along with other activator markers (Skinner, 
Yuan et al. 1997; Janssen, Kruisselbrink et al. 2001; Hemandez-Pando, Aguilar et al. 2008). 
Therefore, the effect of MOMP on these markers could be masked by the powerful effect of 
M. vaccae acting as an adjuvant.
Finally, these results suggest that rMOMP modulates host immune response via 
inhibition the percentage of APC (peritoneal macrophages) expressing CD40 molecules, 
which act as a second co-stimulatory signal after IFN-y secretion by Thl cells, leading to a 
wide range of suppressive immune responses (Caux, Burdin et al. 1994; Grewal and Flavell 
1998; Suttles and Stout 2009). That effect was combined with enhancing the percentage of 
CD4^ T cells expressing CTLA-4 and CD25 suppressive molecules that are considered 
classical Treg cell markers. However, investigating the effect of MOMP on the well 
documented suppressive marker, FoxP3 is necessary. Another important finding from this 
study was that the inhibitory effect of rMOMP on the percentage of CD4^ T cells expressing 
CD3 molecule. These findings support our hypothesis that MOMP may have anti­
inflammatory properties, causing suppression of immune responses. Therefore, these 
observations indicate the anti-inflammatory properties of MOMP that can potentially be 
harnessed to treat auto-immune diseases such as atherosclerosis.
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CHAPTER 6
EFFECT OF IMMUNISATION WITH RECOMBINANT CH. 
PNEUMONIAE MOMP ON THE DEVELOPMENT OF 
ATHEROSCLEROSIS
135
6.1. INTRODUCTION
The pathological inflammatory mechanism involved in atherogenesis is regulated, 
amongst other means, by polarisation of Thl versus Th2 immune responses (Hansson and 
Libby 2006). It has been reported that Thl cells act as pro-atherogenic, whereas Th2 cells act 
as an athero-protective manner (Hansson, Libby et al. 2002). Recently, other T cell subsets 
such as Treg and T hl7 cells have also been shown to regulate the balance between pro- and 
anti-atherogenic effects. Additionally, it is now well known that this inflammatory 
mechanism is triggered by the accumulation of LDL and cholesterol in the arterial wall. 
Understanding this pathological inflammatory mechanism of atherosclerosis has led to the 
identification of novel therapeutic agents with the potential to modulate the immune response 
(Nilsson, Hansson et al. 2005; Hansson 2009).
Two main approaches have been used to manipulate the progression of this 
inflammatory disease: Immuno-suppressive drugs and immunisation (Hansson and Nilsson 
2009). A wide range of immuno-suppressive drugs have been applied to animal models and 
humans; these include anti-inflammatory corticosteroids, cytotoxic drugs and fungal and 
bacterial dérivâtes that inhibit T cell activation (Marx and Marks 2001; Hansson and Nilsson 
2009). Most of these drugs act as blocking agents of TNF-a receptors, in order to suppress 
the pathological inflammatory immune response not only by inhibiting the expression of pro- 
inflammatory cytokines and chemokines but also by reducing MMP production without 
alteration of the plasma lipid profile (Seriolo, Paolino et al. 2006; van Eijk, de Vries et al. 
2009). Other effective therapeutic agents block either IL-6 or IL-1 receptors, although some 
of these drugs are associated with increasing blood lipid levels clinically (Markus, Labrum et 
al. 2006; Salloum, Chau et al. 2009). The most successful anti-inflammatory drugs are the 
statins, which are relatively safe and efficient at lowering blood lipid concentration (Mega, 
Morrow et al. 2006; Morrow, de Lemos et al. 2006; Steffens and Mach 2006).
The other, prophylactic rather than treatment approach for atherosclerosis, is 
immunisation. The success of this approach depends mainly on understanding the role of the 
specific effector CD4^ T cell subsets (Thl, Th2, T h l7 and Treg cells) involved in 
atherosclerosis and on targeting specific markers involved in modulation of immune 
homeostasis. The latter targets are the co-stimulatory molecules, such as ICOS, PD-1, 
OX40L, CD40, CD40L and CD 137 (Ait-Oufella, Salomon et al. 2006; Gotsman, Sharpe et al. 
2008; Klingenberg and Hansson 2009; Olofsson and Bjorkbacka 2009). The basic principle
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of this approach is expansion of the protective Treg pool that can be prompted either by 
active administration of selective anti-inflammatory antigens or by adaptive transfer of Treg 
cells expanded ex vivo (Mor, Luboshits et al. 2006; de Boer, van der Meer et al. 2007). 
Several antigens have been used to induce tolerance and arrest progression of the 
inflammatory responses. Some of these antigens were derived from oxLDL, for example 
oxidized phospho-lipid; the first antigen identified from oxLDL (Palinski, Horkko et al. 1996; 
Binder, Horkko et al. 2003) and apoB-100, obtained after proteolytic degradation of oxLDL 
(Hermansson, Ketelhuth et al. 2011). Other antigens, such as HSP60/65 and (32-glycoprotein 
I, have also been used for immunisation, which inhibit atherosclerosis development by 
inducing Treg cells (Maron, Sukhova et al. 2002; George, Yacov et al. 2004; Hansson and 
Nilsson 2009).
Interestingly, some experimental studies have shown that the atherogenic immune 
response can be modulated using selective immuno-suppressive antigens from pathogens, via 
expansion of anti-atherogenic Treg cell populations. The use of measles virus nucleoproteins 
is one example of this approach (Ait-Oufella, Horvat et al. 2007; Griffin 2010). One 
pathogen used to modulate the progression of atherosclerosis development by producing 
antibodies blocking oxLDL epitopes, is Streptococcus pneumonia, which shares molecular 
mimicry with oxLDL epitopes (Binder, Horkko et al. 2003). Recently, Mycobacterium bovis 
(Bacillus Calmette-Guérin; BCG) killed by extended snap freeze-drying has been also used to 
prevent and treat atherosclerosis through its action of enhancing the proliferation of Treg 
cells, by inhibition of NF-k|3 activation, and increasing the expression levels of peroxisome 
proliferator-activated receptor (PPAR)-y without altering PPAR-a levels (Marchai 2011).
Previous studies have shown that the Ch. pneumoniae MOMP can induce a Th2 
driven anti-inflammatory immune response and inhibit macrophage and T cell proliferation in 
vitro and in vivo (Shaw, Grund et al. 2002; Bermudez-Fajardo 2011). We have previously 
found that this effect is due to an increase in the proliferation of Treg cells, which could 
greatly inhibit plaque development in atherosclerotic experimental animal models. This 
protective effect is also linked to a down-regulation of specific receptors that participate in 
the initiation of pro-inflammatory reactions (Bermudez-Faj ardo 2011). In the light of this 
accumulated evidence, we decided to investigate the anti-inflammatory properties of MOMP 
on atherosclerosis development using an apoE'^' mouse model.
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ApoE'^' mice are one of the most widely used and the best characterised models 
available to study atherosclerosis development. This animal model was generated in 1992 by 
introducing a mutation to the apoE gene that encodes the protein responsible for transport of 
cholesterol and other lipids from peripheral tissues to the liver (Greenow, Pearce et al. 2005). 
Chimeric mice were generated by blastocyst injection of C57B1/6J mice to produce mutant 
embryonic stem cells. These mice produced chimeras that transmitted the mutant apoE gene 
to their progeny. Mice homozygous for the disrupted gene were produced from 
heterozygotes after several crossings. The fertility of homozygous animals is similar to the 
wild-type mice. Moreover, the body weight for these animals is similar to normal mice, 
although there are differences in their lipid and lipoprotein profiles (Piedrahita, Zhang et al. 
1992; Capecchi 2001). The apoE'^' strain of mice have 5 times higher levels of cholesterol 
compared to their background strain litter mates: 8 mmo/L compared to 2 mmo/L in 
C57B1/6J mice. In addition, apoE'^" mice carry only 45% of the normal levels of HDL and 
they have 68% more triglycerides than wild-type mice and are also characterised by a 
dramatic shift in the plasma lipoprotein profile, from HDL to VLDL (Jawien, Nastalek et al. 
2004). ApoE"'^ " mice develop atherosclerosis spontaneously with normal chow diet, with the 
possibility to accelerate onset and progression by the provision of a high fat diet (Breslow 
1996; Hansson 2002).
Lesion development in this strain of mice is similar to that in humans (Nakashima, 
Plump et al. 1994; Coleman, Hayek et al. 2006). For example, apoE'^' mice show a 
significant increase in the expression of adhesion molecules on endothelial cells when 4-5 
weeks old, leading to an increase in the migration of monocytes into the intimai layer. At 6- 
10 weeks of age, these mice exhibit fatty streak lesions composed of foam cells and SMCs. 
By the time the fatty streaks develop into advanced lesions, plaques are characterised by the 
development of a necrotic core surrounded by proliferating SMCs with a variable amount of 
collagen and elastin deposition with the potential to develop into fully calcified lesions 
(Reddick, Zhang et al. 1994). Recent studies have confirmed that this mouse strain is 
susceptible to plaque rupture, especially in the brachiocephalic artery when fed on a high fat 
diet (Williams, Johnson et al. 2002). In addition to this, it has been reported that the immune 
response for apoE" '^ mice is mainly Thl-mediated and characterised by high levels of IFN-y 
secretion (Zadelaar, Kleemann et al. 2007). Based on this evidence, we hypothesise that the 
anti-inflammatory properties of MOMP may be capable of modulating the inflammatory 
mechanisms of atherosclerosis development, leading to the arrest of atherogenesis.
138
6.2. SPECIFIC AIM
The aim of this chapter was to investigate the effect of rMOMP expressed either by 
M  vaccae or pcDNA-MOMP on atherosclerosis development in vivo.
6.3. OBJECTIVES
The objectives listed below were necessary to fulfil the above stated aim:
• To investigate the effect of rMOMP on the proliferation of CD4^, CD8^ T and Treg 
cells from the splenocytes of immunised mice using flow cytometry analysis.
• To assess the effect of rMOMP on the cellular immune response by measuring the 
concentration of IFN-y, IL-10, IL-4 and TGF-p levels in the supernatant of 
splenocytes isolated from immunised mice using ELISA.
• To study the effect of rMOMP on the humoral immune response by measuring the 
production of specific anti-rMOMP IgGl, IgG2a, IgM and IgA in the plasma of 
immunised mice using ELISA.
• To examine the effect of rMOMP immunisation on the plasma lipid profile (total 
Cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides) using commercially 
available kits.
• To study the effect of rMOMP immunisation in the development of atherosclerotic 
plaques in the aortic sinus and brachiocephalic artery using histological and 
morphometric analysis.
• To determine the effect of rMOMP immunisation on atherosclerotic plaque stability 
by measuring collagen and SMC compositions in sections of aortic sinus and 
brachiocephalic arteries using histological and morphometric analysis.
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6.4. MATERIALS AND METHODS
6.4.1. Mice
6-8 weeks old male apoE deficient mice (apoE’^ '), strain B6.129P2-ApoetmlUnc/J 
(Charles River Ltd, UK) bred in house, were used in this study. Animals were housed in 
standard conditions: Temperature; 20-22°C, relative humidity; 30-70%, 12 hrs light: dark 
cycle and with free access to food and water. Animals were divided into 6 groups of 10 
animals each. Groups consisted of untreated controls; wild-type mice, M  vaccae control, M. 
vflcc«e-rMOMP+SPS, M. vaccae-rMOMP-SPS, pcDNA3.1 control and pcDNA-MOMP 
treated. Experiments were conducted in accordance with the local and Home Office animal 
(Scientific Procedures) Act, 1986.
6.4.2. Immunisation protocol
Mice were fed a chow diet for 16 weeks. All groups of 10 animals were immunised 
intranasally as described previously (Chapter 2, Section 2.2.2). Three groups were 
immunised with 2.5x10^ CPU of M  voccae-rMOMP+SPS, M. vaccae-rMOMP-SPS or wild- 
type M  vaccae in a 20pL total volume of PBS. The other 2 groups were immunised with 
lOOpg of empty pcDNA3.1 or pcDNA-MOMP in 20pL of PBS. In addition, there was an 
extra control group that remained untreated for the duration of the experiment. Animals 
received three boosters two weeks apart (at weeks 2, 4, 8), followed by a fourth booster at 
week twelve (Figure 6.1). Mice were euthanized at week sixteen (21 to 22 weeks old) by 
intra-peritoneal injection with sodium pentobarbital (lOOmg/kg) (VetTech, UK). Blood was 
collected from the abdominal aorta and plasma was obtained after centrifugation at room 
temperature for 10 min at 6000 x g, and then stored at -80°C until further analysis. Spleens 
were also collected from each animal. Animals were then perfused via the left cardiac 
ventricle with PBS at a constant pressure of 100 mmHg (ImmHg = 133 Pa). The 
brachiocephalic artery and heart were dissected free of connective tissue and fat, then fixed in 
10% (v/v) formalin in PBS for histological and immunohistochemistry analysis.
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F igu re 6 .1 . T h e Im m u n isa tio n  p r o to c o l u s e d  to  s tu d y  th e  e f f e c t  o f  th e  Ch. pneumoniae 
MOMP on  a th e r o s c le r o s is  d e v e lo p m e n t  u s in g  a p o E  m a le  m ic e . Six groups, 10 anim als 
each, w ere used. Anim als received 5 doses of lOOpg o f pcD NAS.l or pcDNA-M O M P, 2.5x10® 
CPU of M. vaccae-rMOM P+SPS, M. vaccae-rM OM P-SPS or w ild-type M. vaccae control in a 
total volum e o f 20pL PBS. Blood was collected from  the tail by vein puncture during pre­
immunisation and before each booster dose. Upon term ination, blood was collected from the 
abdominal aorta. The spleen, heart and brachiocephalic artery were collected fo r further studies.
6.4.3. Detection of Treg cells by flow cytometry analysis
Spleens were eollected after termination and splenocytes were isolated and counted as 
described in Chapter 2, section 2.2.3. Briefly, 1x10^ cells per sample were labelled with rat 
anti-mouse fluoreseently tagged monoclonal antibodies against: CD4 (FITC) or CD8 (FITC), 
CD25 (RPE), (AbD Serotec, UK) and FoxP3 (Alexa Fluor-647, BioLegend, UK). Samples 
were analysed by flow cytometry using a BD FACS Canto (BD Biosciences, UK) and BD 
FACS Diva™ Software (BD Bioseienees, UK). A total of 5x10^ events were reeorded and 
analysed per sample.
6.4.4. Cytokine profile measurement
Cytokines (IFN-y, IL-4, IL-10 and TGF-P) were measured in the plasma and the 
supernatant of splenocyte cultures using commercially available ELISA kits from Peprotech 
Ltd and eBioscienee (UK), following the manufacturer’s instructions. Results were obtained 
using an ELISA plate reader as described in Chapter2; Section 2.2.4.
6.4.5. Plasma antibody measurement
The humoral immune response was monitored by measuring specific anti-rMOMP 
IgGl, IgG2a, IgM and IgA antibodies in the plasma of immunised animals by ELISA as 
previously described Chapter 2, Section 2.2.5.
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6.4.6. Analysis of atherosclerotic plaques and plaque vulnerability
Both aortic sinus and brachiocephalic artery were sectioned into 8pm/sections. The 
plaque lesions were measured using standardised protocols (Paigen, Morrow et al. 1987; 
Tangirala, Rubin et al. 1995; Rosenfeld, Polinsky et al. 2000; Johnson, George et al. 2005) as 
described in the following sections.
6.4.6.1. Histology 
Collection of tissues
Animals were euthanized as described above. The heart and the ascendant aorta 
containing the brachiocephalic trunk, the left carotid artery and sub-clavian artery were 
dissected and fixed for no less than seven days in 10% (v/v) formalin in PBS for histological 
and immunohistochemistry analysis.
Tissue dissection
The brachiocephalic artery was separated from the aortic trunk and trimmed as 
follows: The ascending aorta was sectioned at a point close to the heart (Figure 6.2) while the 
descending aorta was kept long to facilitate tissue handling using heated forceps during the 
embedding process. The three arteries (the brachiocephalic trunk, the left common carotid 
and the left sub-clavian artery) were trimmed at an approximately 2 mm distance from the 
aorta.
For the aortic sinus, the bottom half of the heart was cut off in a plane parallel to the 
atria using a sharp razor blade (Paigen, Morrow et al. 1987), see figure 6.3 A. After 
brachiocephalic and aortic sinus trimming, the tissues were routinely processed by passing 
through a set of graded alcohol solutions (70%, 80%, 90%, 100% and another jar of 100% 
absolute ethanol) for dehydration using a Histokinette (British American Co. Ltd., Slough) 
and finally embedding in paraffin wax. The wax used was Fibro-wax (BDH Ltd) with a 
melting point of 56°C.
Wax embeddiug
The brachiocephalic trunk and left common carotid artery were embedded together 
pointing upwards and maintained in a vertical position (Figure 6.2. A). The front of the 
plastic cassette was labelled to easily orient the tissue, with the heart oriented so that the 
surface to be cut was resting on the base of the mould and blocked (Figure 6.3).
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artery. (A). The brachiocephalic trunk, left comm on carotid and left subclavian artery w ere trim m ed 
at an approxim ately 2mm distance from the aorta. (B ). The aortic arch was then trim m ed at 2 
places using m icrosurgery scissors and forceps. (C). Handling o f the tissue fo r paraffin em bedding 
using heated forceps to orientate in the casette. (D). Sectioning direction, (black lines) shows the 
area o f interest used fo r m orphometric, SMC and collagen analysis. (E). A series o f sections 30 
m icrons apart of the brachiocephalic trunk. The first level was considered as the first section where 
a com plete tunica adventitia was identified after H&E staining. (F). Position o f sections on the 
slides. (RSA: right subclavian artery, RCCA: right comm on carotid artery, BT: brachiocephalic 
trunk). This diagram was kindly prepared by Dr. Alexandra Bermudez-Fajardo.
Serial sectioning
Blocks containing the brachiocephalic artery were trimmed using a Microtome 2040 
Autocut (Cambridge Instrument Co., Inc., New York). The angle of the block in the holder 
was adjusted as required to obtain an appropriate orientation in relation to the blade holder
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(aorta, blue shadowed area. Figure 6.2 D). Once the brachiocephalic artery was visualised as 
a clear whole vessel (defined as level 1), sections of 8pm thickness, 30pm apart, were 
collected and mounted, using 2 consecutive sections per slide (Figure 6.2 E & F). A total of 
12 sections per sample/animal were collected.
To section the aortic sinus, tissue thickness for the cut section was set to 15pm and 
sectioning was initiated when the part of the block that contained the heart tissue was 
visualised. Once a complete heart section was visible, the tissue was placed on a slide and 
the anatomic location of the section was checked under the microscope regularly to make 
sure that the aortic sinus was being approached. The presence of the left and right atria 
suggested that the sinus was near (Figure 6.3; C-I). The aortic sinus usually appears rounded, 
with a thin the aortic wall and indistinct valves. Sections were saved when the valve leaflets 
became clearly visible (Figure 6.3, C-III). The thickness of the cut section was then changed 
to 8pm and sections were collected until the round aorta and the entire valve leaflets (valve 
cusps) disappeared (Figure 6.3, C-IV); this occurred after 20 to 26 sections. Slides were 
stored in an incubator at 37°C for 1 day to dry before staining.
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(A). Heart dissected from the aortic arch. The lower half o f the heart was cut at line A. Line B 
represents the beginning o f the aortic sinus that is recognised by the presence o f valves and valve 
cusps, which start to vanish at line D. (B). Handling o f heart tissue fo r embedding using heated 
forceps and the sectioning direction, (white lines) shows the area o f interest used fo r m orphom etric, 
SMC and collagen analysis. The average distance o f this area is approxim ately 300pm . (0 ). A  series 
o f aortic sinus sections, 30 m icrons apart stained with H&E. (I) Section approxim ately 100 m icrons 
away from line A, showing the two ventricles. (II). The aortic sinus starts to appear as tw o valves. 
(III). The first section showing the 3 valves and valve cusps appearing as a bulging shape until (IV) 
The last o f a series of sections, taken up until the d isappearance o f valve cusps and the appearance 
o f the aortic sinus as a round shape.
Staining with haematoxvlin and eosin
For morphometric studies, sections of the braehiocephalic artery and the aortic sinus, 
were stained with haematoxylin and eosin (H&E) using the assay developed by Culling in 
1963 (Culling. 1963). Briefly, slides with mounted sections were placed on a rack and the 
following staining procedure was performed:
• De-wax in xylene (3 min).
• Transfer to 100% alcohol (1 min).
• Rehydrate in 70% alcohol (1 min).
• Rehydrate in 50% aleohol (1 min).
• Rehydrate in distilled water (1 min).
• Stain in haematoxylin (15 min).
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Rinse in running tap water (1 min).
Differentiate in 1% acid alcohol (5-10 sec).
Blue in running tap water (10 min).
Stain in 1% eosin (2 min).
Rinse briefly in tap water to wash away excess stain.
Dehydrate in 85% alcohol (0.5 min).
Dehydrate in 100% alcohol twice (0.5 min).
Clear in xylene twice (0.5 min each).
Mount immediately using DPX mounting medium (Fisher Scientific, UK).
Detection of elastin and collagen using Orcein/van Gieson staining
Paraffin embedded sections of the brachiocephalic artery and the aortic sinus were 
stained by Orcein/van Gieson to differentiate elastin from collagen, following Carleton’s 
protocol (Culling. 1963; Carleton 1967). The reagents used for this staining procedure are
given in Table 6.1.
T a b le  6 .1 . O rce in /v a n  G ie s o n  r e a g e n ts
Weigerts iron 
haematoxylin
Solution A: 1% (w/v) iron haematoxylin in absolute ethanol.
Solution B: 4% (v/v) aqueous ferric chloride solution and 1% (v/v) of 
concentrated HCl dissolved in distilled water.
Orcein solution
1% (w/v) orcein , 1% (v/v) concentrated HCl in 80% (v/v) ethanol (Fischer 
science, UK).
Weigerts iron haematoxylin solutions were purchased from Sigma, UK as a kit.
Orcein is a vegetable stain that is very specific for elastin fibres; staining the very fine 
fibres a deep brown colour. Van Gieson is a specific stain for collagen and gives a pink red 
coloration. Weigerts iron haematoxylin was used to stain the nucleus in dark blue. The 
sections were processed following the protocol outlined below:
• De-wax in xylene (3 min).
• Rehydrate in 96% ethanol (1 min).
• Rehydrate in 70% ethanol twice (1 min each).
• Rehydrate in distilled water for (1 min).
• Elastin staining with Orcein for (30 min).
• Rinse in distilled water for (1 min).
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• De-coloration in 95% ethanol (2 min).
De-coloration in 100% ethanol (2 min).
De-coloration in 1% acid alcohol (8 min).
Wash in tap water (5 min).
Staining nuclei in Weigerts iron haematoxylin (15 min). 
Wash in tap water (1 min).
Differentiate in 1% acid alcohol (as required).
Wash in tap water (10 min).
Rinse in distilled water (30 sec).
Staining the collagen with Van-Gieson solution (2 min). 
Rinse in distilled water (0.5 min).
Dehydrate in 80% alcohol twice (0.5 min eaeh). 
Dehydrate in 95% aleohol twice (0.5 min each).
Clear in xylene twice (0.5 min each).
Mount immediately using DPX mounting media.
Immunohistochemistry
- De-waxing
Paraffin sections were prepared for immunohistoehemistry by clearing the paraffin 
with two changes of xylene, immersing the slides fully for 5 min eaeh time (de-waxing). 
Slides were rinsed twice with 100% ethanol for 3 min each. Then, slides were washed twice 
with 95% ethanol for 3 min and transferred into 80% ethanol for another 3 min, followed by 
gentle washing with running tap water for 1 min. All slides were kept in PBS for 30 min 
until used for antigen retrieval. Once the sections had been rehydrated, they were kept wet to 
avoid drying.
- Antigen retrieval
Antigen retrieval in the paraffin embedded section was carried out by ineubating 
sections with Img/mL trypsin (Sigma, UK) and resuspending in H2O2 for 30 min at 37°C. 
Sections were then washed twice in PBS for 5 min, followed by incubation in 3% (v/v) H2O2 
(Sigma, UK) prepared in deionised water for 5 min at room temperature. Sections were
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washed twice in PBS for 5 min, the solution deeanted and the excess wiped off carefully 
around the tissue seetion.
- Blocking
Bloeking of non-specific binding sites was carried out using 50pL of 20% (v/v) goat 
normal serum (Serotec, UK) in PBS for 1 hr at 37°C in a sealed, humidified chamber. Excess 
serum was removed.
- Detection
Sections were treated with lOpg/mL of mouse monoclonal anti-actin a SMC antibody 
(Sigma, UK) diluted in 10% (v/v) of normal goat serum in PBS, or lOpg/mL of the matching 
isotype control (mouse IgG2a, Serotee, UK) prepared in the same way (Table 6.2). Slides 
were incubated over night at 4°C and were washed three times in PBS for 5 min. Excess PBS 
was wiped off as described previously. Sections were then incubated with lOpg/mL of goat 
anti mouse-biotinylated polyclonal antibody (DAKO, UK) diluted in 10% (v/v) of normal 
goat serum in PBS for Ihr at RT in a humidified chamber. Sections were finally washed three 
times for 5 min in PBS.
T a b le  6 .2 . A n tib o d ie s  u s e d  fo r  SM C d e te c t io n  in a th e r o s c le r o s is  p la q u e s
Antibodies Supplier Working concentration
Mouse anti-actin, a  SMC monoclonal antibody. Sigma lOpg/mL
Normal mouse IgG2a Serotec lOpg/mL
Goat anti-mouse-biotinylated polyclonal antibody DAKO lOpg/mL
(Appendix 2, Tab la i).
- Developing
Sections were incubated with the substrate: 50pL of HRP-labelled ExtrAvidin 
(Sigma, UK), at a 1:50 dilution with 10% (v/v) normal goat serum in PBS for 30 min at RT. 
Sections were then rinsed three times for 5 min in PBS. Excess PBS was removed and 
carefully wiped off around the tissues. Colour development was aehieved by incubating the 
sections with 50pL of DAB solution (DAB Chromogen + Substrate Buffer, at a 1:50 dilution, 
(DAKO, UK)) for 1-2 min. The reaction was stopped by washing before any background 
staining appeared in the negative controls. Sections were immediately rinsed for 5 min in 
running tap water and counter-stained with Harris’s haematoxylin and again rinsed briefly 
with tap water. Colour differentiation was carried out using 1% (v/v) of acidified aleohol for
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5-10 sec and washed for 10 min in tap water. Sections were dehydrated using an ascending 
series of ethanol solutions (70%, 80%, 95% and two changes of 100% absolute ethanol) and 
finally, all slides were mounted using DPX mounting medium.
- Morphometric analysis
For the morphometric analysis, a Leica microscope, connected to a Leica camera and 
corresponding software were used to capture the images. All images were captured with the 
same number of pixels (764 width x 574 height) and the same objective lens (3x for aortic 
sinus and lOx for brachiocephalic artery). ImageJ software v. 1.36b (Wayne Rasband NIH, 
USA, freely available from http://rsb.info.nih.gov/ij/) was used for image analysis (Rasband 
1997-2009.; Abramoff 2004). A measuring calibration graticule (100pm) was used to set up 
the scale by capturing images of the graticule using the same magnification as for the images 
taken from the aortic sinus (4x) and the brachiocephalic artery (lOx). In the aortic sinus, 
plaque lesions were measured in each aortic sinus valve. Then, the total plaque area of each 
aortic sinus was calculated by taking the summation for each aortic sinus valve, see Figure 
6.4.
PI «au» 2
Vaiva 1
Ptaqu* 1
Valve 3
F igu re 6 .4 . E x a m p le  o f  th e  s e t  up  for  m o r p h o lo g ic a l a n a ly s is  in a o r tic  s in u s .  (A) Shows 
a section or tne aortic sinus to be measured. (B) Shows the m easurem ent of three valves of 
aortic sinus. The areas highlighted correspond to the plaques. The first valve has 2 plaques 
measured separately; so the total plaque size fo r the first valve = p laquet + plaque2. Plaque 
size for second valve = plaque1+ plaque2. The third valve = p laque l only. The total size of 
plaque fo r this aortic sinus = plaque area of the first valve + plaque area of the second valve 
+ plaque area o f the third valve.
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Three levels o f the  brachiocephalic trunk , 20 m icrons apart, w ere  d ig ita lly  captured (Figure 
6.5). Level In the  firs t section w here  a com ple te  tun ica adven titia  could be iden tified  surrounding  
the  arte ry, th is  was designated as level 1.
Ext ilastica
F igu re 6 .5 . E x a m p le  o f  th e  s e t  up for  m o r p h o lo g ic a l a n a ly s is .  (A) Shows a section o f the 
brachiocephalic artery to be measured. (B) Shows the m easurem ent o f three d ifferent areas in the 
section. The areas highlighted correspond to the tunica elastica externa, the tunica elastica 
interna and the lumen. {This figure was extracted from Mr Carlos Lopez-Mendez MSc thesis, 
University o f Surrey, 2006).
In the brachiocephalic artery, the plaque, elastic external lamina (EEL) and elastic 
internal lamina (EIL) areas were measured, see Figure 6.4. From these measurements, the 
tunica media, lumen and total vessel areas were calculated using the following equations:
Plaque area 
Media area 
Lumen area 
Total vessel area
PA
EEL area - EIL area 
E IL -P A
EEL or = PA + lumen area + media area
6.4.6.3. Measurement o f collagen and smooth muscle cell content
Collagen and SMCs in the brachiocephalic artery and aortic sinus plaques were 
measured and represented as a percentage of the total plaque area using ImageJ software by 
adjusting the colour of the threshold at maximal and minimal signals.
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6.4.7. Determination of plasma lipid levels
Plasma LDL- and HDL-cholesterol were determined using a commercial kit from 
Randox Laboratories Ltd (Northern Ireland, UK). Total cholesterol and triglycerides were 
determined using commercial kits from Instrumentation Laboratory UK Ltd (Cheshire, 
England, UK) following manufacturer’s recommendations. Measurements were carried out 
using an ILab-650 clinical chemistry auto analyzer (Instrumentation Laboratory UK Ltd).
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6.5. RESULTS
6.5.1. rMOMP reduces atherosclerotic plaque development
The effect of immunisation with rMOMP expressed by M. vaccae or with DNA 
eukaryotic expression vectors on the development of atherosclerotic plaques in 
brachioeephalic arteries and the aortic sinus was examined. A summary of the results of the 
morphometric analysis carried out in brachiocephalic arteries is presented in Table 6.3.
T ab le  6 .3 . M orp h om etr ic  a n a ly s is  o f  th e  e f f e c t  o f  im m u n isa tio n  o n  p la q u e  d e v e lo p m e n t  in 
b r a c h io c e p h a lic  a r te r ie s  o f  a p o E  m ic e .
study group
Lumen area 
(xlO^ pm^)
Media area 
(xio^ pm^)
Plaque area 
(xio^ pm^)
TV area 
(xio^ pm^)
% of Collagen 
content
% of SMC 
content
U ntreated
n=5
94.5 ± 36.8 164 ± 45 77.1 ±50.5 336 ± 105 n=5 42.7 ± 4.5 n=5 25.5 ± 9.7
M. vaccae  
n=8
91.5 + 34.0 300 ± 36.7 51.2 ±26 .6 316 ±85.5 n=7 51.0 ± 7 n=5 15.5 ±3 .5
M . i/accoe-rM OM P+SPS  
n=10
85.0 ± 1 6 .6 137 ±43 .0 27.3 ± 29.7 250 ± 77.0 n=4 5 6 .0  ± 4 t n=4 23.0 ± 9.0
M. voccoe-rM OM P-SPS  
n=9
209 ± 179 131 ± 81 2 .5  ± 2 .9 t t ,* * 344 ± 25 n=0 None n=0 None
pcD N A S.l
n=5
83.0 ± 32 333 ±48 .6 43.0 ± 5 4 460 ± 49 n=5 57.0 ± 10 n=5 18.0 ± 7
pcDNA-MOMP
n=8
112 ± 2 0 134 ± 15 36.7 ±45 .2 344 ± 47 n=5 54.5 ±8 .1 n=5 27.0 ± 8
Values are presented as mean ± SD. Results were considered significant wfien *p < 0.05 and **p < 0.01.(tsignificant vs. 
untreated control group, ‘ significant vs. wild-type M. vaccae).
Morphometric analysis of brachiocephalic arteries showed that pcDNA-MOMP 
treatment had no effect on the plaque area development compared to other control groups. 
Furthermore, the treatments with pcDNA3.1 or pcDNA-MOMP had no effect on the lumen, 
media or total vessel areas eompared to control groups, see Figure 6.6 A. The same analysis 
showed that animals immunised with M. vaccae expressing rMOMP without signal peptide 
sequence showed a significant reduction in plaque size compared with untreated and wild- 
type M. vaccae control groups {p < 0.01). This treatment significantly arrested the 
development of atherosclerosis, as it was found that only 4 out of 9 animals contained small
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measurable plaques and the rest had no plaques at all. Furthermore, no changes in the tunica 
media, lumen and total vessel areas were observed. Interestingly, the group treated with M 
vaccae expressing MOMP with the signal peptide sequence showed a trend of decreased 
plaque size, but this was not statistically significant, see Figure 6.6 B.
rMOMP encoded bv eukaryotic 
expression vector
^  1x10"- — I—
! A3 5.10".
 ^ . . . _ l
pcDN A O .I pcD N A -M O M P
untr«3t*d
£  5x10".
(, 4x10".
2x10"
I
rMOMP expressed bv M. vaccae
£
U n t r e a t e d  M. vaccae M  V a c c a e
-rM O M P -eS P S 4 -M O M P -S P S
I
£
: 1x10"
I
U n tr e a te d  M. vaccae M. Vaccae 4^0MP4-SPS M. Vaccae -fM O M P -i-SP S w M O M P -S P S
£ 1.0x10*-
M, vaccae M. Vaccae M. Vaccae 
-rM O M P -rS P S h-M O M P -S P S
U n t r e a t e d  Af. r -a c ca e  M.Vaicae M. Vaccae 
-rM O M P + S P S  4 -M O M P -S P S
F igu re 6 .6 . E ffec t o f  in tra n a sa l v a c c in a t io n  w ith  rMOMP e x p r e s s e d  by M. vaccae or  p cD N A - 
MOMP o n  a th e r o s c le r o t ic  p la q u e  d e v e lo p m e n t  in th e  b r a c h io c e p h a lic  artery o f  a p o E ' m ic e .
(A) Shows the effect o f rMOMP expressed by eukaryotic expression vector on a therosclerosis 
developm ent. (B) Shows the effect o f rMOMP expressed by M. vaccae with or w ithout signal peptide 
sequence on atherosclerosis developm ent. The group treated with M. vaccae-rM O M P-SPS 
significantly decreased plaque size compared with untreated and wild M  vaccae control groups. 
Values are displayed as mean ± SD, results considered significant when ** p <  0.01.
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The effect o f  intranasal rMOMP immunisation on atherosclerotic plaque development 
in the aortic sinus was also investigated (see summary o f  results in Table 6.4). The analysis 
revealed that immunisation with rMOMP expressed by different vectors has no effect on 
plaque size in the aortic sinus; see Figure 6.7.
T ab le  6 .4 . E ffec t o f  rMOMP o n  a th e r o s c le r o s is  d e v e lo p m e n t  in th e  a o r tic  s in u s .
Study group
Plaque area 
(xlOP pm^)
% of Collagen 
content
% of SMC 
content
Untreated n=7 156± 128 0=7 24.6± 10.3 0=8 26.1 ± 14.1
M. vaccae n=7 149 ± 62 0=10 26.0 ± 12 0=7 20.5 ±7.9
M. vflcc«e-rMOMP+SPS 0=7 95.0 ± 44 0=9 20.1 ±4.1 0=9 24.1 ±7.1
M. v«ccff^-rMOMP-SPS 0=7 79.1 ±40.1 0=9 39.6 ± 10.3 0=7 41.0± 12**
pcDNA3.1 0=7 130 ±63 0=5 27.8 ±7.5 0=6 12.4 ±7.8
pcDNA-MOMP 0=7 113 ±62 0=8 25.0 ± 14 0=7 13.1 ±9.1
Values are presented as mean (n=10) + SD. Results were considered significant when * p < 0.05 and ** p < 0.01. (t Significant 
versus untreated and * significant versus wild M. vaccae or pcDNAS.I).
rMOMP encoded bv eukaryotic rMOMP expressed bv M.
expression vector vaccae
pcD N A 3 pcD N A -M O M PU n t r e a t e d
3 x 1 0 "
^  2 x 1 0 " -
® 1x 1 0 " T
Untreated M. vaccae M .Vacc^  AtDQccae 
-rMOMP+SPS -rMOMP-SPS'
F igu re 6 .7 . E ffect o f  rMOMP on  a th e r o s c le r o s is  d e v e lo p m e n t  in th e  a o r tic  s in u s  o f  apoE'^' 
m ice . (A). Shows the effect o f rMOMP on plaque area size when expressed by a eukaryotic 
expression vector. (B). Shows the effect of treatm ent on plaque area size when rMOMP w ith or 
w ithout signal peptide sequence is expressed by M. vaccae. Values are presented as mean 
(n = 1 0 )± S D .
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6.5.2. Immunisation with rMOMP enhances the stability of atherosclerotic
plaques
In addition to the above mentioned analysis, the effeet o f  immunisation on plaque 
stability was also examined by measuring the content and distribution o f  elastin, collagen and 
SMCs within atherosclerotic plaques using Orcein-van Gieson staining and a mouse anti a- 
actin SMC antibody, respectively. The effect o f  the treatment on the stability (Collagen and 
SMC) o f  atherosclerosis plaque developed in brachiocephalic arteries was summarised Table 
6.3 and the same effect on aortic sinus was summarised in Table 6.4. Orcein-van Gieson  
stain colours elastin fibres dark brown, collagen a pink reddish colour, nuclei dark purple and 
muscles, cytoplasm, red blood cells and fibrin in with a yellow  colour. 
Immunohistochemistry staining with mouse anti a-actin SMC antibody stains SMCs a brown 
and nuclei are stained blue, see Figures 6.9 and 6.11.
rMOMP encoded bv eukaryotic rMOMP expressed bv M.
expression vector vaccae
40-1
U n t r e a t e d  pcO N A 3.1 pcD N A -M O M P
c.
U n t r a t e d  p cD N A 3.1  p cD N A -M O M P
40-1
2  30
o  10-
so
(B 80
£<Q
o 6 0 -
4 0  H
-5-e® 20 
n
Untreated
r  * 
r
Untreated
Mvaccae MVaccae 
-rMOMP+SPS
M vaccae MVaceae 
-rMOMP+SPS
F igu re 6 .8 . E ffec t o f  rMOMP o n  a th e r o s c le r o t ic  p la q u e  SM C an d  c o lla g e n  c o n te n t  in th e  
b r a c h io c e p h a lic  a r ter ie s . (A). pcDNA-M OM P had no effect on SMC proliferation or collagen 
synthesis w ithin plaques. (B). M. vaccae-rMOMP+SPS s ignificantly enhanced collagen synthesis 
compared with the untreated group but had no effect on SMC content. Values are presented as 
mean (n=10) ± SD. Results were considered significant when * p <  0.05.
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The analysis of brachiocephalic arteries shows that treatment with pcDNA-MOMP 
had no effect on SMC and collagen compositions; see Figures 6.8 A & 6.9 and Table 6.3. 
The group treated with M. vaccae-rMOMP-SPS was excluded from this analysis since 
plaques did not develop in these animals. Immunisation with rMOMP with signal peptide 
sequence had no effect on SMC content, although the same treatment significantly induced 
collagen synthesis compared with the untreated control group (p < 0.05); see Figures 6.8 B &
6.9 and Table 6.3.
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Elastin/Collagen
Untreated
/W, vaccae
M. vaccae- 
rMOMP+SPS
M. vaccae- 
rMOMP-SPS
f  pcDNAS.1
pcDNA-MOMP
F igu re 6 .9 . E ffect o f  in tra n a sa l rMOMP im m u n isa tio n  o n  a th e r o s c le r o s is  p la q u e  
d e v e lo p m e n t  in th e  b r a c h io c e p h a lic  artery o f  a p o E  ' m ic e . Representative histological 
sections o f brachiocephalic arteries from  apoE'^' m ice that were immunised with rM OM P 
expressed by M. vaccae or eukaryotic expression vectors. Sections were stained w ith H&E, 
Orcein/van G ieson (for elastin/collagen detection) or SMC a-actin. Im ages w ere 
photographed with the same pixel num ber and using the sam e objective (10x) as described in 
the Materials and Methods, scale bar 200pm.
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The effect of the treatment on the compositions of plaque development in the aortic 
sinus was also investigated (result was summarised in Table 6.4). This study showed that 
treatment with pcDNA-MOMP had no effect on SMC and collagen composition; see Figures
6.10 A & 6.11. On the other hand, the analysis showed that the percentage of SMC cells 
increases in the plaques of animals treated with M. vaccae-rMOMP-SPS compared to those 
immunised with M. vaccae only {p < 0.05). No other statistically significant effects were 
observed (see Figures 6.10 B & 6.11).
rMOMP encoded bv eukaryotic 
expression vector
rMOMP expressed bv M.
vaccae
<5 3 0 -
U n t r e a t e d  pcD N A 3.1  p cD N A -M O M P
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Untreated At vaccae Af. Vaccae At Vaccae 
-rMOMP+SPS -rMOMP-SPS
F igu re 6 .1 0 . E ffect o f  rMOMP o n  th e  c o m p o s it io n s  o f  p la q u e  d e v e lo p m e n t  in th e  a o r tic  
s in u s  (A) rMOMP expressed by pcDNA-M O M P has no effect on SMC proliferation or 
collagen synthesis in the plaques. (B) M. vaccae-rMOMP-SPS  significantly enhanced the 
proliferation of SMCs in the aortic sinus compared to the group treated with M. vaccae. Values 
are presented as mean (n=10) ± SD. Results were considered significant when *p < 0.05.
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H&E Elastin/Collagen SMC
ti
Untreated
M. vaccae
M. vaccae- 
rMOMP+SPS
M. vaccae- 
rMOMP-SPS
pcDNA3.1
pcDNA-MOMP
F igu re 6 .1 1 . E ffec t o f  in tra n a sa l rMOMP im m u n isa tio n  o n  a th e r o s c le r o s is  d e v e lo p m e n t  
in a o rtic  s in u s  in a p o E ' m ic e . Representative histological sections o f aortic sinus from 
apoE'^' m ice that were immunised with rMOMP expressed by M. vaccae or eukaryotic 
expression vectors. Sections were stained with H&E, Orcein/van G ieson (for e lastin/collagen 
detection) or SMC a-actin. Images w ere photographed with the same pixel num ber and 
using the same objective (lOx), scale bar 100 pm, as described in the Materials and 
Methods.
159
6.5.3. Immunisation with rMOMP induces the proliferation of Treg cells
After observing the effect of treatment on atherosclerotic plaque development and 
compositions, we decided to investigate whether treatment with rMOMP could modulate 
other immune parameters. The effect of immunisation using rMOMP expressed by different 
vectors on the proliferation of CD4^ and CD8^ T cells and their corresponding 
CD4^CD25^Foxp3^ and CD8^CD25^Foxp3^ Treg sub-populations was examined. The 
results show (Figure 6.12 A) that treatment with pcDNA-MOMP or with pcDNA3.1 caused 
no statistically significant effects on the proliferation of CD4^ T cells compared to control 
groups. On the other hand, treatment with pcDNA-MOMP or with pcDNA3.1 alone 
significantly increased the proliferation of CD8^ T cells compared to the untreated control 
group (14.3 ± 5.5% 1.9 ± 0.6% and 14.3 ± 5.5% 21.5 ± 4.3%, p  < 0.05, p  < 0.01,
respectively), see Figure 6.12 B.
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F igu re 6 .1 2 . E ffect o f  rMOMP e x p r e s s e d  by pcD N A -M O M P e u k a ry o tic  e x p r e s s io n  v e c to r  on  
CD4^ and  CD8^ T c e ll p ro liferation . (A) Representative flow  cytom etry contour plots (with outliers) 
and a corresponding graph showing the effect of the treatm ents on C D4‘" l  cells. (B) R epresentative 
flow  cytom etry contour plots (with outliers) and a corresponding graph showing the effect o f the 
treatm ents on CDS^'T cells. Data are displayed as mean (n=10) ± SD. S ignificance levels w ere set 
at: *p < 0.05, ** p  < 0.01, *** p < 0.001.
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Treatment with pcDNA-MOMP or pcDNAS.l significantly increased the numbers of 
CD4^CD25^FoxP3^ Treg cells compared to the untreated control group (1.4 ± 1% and 1.4 ± 
0.9% vs 0.3 ± 0.1%, p  < 0.05, respectively), see Figure 6.13 A. In contrast, none of the 
treatments showed any effect on the percentage of CD8"^CD25^FoxP3^ Treg cells, see Figure 
6.13 B.
CD4+CD25+FoxP3+ T regs
3
pcD N A 3.1 pcDNA-M QM PU ntreated
1.4%1.4%
A4
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O
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01 o.rr
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Untreated pcDNAS.I pcDNA-MOMP
F igu re 6 .1 3 . E ffec t o f  rMOMP e x p r e s s e d  by DNA e u k a r y o tic  e x p r e s s io n  v e c to r  o n  T reg  
p o p u la t io n s . (A) Representative contour plots with outliers show ing the effect o f pcDNAS.I 
and pcDNA-M O M P on CD4"^CD25'"FoxP3'^Treg cell numbers. (B) Representative contour plots 
with outliers showing no effect o f the treatm ents on C D 8’'CD25'"FoxP3’' Treg cell numbers. 
Data is displayed as in graphs as mean ± SD. Levels o f significance are *p ^  0.05, ** p  ^  0.01,
*** p < 0.001.
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The above mentioned analysis was also carried out to study the effect of 
immunisation with rMOMP +/- SPS expressed by M. vaccae on these populations of T cells. 
rMOMP without SPS, expressed by M. vaccae significantly inhibited the number of CD4^ T 
cells compared to wild-type M. vaccae and untreated control groups (6.2 ± 1.9% v.9 23.5 ± 
5% and 19 ± 2.6%, p < 0.001, p <0.01 respectively), see Figure 6.14 A. The same treatment 
(M vaccae expressing MOMP without SPS), significantly stimulated the proliferation of 
CD8^ T cells compared to wild-type M. vaccae and untreated control groups (11.5 ± 2.4% vs 
2 ± 1% and 1.9 ± 0.7%, p? < 0.001 for both), see Figure 6.14 B.
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F igu re 6 .1 4 . E ffec t o f  rMOMP e x p r e s s e d  by M. vaccae o n  CD4^ and  CDS"  ^ I  c e l l s .  (A).
Representative flow  cytom etry contour plots w ith outlayers and graphs showing the effect o f the 
treatm ents on the number o f CD4'" T  cells. (B). R epresentative flow  cytom etry contour plots w ith 
outlayers and graphs showing the effect o f the treatm ent on the num ber of CDS'" T  lym phocytes. 
Data is displayed as mean ± SD. Levels o f significance are *p < 0.05, ** p  < 0.01, *** p  < 0.001.
The effect of the rMOMP on the proliferation of CD4^CD25^FoxP3^ Treg and 
CD8^CD25^FoxP3^ Treg sub-populations was also examined. Animals treated with M. 
vaccae expressing rMOMP +/- SPS significantly induced the proliferation of 
CD4^CD25^FoxP3^ Treg populations compared to untreated and M  vaccae control groups 
(1.3 ± 0.4% vv 0.3 ± 0.1% and 0.2 ± 0.1%, p  < 0.01, p  < 0.001, respectively), see Figure 6.15 
A. Conversely, the results show that immunisation of animals with M. vaccae alone
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significantly inhibited the proliferation of CD8^CD25"^FoxP3^ Treg populations compared to 
untreated animals (0.01 ± 0.03% V5' 0.1 ± 0.05%, p  < 0.01). In contrast, numbers of these 
cells were significantly increased in the group treated with M vaccae expressing MOMP 
+SPS compared to mice treated with wild-type M  vaccae (0.2 ± 0.2% vs 0.01 ± 0.03%, p  < 
0.001), see Figure 6.15 B.
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F igu re 6 .1 5 . E ffect o f  rMOMP e x p r e s s e d  by M. vaccae o n  th e  p ro lifera tio n  o f  
CD4^CD25^FoxP3^ T reg an d  CD8^CD25^FoxP3^ T reg p o p u la t io n s . (A). Representative 
contour plots (with outliers) and corresponding graphs showing the effect o f treatm ents on the 
num ber of CD4’"CD25'^FoxP3'‘ Treg populations. (B ) shows the sam e analysis but fo r the 
CD8+CD25-t-FoxP3+Treg population. The results are sum m arised and plotted as mean (n=10) ± 
SD. S ignificance levels were set as*p < 0.05, ** p  < 0.01, *** p < 0.001.
6.5.4. rMOMP induces a predominant anti-inflammatory cytokine profile
In order to examine the effect of treatments on the immune response, the levels of 
IFN-y, IL-4, IL-10 and TGF-p cytokines in the plasma and supernatant of splenocytes
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isolated from immunised animals were measured using commercial ELISA kits. 
Unfortunately, the concentrations obtained in the plasma were below the detection limit of 
the assays and should therefore be interpreted with caution. Our results revealed that 
pcDNA-MOMP had no effect on the synthesis of IFN-y, IL-4, IL-10 or TGF-p. On the 
contrary, immunisation with pcDNA3.1 alone increased the levels of IFNy when compared to 
untreated animals (1904 ± 201pg/mL v.s' 1323 ± 225pg/mL,/? < 0.05), but not when compared 
against other groups, see Figure 6.16
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TGF-P levels, respectively. Data is presented as mean (n=10) ± SD. S ignificance levels w ere set 
as;* p < 0.05, ** p < 0 .01, *** p < 0.001.
The effect of M. vaccae expressing rMOMP on the cytokine profile of splenocyte 
supernatants was also studied. The analysis of the synthesis of cytokines in the supernatant 
of cultured splenocytes showed a significant reduction in the levels of IFN-y from the animals
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immunised by wild-type M. vaccae  compared to untreated ones (769 ± 331pg/mL vs 1329 ± 
237pg/mL,p < 0.05). Conversely, levels of IFN-y significantly increased in mice immunised 
with M. vaccae expressing rMOMP +/- SPS compared to the M. vaccae control group (1314 
± 377pg/mL and 1667 ± 394pg/mL V5 769 ± 331pg/mL, p  < 0.05, p  < 0.001, respectively), 
although these values were not significantly higher compared to those observed in untreated 
animals, see Figure 6.17 A.
A similar effect was observed for IL-4, where only a significant increase was only 
noted in animals immunised with M vaccae  expressing MOMP without SPS compared to 
those immunised with wild-type M. vaccae  (1490 ± 459pg/mL v.s' 893 ± 31 lpg/mL,/> < 0.05), 
see Figure 6.17 B. Animals immunised with M. vaccae  expressing rMOMP either with or 
without SPS showed significant increases in the levels of IL-10 compared to those 
immunised with wild-type M. vaccae  (1330 ± 493pg/mL and 1649 ± 372pg/mL v.s' 1033 ± 
342pg/mL, p <  0.05, p  < 0.01, respectively); see Figure 6.17 C. The same effect was 
observed on the levels of TGF-p (1014 ± 300pg/mL and 1451 ± 523pg/mL vs 502 ± 
21 lpg/mL,/7 < 0.05,/? < 0.001, respectively), see Figure 6.17 D.
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Cytokine levels were measured by ELISA in supernatants o f splenocytes isolated from 
immunised animals after PMA and lonomycin treatm ent. G raphs show the effect o f treatm ents 
on the synthesis of (A) IFN-y, (B) IL-4, (C) IL-10 and (D) TGF-p. Data is presented as mean 
(n=10) ± SD. S ignificance levels were set as: * p  < 0.05, ** p  < 0.01, *** p  < 0.001.
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6.5.5. Effect of immunisation with rMOMP expressed by M  vaccae and pcDNA- 
MOMP on the antigen-specific humoral immune response
In parallel with the above described analysis of cytokines, we also examined whether 
immunisation with rMOMP could affect the production of rMOMP-specific antibodies. To 
this end, we measured the levels of antigen-specific IgGl, IgG2a, IgM and IgA, in the plasma 
using ELISA as described in Chapter 2. The analysis suggests a potential cross reaction of 
rMOMP-specific antibodies with host proteins as the results showed high detection levels of 
specific antibodies in the plasma of not only untreated animals (Figure 6.18) but also in the 
plasma collected at day 0 (data not shown). IgG2a could not be quantified as the values 
obtained were below of the detection limit of the assay used. IgG2a results are therefore 
omitted from Figure 6.18.
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by rMOMP expressed by pcDNA-MOMP. (B). Hum oral immune response induced by rM OMP 
expressed by M  vaccae.
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6.5.6. Immunisation with rMOMP expressed by M. vaccae and DNA eukaryotic 
expression vectors affects the plasma lipid profile
Finally, the plasma total cholesterol, triglycerides, HDL-cholesterol (HDL-c) and 
LDL-cholesterol (LDL-c) were measured in the plasma of immunised animals in order to 
evaluate the effect of rMOMP on plasma lipid profiles, see Table 6.5.
T ab le  6 .5 . E ffec t o f  rMOMP e x p r e s s e d  b y  M. v a c c a e  an d  e u k a r y o tic  e x p r e s s io n  v e c to r s  o n  
p la sm a  lip id  p ro file  o f  a p o E ' m ic e  fe d  n orm al c h o w  d iet.
Treatment
Group
Total Cholesterol 
(mmol/L)
LDL-c
(mmol/L)
HDL-c
(mmol/L)
T riglycerides 
(mmol/L)
Untreated 15.8 ±  1.4 15.5 ± 1.6 1.0 ±0.1 1.4 ±0 .8
M. vaccae 14.9 ±  1.5 12.9 ±5 .2 0.5 ±0.1 1.8 ±1 .2
M  vflccfle-rMOMP+SPS 14.5 ± 2 .0 14 ± 2 0.4 ± 0 .1 * 1.6 ±0 .5
M. vflccfle-rMOMP-SPS 13.6 ±  2 .5 f 13.4 ±2 .5 0.3 ±  0.1* 1.5 ±0 .4
jpcDNAS.l 16.7 ±2 .5 14±1 0.7 ±  0 .2 ft 2.6 ±  l . l f t
pcDNA-MOMP 15.1 ±2 .5 14.6 ±2 .5 0.4 ±  0 .2 *** 1.5 ±  0.5*
Values are presented as mean (n=10) ± SD. Results were considered significant when * p £ 0.05, ** p s  0.01, *** p s  0.001. (t 
Significant versus untreated, ^significant versus wiid M. vaccae or pcDNAS.l).
The results show that immunisation with pcDNA-MOMP has no effect on the levels 
of total cholesterol and LDL-e. However, animals immunised with pcDNAS.l showed 
significant increases in the levels of HDL-c and triglycerides compared with the untreated 
control group (p < 0.01), whereas animals immunised with pcDNA-MOMP demonstrated 
significantly decreased levels of HDL-c and triglycerides (p < 0.001, p  < 0.05, respectively), 
see Figure 6.19 A. Treatment with rMOMP expressed by M. vaccae had no effect on the 
levels of triglycerides and LDL-c, whereas animals immunised with M  vaccae expressing 
MOMP, with or without SPS, showed significant reductions in the levels of HDL-c compared 
with the M  vaccae control group (p < 0.05). Additionally, M. vaccae expressing rMOMP 
without signal peptide sequenee caused a significant decrease in the levels of total cholesterol 
compared to the untreated group (p < 0.05), see Figure 6.19 B.
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6.6. DISCUSSION
The pathological inflammatory nature of atherosclerosis has triggered numerous 
studies in search of novel therapeutic anti-inflammatory agents to treat the disease (Steffens, 
Burger et al. 2006). Several experimental attempts to induce immuno-protection in the 
context of atherosclerosis have already been made and can be generally classified into two 
main categories: Immuno-suppressive drugs and vaccines (Hansson 2002; Hansson and 
Nilsson 2009). Compounds developed under either of these two categories either disrupt 
inflammatory signalling or enhance immune protection by inducing the proliferation of T cell 
sub-populations, which mainly involves Treg cells (Sherer and Shoenfeld 2006; Shevach 
2006; Sakaguchi, Yamaguchi et al. 2008). There are several anti-inflammatory antigens used 
as vaccines to prevent atherosclerosis development. In this regard, pathogen-derived specific 
antigens have been used to modulate the inflammatory response during atherosclerosis 
development, taking advantage of the inherent ability of pathogens to modify host immune 
responses in order to survive inside the infected cell for long time (Binder, Horkko et al. 
2003; Ait-Oufella, Horvat et al. 2007).
Based on the findings in previous chapters, this study examined for the first time the 
effect of intranasal immunisation with rMOMP on the size and composition of plaque lesions 
developed in the brachiocephalic artery and the aortic sinus of apoE'^' mice using established 
methodologies (Paigen, Morrow et al. 1987; Rosenfeld, Polinsky et al. 2000).
The brachiocephalic artery (also known as the innominate artery) is a small vessel 
connecting the aortic arch to the right sub-clavian and right carotid artery. This artery is 
characterised by the development of heterologous atherosclerotic plaques (Rosenfeld, 
Polinsky et al. 2000). In addition, this location of the arterial tree in mice is capable of 
developing vulnerable plaques (Bond and Jackson 2011). The aortic sinus is the initial 
segment, of approximately 300pm, of the ascendant aortic arch containing the aortic valves, 
which are characterised by the development of homologous atherosclerotic plaques (Paigen, 
Morrow et al. 1987). Numerous reports have shown that these two areas are the most 
susceptible segments for the development of atherosclerosis due to their anatomical location 
that faces non-laminar blood flow and shear stress and are exposed to known modulators of 
endothelial cell function (McMillan 1985). Interestingly, our results showed that treatment 
with rMOMP without signal peptide sequence (M voccrze-rMOMP-SPS) significantly 
arrested plaque formation in the brachiocephalic artery and this was accompanied by no
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adverse effects on the media, lumen and total vessel areas. Immunisation with M. vaccae- 
rMOMP+SPS and M  vaccrze-rMOMP-SPS showed a trend towards inhibition of plaque size 
in the aortic sinus but this was not statistically significant. On the other hand, treatment with 
pcDNA-MOMP had no effect on plaque size in the brachiocephalic artery or in the aortic 
sinus.
We also studied the plaque composition; an important parameter used to assess plaque 
stability. This was carried out by measuring SMC and collagen content within the plaque, as 
surrogate indicators of intra-plaque inflammation. A stable fibrous cap is rich in collagen and 
SMCs, providing flexibility to the blood vessel and therefore a lower propensity to rupture 
(Bauriedel, Hutter et al. 1999; Newby and Zaltsman 1999; Rekhter, Hicks et al. 2000). For 
this analysis the animal group immunised with M  vaccae-rMOMP-SPS were excluded, as 
they developed no plaques in their brachiocephalic arteries. The other groups showed no 
effect either on SMC or on collagen deposition in brachiocephalic artery compared with other 
control groups. Furthermore, evaluating the effect of immunisation on plaque development 
in the aortic sinus revealed that the M  vrzccae-rMOMP- SPS treated group developed a 
significantly increased number of SMCs within plaque lesions compared with controls, 
whereas the pcDNA-MOMP treated group showed no effect on SMC proliferation or 
collagen deposition. Overall, these results provide evidence for the first time that rMOMP 
expressed by M. vaccae without signal sequence is capable of arresting atherosclerotic plaque 
development and that this treatment also enhances the stability of plaques by increasing their 
SMC and collagen content.
To understand the mechanisms behind these effects in the context of inflammation 
and immunity, we studied different immune parameters involved in the modulation of 
atherosclerosis. The first parameter examined was whether the treatment induced Treg cells 
proliferation or not, as these cells are well known to have an athero-protective effect 
(Hansson and Berne 2004; Gotsman, Grabie et al. 2006; Taams, Palmer et al. 2006; Taleb, 
Tedgui et al. 2008; Belkaid and Tarbell 2009). Our findings showed that rMOMP expressed 
by M  vaccae significantly increased the numbers of CD4^CD25^FoxP3^ Treg cells compared 
with other control groups. This is a remarkable finding as it is known that apoE'^' mice are 
genetically predisposed to pro-inflammatory responses because of their C57B1/6J genotype, 
as confirmed by the normally high levels of circulating IFN-y that naturally inhibits the 
proliferation of Treg cells. In addition, it is known that the number of splenic Tregs 
decreases as these animals get older (Mor, Planer et al. 2007). Despite this, our treatment
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was capable of enhancing the proliferation of Treg cells. Moreover, immunisation using M  
vaccae expressing rMOMP enhanced the proliferation of CD4^ Tregs while reducing the 
proliferation of total CD4^ T cells, which are the most dominant sub-population of T cells in 
atherosclerotic plaques (Zhou, Nicoletti et al. 2000; Zhou, Robertson et al. 2005). We 
hypothesise that this down-regulation of total CD4^ T cells may be due to inhibition of 
effector CD4^ T cells by Treg cells, as has previously been reported (Ohkura and Sakaguchi 
2010) or by conversion of the naïve pool of CD4^ T cells into Treg cells upon vaccination 
(Jonuleit, Schmitt et al. 2002; Workman, Szymczak-Workman et al. 2009). This hypothesis 
suggests an antigen-specific effect on the generation of these cells; however, this theory 
requires further demonstration.
Treg cells are known to reverse the proportion of pro-inflammatory Thl cells within 
unstable coronary arteries in humans (Han, Liu et al. 2007). Moreover, it is known that 
depletion of CD4^CD25^FoxP3^ Tregs by blocking the function of CD25 (the a  chain of the 
IL-2 receptor) enhances atherosclerosis development in apoE'^' mice. This has been 
demonstrated by the development of plaques with a thinner fibrous cap and enhanced 
recruitment of inflammatory cells, leading subsequently to greater plaque rupture (Ait- 
Oufella, Salomon et al. 2006; Ait-Oufella, Horvat et al. 2007; Mor, Planer et al. 2007). CD4^ 
Treg cells have also been shown to enhance the stability of plaque lesions by inducing 
collagen synthesis by SMCs (Ait-Oufella, Salomon et al. 2006).
To our knowledge, this is the first study to report the effect of rMOMP on another 
sub-population of Treg cells, the CD8^CD25^FoxP3^ population. These cells are less well 
characterised and have been shown to exert an inhibitory effect on CD4^ T cells via a direct 
cell-to-cell contact mechanism (Cosmi, Liotta et al. 2003). The results of this study revealed 
that immunisation with M. voccae-rMOMP+SPS significantly increased the numbers of 
CD8  ^Treg cells compared with untreated mice and those treated with wild-type M. vaccae, 
whereas the group treated with M. vaccoe-rMOMP-SPS showed no effect on the proliferation 
of these cells. Unfortunately, we currently have no explanation for this effect and no similar 
experiments have been reported in the literature before. Treatment with pcDNA-MOMP and 
pcDNA3.1 induced the same level of CD4^ Treg no effect on Treg cell proliferation, 
suggesting a vector-mediated effect although the same treatment has been shown in the 
preliminary experiment of Chapter 4 its capability to stimulate the same level of CD4^ Treg 
proliferation using C57bl/6J mice. A potential explanation for this, as we mentioned in 
Chapter 5, could be that the amount of protein expressed by the plasmid may not be enough
171
to affect or to modulate the immune response in these animals over that induced by the vector 
itself (Ohkura and Sakaguchi 2010). Under-expression of the target protein could also be 
related to plasmid degradation in the harsh mucosal environment experienced upon intranasal 
dosing. Overall, these results indicate that rMOMP protein is able to induce athero-protective 
Treg cells, particularly CD4^CD25^FoxP3^ Tregs. These are one of the most potent 
parameters involved in halting the progression of plaque development in the brachiocephalic 
artery and enhancing plaque stability by increasing SMC proliferation and collagen content.
Another parameter analysed was the synthesis of pro- v.s. anti-inflammatory cytokines 
induced by immunisation. It is widely accepted that treatments altering the cytokine milieu 
will affect the progression status of atherosclerotic plaques indirectly (Baidya and Zeng 2005; 
Galkina and Ley 2009). We measured the secretion of IFN-y (a potent pro-inflammatory 
Thl-derived cytokine), IL-4 (an indicator of anti-inflammatory Th2 immune responses) and 
the most potent anti-inflammatory and suppressor cytokines (IL-10 and TGF-p) in the 
supernatant of splenocytes isolated from immunised animals. Supernatants were used as 
concentrations of these cytokines in plasma where below the detection limit of the assay 
used. The results show that rMOMP with and without SPS, expressed by M  vaccae 
significantly increased IFN-y secretion compared with control groups, while secretion of IL-4 
was only increased by immunisation with M. vaccag-rMOMP-SPS. Interestingly, the same 
treatment enhanced IL-10 and TGF-p secretion, supporting our hypothesis that MOMP 
possesses anti-inflammatory properties.
There is strong evidence supporting the role of IL-10 in atherosclerosis. IL-10 
deficient mice fed a high fat diet develop atherosclerotic lesions that undergo increased 
infiltration of inflammatory cells and display high levels of pro-inflammatory cytokines 
(Mallat, Besnard et al. 1999; Mallat, Heymes et al. 1999; Pinderski, Fischbein et al. 2002). 
Double knockout ILlO'^ /apoE'^' mice and IL-10 deficient LDL'^' mice have shown a 
predominant Thl immune response with increased infiltration of activated T cells and 
macrophages in the lesions (Potteaux, Esposito et al. 2004; Caligiuri and Nicoletti 2006). 
However, the precise effects of IL-10 on other cells such as DCs, macrophages and specific 
subsets of T cells remain unclear (Taleb, Tedgui et al. 2008). Understanding these unknowns 
may shed light on some of the effects found in our study. The results showed that the 
reduction in the plaque size was compined with increase in the level of IL-10; confirming the 
anti-atherogenic effect of IL-10.
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TGF-p was another important cytokine that was measured as part of this study. Our 
results show that animals immunised with rMOMP with or without SPS expressed by M 
vaccae significantly increased the level of this cytokine compared to wild-type M. vaccae. 
Interestingly, rMOMP expressed by M  .vaccae was able to arrest the inflammatory effect of 
wild-type M. vaccae by increasing the level of TGF-p. This cytokine has wide suppressive 
effects on a variety of cells (Horwitz, Zheng et al. 2003). TGF-p regulates the immune 
response via several mechanisms including regulation of T cell growth and development 
(Letterio and Roberts 1998), inhibition of Thl and Th2 differentiation (Heath, Murphy et al. 
2000), stimulation of the expression of suppressive marker CTLA-4 on CD4^ T cells 
(Yamagiwa, Gray et al. 2001; Zheng, Gray et al. 2002), suppression of B cell activation 
(Horwitz, Gray et al. 2002), stimulation of CD8^ T cells to suppress antibody production 
(Gray, Hirokawa et al. 1994; Gray, Hirokawa et al. 1998; likuni, Lourenco et al. 2009) and 
protecting Treg cells from apoptosis (Horwitz, Zheng et al. 2003). TGF- p is involved not 
only in the production of inducible Treg (iTreg) cells but also in the modulation of natural 
Treg (nTreg) cell development (Curotto de Lafaille and Lafaille 2009). Furthermore, it has 
been reported that the combined secretion of IL-10 and TGF- p, as observed in this study, 
exerts a more powerful suppressive effect on chronic inflammation (Zeller, Panoskaltsis- 
Mortari et al. 1999; Chen, O'Shaughnessy et al. 2003). The anti-atherogenic effect of TGF-p 
has been confirmed by several studies (Mallat, Go)ova et al. 2001; Robertson, Rudling et al.
2003) and is in agreement with the athero-protective effects induced by immunisation with 
M. vaccae expressing rMOMP without SPS observed in our study.
The other cytokine that was significantly increased upon treatment with M  vaccae 
expressing rMOMP without SPS was IL-4. This cytokine is secreted mainly by Th2 cells, 
macrophages and mast cells (Paul and Seder 1994; Seder and Paul 1994). IL-4 is the major 
cytokine that drives ThO differentiation into a Th2 phenotype, and is therefore known for its 
anti-atherogenic effects (Mosmann, Cherwinski et al. 1986). Very early studies described IL- 
4 as an athero-protective cytokine due to its ability to reduce plaque size or to minimise the 
lesion area (Vadiveloo, Stanton et al. 1994). IL-4 effectively inhibits Thl immune responses, 
macrophage activation and IFN-y production and down-regulates pro-coagulant expression 
by endothelial cells (Seder and Paul 1994). However, more recent studies contradict this 
initial claim, giving IL-4 a pro-atherogenic role at different time points during the 
development of atherosclerotic plaques. For example, IL-4 has been shown to up regulate 
oxLDL-binding scavenger receptor expression and inhibit nitric oxide synthesis, both of
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which are pro-atherogenic effects (Bogdan, Vodovotz et al. 1994; Mehindate, al-Daccak et al. 
1996; King, Cassis et al. 2007).
Despite the former interesting findings, the results obtained in relation to the secretion 
of IFN-y where most surprising and intriguing. IFN-y is secreted by various cell types such 
as macrophages, NK cells, Thl CD4^ T cells, B cells and DCs (Schroder, Hertzog et al.
2004). We observed an up-regulation of the synthesis of IFN-y, together with an increase in 
the proliferation of CD4^ Treg cells and the production of other anti-inflammatory cytokines 
such as IL-10 and TGF-p. Interestingly, we found that previous studies have reported that 
IFN-y is critically involved in the conversion of CD4^CD25" T cells to CD4^CD25^ T cells by 
increasing the expression of FoxP3 and by triggering its regulatory function (Ding, Lu et al. 
2006; Wang, Hong et al. 2006; Zhang 2007), therefore playing a dual role in inflammatory 
reactions.
There is accumulating evidence suggesting that IFN-y has a dual function in the 
context of atherosclerosis at specific stages of its development. This cytokine has been 
classically shown to have a pro-atherogenic effect by inducing leukocyte recruitment to 
lesion sites through enhancement of the expression of adhesion molecules such as VCAM-1 
and ICAM-1 on endothelial cells. This in turn, increases the production of chemokines such 
as those belonging to the CXC family, which enhance leukocyte recruitment (Gupta, Pablo et 
al. 1997; Buono, Come et al. 2003). Furthermore, IFN-y positively regulates the 
accumulation of lipids in the lesions by decreasing cholesterol efflux from macrophages 
leading to foam cell formation and enhancing plaque destabilisation. This mechanism is 
associated with an increase in MMP synthesis by SMCs, which further destabilises plaques 
by degrading collagen and extracellular matrix (Harvey and Ramji 2005).
In contrast to the above mentioned effects, other studies have reported that IFN-y can 
also have anti-atherogenic properties by reducing the uptake of oxLDL by macrophages via 
down-regulation of scavenger receptor, LDL-c or VLDL-c expression, leading to a reduction 
in foam cell formation (Geng and Hansson 1992; LaMarre, Wolf et al. 1993; Kosaka, 
Takahashi et al. 2001). Moreover, IFN-y inhibits oxidation of LDL by macrophages, which 
is crucial for nitric oxide generation and therefore an essential step in atherogenesis (Christen, 
Thomas et al. 1994; Fong, Albert et al. 1994; Niu, Xia et al. 2000). In this way, IFN-y acts as 
a potent anti-oxidant. Additionally, IFN-y up regulates the expression of immuno- 
,suppressive molecules such as PD-Ll, and inhibits T hl7 cell development, hence
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ameliorating inflammatory damage (Tsushima, Tanaka et al. 2006; Kastelein, Hunter et al. 
2007).
In our mouse model, the high levels of IFN-y observed may have been facilitating the 
proliferation of sub-populations of Treg cells (i.e. Trl), which mainly develop in the 
peripheral organs and secrete high levels of IL-10 and moderate levels of IFN-y themselves 
(Roncarolo, Gregori et al. 2003; Haringer, Lozza et al. 2009). The Trl phenotype of Treg 
cells is usually stimulated by a combination of IL-10 and TGF-p, and represent 
approximately a quarter of all CD4^ T cells (Jonuleit, Schmitt et al. 2000; Levings, 
Sangregorio et al. 2001; Trinchieri 2001; Levings, Bacchetta et al. 2002), thus matching the 
results obtained in this study. The results show that treatment with M. vaccae expressing 
rMOMP, in particular the variant without the SPS results in a smaller plaque size in 
combination with increased SMC proliferation. It is known that SMCs secret high levels of 
IFN-y (Campbell and Campbell 1994; Ruan, Moorhead et al. 2006) and the increase in the 
percentage of SMCs upon the treatment could be an alternative explanation for the high 
levels of IFN-y detected in the treatment group showing a dramatic reduction in 
atherosclerotic plaque size.
Our study showed that rMOMP could be inducing an athero-protective immune 
response via secretion TGF-P and IL-10, the enhancement of Treg cell proliferation and by 
driving the immune response towards a Th2 phenotype, as confirmed by the high levels of 
IL-4 detected. This effect was specifically observed in mice immunised with M  vaccae- 
rMOMP-SPS. Overall, our results demonstrated that the anti-inflammatory response induced 
by M  voccag-rMOMP-SPS is more effective than that induced upon M. vaccae- 
rMOMP+SPS administration. A potential explanation for this observation is that the amount 
of protein expressed by M  vaccag-rMOMP+SPS was less than that expressed by M. vaccae- 
rMOMP-SPS. Much evidence in the literature supports the theory that signal peptide 
sequences decrease the amount of protein expressed due to protein translocation difficulties 
leading to proteins becoming trapped inside the host cells and thus reducing the total yield 
(Dascher, Roll et al. 1993; Hoelzle, Hoelzle et al. 2003).
We also examined the effect of rMOMP on the lipid profile of immunised apoE" '^ 
mice. The atherogenic lipid profile is generally characterised by high levels of total 
cholesterol, triglycerides and LDL-c (‘bad’ cholesterol) in combination with low levels of 
HDL-c (‘good’ cholesterol) (Menown, Murtagh et al. 2009). Our results showed that
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rMOMP with or without SPS expressed by M. vaccae significantly decreased HDL-c levels 
compared with wild-type M. vaccae while having no effect on triglyceride or LDL-c levels. 
However, animals treated with pcDNA-MOMP, which revealed no effect on the 
atherosclerosis development, showed a significant reduction in the levels of triglycerides and 
HDL, without effect on the total cholesterol or LDL-c levels. Coincidentally, in animals 
immunised with M  vaccae expressing rMOMP, with or without SPS, we detected low levels 
of HDL-c and high levels of IFN-y. This correlation suggests that IFN-y may have a role in 
inhibiting reverse cholesterol transport. This has been previously attributed to a down- 
regulation of the ATP-binding cassette transporter 1 (ABCl) molecule; ABCl modulates 
intracellular cholesterol levels in the liver and peripheral cells by effluxing excess cholesterol 
to lipid-poor apoA-I to form HDL (Panousis and Zuckerman 2000). Previous studies 
reported this effect when they treated murine peritoneal macrophages with IFN-y. These 
cells showed a dose-dependent reduction in cholesterol efflux caused by down-regulation of 
ABCl expression. The same effect has been found in THP-1 macrophage derived foam cells 
(Panousis and Zuckerman 2000; Wang, Panousis et al. 2002; Hao, Cao et al. 2009). 
Additionally, it has been found that expression of ABCl positively correlates with the levels 
of HDL measured in the plasma, (Brewer, Remaley et al. 2004; Field, Watt et al. 2008) so it 
should hold true that if IFN-y decreases ABCl expression, HDL levels should decrease 
proportionally.
However, the fact that our treatment seemed to have a negative effect on HDL-c and 
not on LDL-c contradicts the classical views on this topic. Nevertheless, there is a growing 
body of evidence in the literature suggesting that, contrary to what has been classically 
accepted, correlations between lipid profiles and atherosclerotic plaque development may not 
be reliable, especially in animal models (Davenport and Tipping 2003; Elhage, Jawien et al. 
2003; Van Eck, Twisk et al. 2003). Additionally, doubts have been cast on the real suitability 
of the apoE' '^ mouse model (single knockout) to study the effect of any treatments on the lipid 
profile due to genetic modification in apoE gene (Ishibashi, Herz et al. 1994; McGillicuddy, 
Carrier et al. 2001). In this sense, the results derived from our study may require further 
investigation using a different model and/or a human intervention study to ascertain the effect 
of this treatment on the lipid profile.
In summary, our study is the first to use rMOMP; a bacterial-derived protein, 
expressed by heterologous expression vectors, to assess its effect on atherosclerosis 
development. We have shown that intranasal immunisation using these recombinant vectors
176
can significantly reduce or arrest the development of atherosclerotic plaques in the 
brachiocephalic artery of apoE'^' mice. This effect appears to be dependent on the way the 
antigen is exposed to the immune system, but nonetheless mainly triggers T cell-mediated 
immune responses. More specifically, the rMOMP-SPS variant induced a more effective and 
extensive protective response against atherosclerosis than with the variant with SPS. Further 
experiments are required to dissect the effects of MOMP on the molecular mechanisms 
associated with these effects, but nonetheless, this study has made advances towards this 
understanding and has identified some important factors for future scrutiny.
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CHAPTER 7
GENERAL DISCUSSION AND FUTURE WORK
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7.1. DISCUSSION
Realisation that inflammatory mechanisms govern the progression and destabilisation 
of atherosclerotic plaques has driven several studies to develop novel therapeutic agents to 
assuage the process of atherosclerosis and stabilise vulnerable plaques. To date, most of the 
therapeutic strategies developed modulate immune responses involved in atherosclerosis 
development either by blocking inflammatory signals or by inducing immuno-suppressive 
responses, for example by employing a Treg cell expansion regime (Hansson and Nilsson 
2009). Therapeutic agents used to date are derived from a variety of components. For 
example, agents may be derived from an oxLDL molecule as is the apoB-100 antigen 
(Hermansson, Ketelhuth et al. 2011), or may be comprised of auto-antigens, such as 
Hsp60/65 (Maron, Sukhova et al. 2002). Adjuvants such as alum (Wigren, Bengtsson et al. 
2009) or immuno-suppressive antigens from pathogens (Binder, Horkko et al. 2003; Ait- 
Oufella, Horvat et al. 2007; Marchai 2011) may also be used to attenuate the pathological 
immune mechanism. The research described in this thesis belongs to the latter approach, 
whereby pathogens are used as a source of immuno-suppressive antigens.
Whilst reviewing the literature for current research on developing vaccination to 
protect against chlamydial infection, it was found that naïve mice immunised with DCs 
pulsed with the rMOMP of C. trachomatis generated a Th2 immune response, which in the 
context of atherosclerosis is known to be protective (Shaw, Grund et al. 2002). Subsequently, 
our research group showed that rMOMP modulates T cell immunity by inhibiting the 
expression of key activation markers on APCs and CD4^ T cells (Bermudez-Fajardo 2011). 
Based on the collective findings from the literature and from within the research group, we 
hypothesised that MOMP’s anti-inflammatory properties may be sufficient to reduce or arrest 
atherosclerosis development.
In order to test our hypothesis, we first needed to establish a reliable source of MOMP 
protein, which is one of the biggest challenges faced in this field of research today. 
Therefore, the first objective of our study involved the cloning and expression of rMOMP in 
a heterologous protein expression system. M. vaccae was used as a surrogate host to express 
the C. pneumoniae MOMP. The gene encoding MOMP (ompl) was expressed by M. vaccae 
following gene amplification using two different sets of primers designed to obtain two 
distinct fragments of the MOMP gene. The first fragment encoded the full length MOMP 
gene, while the second fragment encoded a truncated form that was missing the DNA 
encoding the first 23 amino acids corresponding to the signal peptide sequence. These two
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fragments were then used to generate two forms of M  vaccae expressing rMOMP; one 
capable of expressing full length of MOMP (M vaccae-rMOMP+SPS) and the other 
expressing MOMP without the signal peptide sequence (M v«ccae-rMOMP-SPS). The 
decision to create two different forms of rMOMP expressed by M  vaccae was made based on 
previous observations from different research groups. Several studies reported that the 
presence of the MOMP signal peptide sequence affected both the amount of recombinant 
protein expressed and the viability of the surrogate host cells (Puohiniemi, Butcher et al. 
1991). However, when generating a truncated protein, there is always a potential to 
inadvertently alter protein function. Therefore, the decision to express both versions was 
made with the intention to surmount such experimental problems.
In this study, an M  vaccae expression system was used as a surrogate host cell in an 
attempt to avoid the pathogenic effects associated with LPS contamination during antigen 
preparation in E. coli (Lahey, Arbeit et al. 2010; Yang, Chen et al. 2010). Although M. 
vaccae is a non-pathogenic bacterium with a genetic system capable of expressing a wide 
range of heterologous antigens (Garbe, Barathi et al. 1994), there are no reports regarding the 
survival of live M  vaccae inside the body or regarding the immune response following 
intranasal inoculation. Therefore, to pre-empt potential problems arising as a result of using 
an M. vaccae expression system, we also chose to deliver rMOMP directly into mice using 
the widely accepted peDNA3.1 eukaryotic expression vector (pcDNA-MOMP) (Penttila, 
Tammiruusu et al. 2004). Advantages of using pcDNAS.l as a delivery system include that it 
is safe, stable at different temperatures and guarantees long-term expression of antigens 
within tissues. Even when administered intranasally pcDNAS.l has proven capable of 
inducing both mucosal and systemic immune responses against visceral leishmaniasis (Doria- 
Rose and Haigwood 2003; Gomes, Pinto et al. 2007).
Disadvantages of pcDNAS.l as an expression vector include variable and 
unpredictable protein expression efficiencies following immunisation, due to DNA 
degradation by several intracellular factors (Donnelly, Ulmer et al. 1997; Doria-Rose and 
Haigwood 2003). Additionally, some studies have also reported that administration of 
recombinant proteins expressed by a DNA plasmids at mucosal sites may induce insufficient 
systemic immune responses due to local enzymatic degradation of the plasmid (Bamfield, 
Brew et al. 2000; Niedzinski, Chen et al. 2003). Therefore, the advantage of using a non- 
pathological antigen expression vector such as M. vaccae, is that it is known to be resistant to 
mucosal degradation and would help to alleviate potential problems arising from the use of 
pcDNA3.1 (Hrouda, Baban et al. 1998; Hadley, Smillie et al. 2005; Hunt, Martinelli et al.
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2005). Taking all evidence into consideration, it was apparent that both vectors did not 
possess all of the desirable properties and both had shortcomings. Thus, it was considered 
prudent to use both vectors and to compare the immunological responses invoked by each.
Most previous studies have involved investigating the immune response induced by 
MOMP in the context of vaccine development against chlamydial infection. This has 
resulted in the limited availability of information in relation to the nature of the immune 
response that rMOMP induced and the mechanisms by which it did so. To date, there are no 
detailed reports on MOMP’s immuno-modulatory properties. Therefore, one of our aims was 
firstly to characterise the immune responses induced by MOMP by studying the effects on 
both the humoral and cell-mediated immune systems, including specific effects on Treg cell 
populations. To this end, the most widely used, inbred strain of mice (C57B1/6J mice) was 
used to eharacterise the immune response induced by rMOMP in vivo. The results of this 
part of the study showed that both full length and truncated rMOMP expressed by M. vaccae 
inereased the secretion of anti-inflammatory cytokines such as IL-10, and enhanced the 
percentage of CD4^ and CD8  ^ Treg cells in the general population. rMOMP with signal 
peptide sequence (M voccac-rMOMP+SPS), was the most effective at mediating these 
effects. Treatment with pcDNA-MOMP inhibited production of the pro-inflammatory 
cytokine, IFN-y and increased the percentage of CD4^ Treg cells while deereasing the overall 
number of CD4^ T cells.
These findings suggest that MOMP has anti-inflammatory properties that are capable 
of dampening down the host immune response. It has been observed that in C57B1/6J mice, 
MOMP decreases the levels of synthesised IFN-y, which is a significant finding as this mouse 
strain is known for its Thl biased immune response (Heinzel, Sadick et al. 1989; Jawien, 
Nastalek et al. 2004). The shift away from a Thl-mediated immune response is coherent 
with the study by Shaw et al. (2002) that reported induction of a Th2-mediated immune 
response upon treatment of mice with DCs pulsed with rMOMP of C. trachomatis (Shaw, 
Grund et al. 2002). Interestingly, high levels of IL-10 were detected in animals immunised 
with MOMP, thereby implicating this cytokine with anti-inflammatory mechanisms. Indeed, 
IL-10 is known to elieit a powerful negative regulatory effect on APCs by down-regulating 
MHC class-II, CD 80 and CD86 molecule expression and thus impairing antigen presentation 
and downstream T eell activation and differentiation. (Yamakami, Akao et al. 2002; S abat, 
Grutz et al., 2010). Hence, following doser analysis of the cytokine milieu stimulated by 
MOMP immunisation, it can be concluded that MOMP favours the induction of un-protective 
Th2 cell immune responses rather than the protective Thl immune response that have
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previously been reported in the literature (Mosmann, Cherwinski et al. 1986; Romagnani 
1996).
Furthermore, we investigated the effect of MOMP on CD4^ and CD8  ^ T cells, to 
facilitate further insight into the potential effects of this protein during infection (Rottenberg, 
Gigliotti Rothfuchs et al. 1999; Kelly 2003). From this analysis we are able to illustrate for 
the first time that MOMP immunisation enhances the percentage of CD4^ and CD8^ Treg 
populations, whieh are known to have suppressive effects on both naïve and memory T cells 
in vivo and in vitro (Sakaguchi, Yamaguchi et al. 2008). Clinical studies reported that these 
populations of Treg cells have been induced during infection by several pathogens sueh as 
Mycobacteria spp. and Listeria monocytogenes. It is known that such pathogens amplify Treg 
cell populations deliberately to suppress host immune responses, thereby increasing bacterial 
survival and replication rates within the host (Redpath, Ghazal et al. 2001; Sakaguchi 2003; 
Couper, Blount et al. 2008).
Specifically, our study revealed that full length rMOMP expressed by M. vaccae- 
rMOMP+SPS increased the percentage of CD8  ^Treg cells; a finding consistent with previous 
research within this group. We earlier reported that macrophages treated with rMOMP and 
co-cultured with CD8  ^ T cells increased expression of CD25 in a dose-dependent manner, 
leading to transformation of CD8  ^ T cells into CD8  ^ Treg cells (Bermudez-Fajardo 2011). 
rMOMP expressed by pcDNA3.1 in the current research, also enhanced CD4^ Treg cell 
numbers with a concomitant decrease in the total number of CD4^ T cells. We hypothesise 
that this effect could be the result of a MOMP-mediated active conversion of naïve CD4^ T 
cells into Treg cells. The other explanation for this finding refers to the inhibitory effeet of 
Treg cells on the conventional CD4^ T cells (Taams and Akbar 2005). This new and exciting 
observation requires further investigation and provides an insightful avenue for future work. 
Overall, the results discussed this far support our hypothesis that MOMP has anti­
inflammatory properties mediated by the induction of Th2 immune responses and by 
increasing the percentage of Treg cells in vivo.
The results discussed above encouraged us to investigate the effect of MOMP on 
selective inhibitory and activation markers involved in APC-T cell crosstalk in vitro. The 
purpose of this investigation was to further understand the immuno-modulatory meehanisms 
underlying the effects of MOMP on the host immune system, while simultaneously clarifying 
the inflammatory mechanisms involved in atherosclerosis. The study showed that MOMP 
expressed by either vector decreased the number of macrophage cells expressing the CD40 
molecule. Furthermore, MOMP protein enhanced the percentage of CD4^ T cells expressing
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CTLA-4 and CD25, while decreasing the percentage of CD4^ T cells expressing CD3 
molecules, which was observed in conjunetion with decreased proliferation. In the context of 
host immunological modulation caused by the pathogen, the observed results could indicate a 
potential mechanism for inhibition of antigen reeognition via the switching off the expression 
of molecules that participate in lymphocyte activation (Medzhitov 2001).
Additionally, suppression of CD40 molecule expression on APCs upon rMOMP 
treatment has an immense impact, not only on innate immune responses, but also on adaptive 
immune responses (Akira, Uematsu et al. 2006; Martin, Agarwal et al. 2010). Previous 
researchers have suggested that there is an inverse relationship between CD40 molecule 
expression and the proliferation of Treg cells; referring once again to a potential immuno- 
suppressor effect of MOMP (Martin, Agarwal et al. 2010). These results therefore suggest 
that the inhibitory effect of MOMP on CD40 may contribute further to the suppression of 
host immune responses not only by enhancing the percentage of negative regulatory T cells 
but by inhibiting T cell proliferation, macrophage activation, inflammatory cytokine secretion 
(IFN-y and TNF-a), B cell activation, B cell differentiation and antibody class switching 
(Andrade, Portillo et al. 2005; Suttles and Stout 2009).
Additionally, this analysis revealed that MOMP may increase the percentage of iTreg 
cells by enhancing the percentage of CTLA-4 and CD25 molecules, while reducing the 
percentage of CD3 molecules expressed by CD4^ T cells. Previous studies have shown that 
the sub-populations of T cells expressing CTLA-4 had a negative regulatory effect on 
immune responses by inducing T cell apoptosis and/or inhibiting T cell activation (Brunner- 
Weinzierl, Hoff et al. 2004; Hoff, Kolar et al. 2010). Moreover, other studies have shown 
that using antibodies to block CD3 molecules leads to an inhibition in T cell activation and 
proliferation by preventing antigen recognition. Block of CD3 antigen presentation causes a 
compensatory increase in the number of T cells expressing CD25 and thereby increases Treg 
proliferation (Belghith, Bluestone et al. 2003; Nishida, Chen et al. 2011). The suppressive 
effect of rMOMP described above, together with its inhibitory effect on the expression of 
CD3 thus corroborates the findings of a significant body of work in this field. One such 
source of evidenee is the clinical use of rMOMP to expand Treg cell populations for the 
treatment auto-immune diseases (Belghith, Bluestone et al. 2003; Bisikirska, Colgan et al.
2005). Overall, these results support our hypothesis that MOMP may have anti-inflammatory 
properties, mediated by inducing Treg cells via modulation of the specific receptors 
expressed on APCs and CD4^ T cells.
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In the context of atherosclerosis, the findings discussed so far suggest that MOMP 
may be capable of modulating the pathological mechanisms of atherosclerosis development 
via its effect on CD40, CTLA-4, CD25 and CD3 markers (Gotsman, Sharpe et al. 2008). 
rMOMP may attenuate the immune response by reducing the percentage of macrophages 
expressing CD40 molecules. The literature has shown interruption of CD40 signalling 
substantially reduces atherosclerotic plaque formation (Mach, Schonbeek et al. 1998; 
Lutgens, Gorelik et al. 1999), and enhances plaque stabilisation by increasing collagen 
content (Lutgens, Cleutjens et al. 2000; Schonbeek and Libby 2001).
Increasing the percentage of CD4^ T cells expressing CTLA-4 and CD25 molecules; 
classical markers of iTreg sub-populations, upon rMOMP treatment suggest another athero- 
protective effeet of MOMP. In the literature, the role of these molecules in animal models is 
well doeumented (Takahashi, Tagami et al. 2000). Interaction of CTLA-4 molecule with B7 
receptor inhibits the immune response and can reduce atherosclerosis progression via 
inhibition of T cell proliferation, cytokine production, and cell cycle progression (Paust, Lu et 
al. 2004). CD25 molecule expressed on Treg cells consume IL-2 secreted by conventional T 
cells, leading to inhibition of CD4^ T cell activation and other inflammatory signals in 
atherosclerosis development (Takahashi, Tagami et al. 2000). In addition to the down- 
regulation of CD3 expression on CD4^ T eells, MOMP may modulate the inflammatory 
mechanisms of atherosclerosis by two different pathways. The first mechanism involves 
diminishing antigen recognition, leading to decreased CD3^ CD4^ T cell proliferation, which 
normally represent 90% of the total T cell composition in lesions of apoE'"^ ' mice (Zhou, 
Stemme et al. 1996; Nishida, Chen et al. 2011). The second mechanism may involve 
induction of Treg cell population expansion (Steffens, Burger et al. 2006; Sasaki, Yamashita 
et al. 2009), as suggested by the increase in CTLA-4 and CD25 molecules observed herein. 
These results therefore emphasise the suppressive effect of rMOMP on the cellular 
composition of aortic atherosclerotic plaques; changing the percentages of macrophages and 
CD4^ T cells that are detected at all stages of atherosclerosis development (Hansson, 
Jonasson et al. 1988) and thus indicating a role for MOMP at all stages of disease 
progression.
Examination of the anti-inflammatory effects of MOMP on atherosclerosis 
development was the next logical step of this investigation and was achieved using apoE '^ ' 
mice as validated animal models of the disease. ApoE'^' mice have constitutively high levels 
of cholesterol; LDL-c and VLDL-c, combined with low levels of HDL-e and are suseeptible 
to the development of atherosclerotic lesions in the arterial tree even when fed a normal chow
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diet (Jawien, Nastalek et al. 2004). The effect of rMOMP on atherosclerosis development 
was examined by measuring the size and composition of atherosclerotic plaques formed in 
both the brachiocephalic arteries and in the aortic sinus (Paigen, Ishida et al. 1990). 
Histological examinations have previously shown that the aortic sinus develops advanced 
lesions whereas enhanced plaque rupture is well documented in brachiocephalic arteries 
(Nakashima, Plump et al. 1994), therefore accounting for the decision to investigate the effect 
of rMOMP treatment in both areas. The effect of rMOMP on the proliferation of CD4^ Treg, 
CD8  ^Treg, CD4^ T cell and CD8  ^T cell populations was examined. Moreover, the effect of 
rMOMP treatment on cellular immunity was determined by measuring the cytokine milieu 
and the humoral immune response was monitored by measuring the levels of specific 
antibodies. Plasma lipid profiles were also investigated to detect any non-immunological, but 
important effects that could manipulate atherosclerosis development.
Interestingly, histologieal analysis revealed that truncated rMOMP (M  vaccae- 
rMOMP-SPS) expressed by M. vaccae arrested the development of atheroselerotie plaques in 
brachiocephalic arteries by 95%. However, the same treatment showed no effect on plaque 
size in the aortic sinus, but did enhance plaque stability by stimulating SMC proliferation. 
Studies of atherosclerosis using brachiocephalic arteries as models of human disease 
progression have been shown to be more useful and relevant in the study of plaque 
development and destabilisation than their counterparts from the aortic sinus (Johnson and 
Jackson 2001). Thus, in our study, the arrest of plaque formation in the brachiocephalic 
artery caused by rMOMP is more likely to correspond to the effect expected in humans 
following rMOMP immunisation. However, sinee the aortic sinus is prone to plaque rupture 
as well, the potential of MOMP to stabilise the plaque is an interesting finding and may well 
extrapolate to humans.
M. vaccac-rMOMP-SPS, also increased the levels of IL-10, IL-4 and TGF-p anti­
inflammatory cytokines and resulted in an increase in IFN-y levels. The high levels of these 
mediators observed may be a result of the effect of MOMP on CD4^ Treg cells, which have 
been shown to secrete low levels of IFN-y and IL-2 upon suppressive antigen treatment 
(Macian, Garcia-Cozar et al. 2002; Gabrysova, Nicolson et al. 2009). IFN-y has been also 
shown to be essential for the conversion of CD4^CD25‘ Treg eells into CD4^CD25^ Treg 
populations by inducing FoxP3 gene expression caused by IFN-y-stimulated IL-2 secretion, 
which is an essential cytokine for Treg cell proliferation (Wang, Hong et al. 2006). The role 
of IFN-y in atherosclerosis has been well debated due to its dual effects on atherosclerosis
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depending on the stage of atherosclerotic development (McLaren and Ramji 2009; Li, 
McLaren et al. 2011). In the early stages of the disease, IFN-y acts as a pro-atherogenic 
cytokine, indueing recruitment of leukocytes through the enhancement of adhesion molecule 
expression by endothelial cells and also by increasing lipid accumulation through inhibition 
of cholesterol efflux (Lusis 2000). However, IFN-y enhances the stability of advanced 
atherosclerotic plaques in later stages of the disease via stimulation of SMC proliferation, 
resulting in the increased secretion of collagen and extracellular matrix eomponents (Hansson 
and Hermansson 2011). Despite these opposing effects,, IFN-y is generally considered as 
potent pro-atherogenic cytokine (Tellides, Tereb et al. 2000; Zhang 2007).
The significant induction of IL-4 could be an indicator that M. v«ccac-rMOMP-SPS 
induces anti-atherogenic Th2 responses (Mosmann, Cherwinski et al. 1986). IL-4 inhibits 
Thl immune responses, macrophage activation and down-regulates the expression of pro­
coagulants by endothelial cells. However, this anti-atherogenic role has been questioned 
recently by studies showing that IL-4 can mediate pro-atherogenic effects via enhancing 
expression of scavenger receptors which invove in oxLDL uptake on macrophages, leading to 
increase in foam cells (Mehindate, al-Daccak et al. 1996; Davenport and Tipping 2003; King, 
Cassis et al. 2007). The levels of two other potent anti-atherogenic cytokines were also 
significantly increased upon M. vaccac-rMOMP-SPS immunisation. The athero-protective 
effect of IL-10 and TGF- (3 cytokines is well documented in both animal and human studies 
(Letterio and Roberts 1998; Chen, O'Shaughnessy et al. 2003; McCaffrey 2009; Hansson and 
Hermansson 2011). Both cytokines have crucial roles in Treg activation through inducing 
expression of the FoxP3 transcription factor (Zeller, Panoskaltsis-Mortari et al. 1999). These 
cytokines also inhibit the activation of macrophages, down-regulate foam cell formation and 
stabilise the atherosclerosis development (Hansson and Hermansson 2011). Therefore, the 
pro-inflammatory effects expected from the increase in IFN-y levels may have been masked 
by the anti-inflammatory effects of IL-4, IL-10 and TGF-P cytokines, which were also raised.
Another effect observed following M. v«ccac-rMOMP-SPS administration was a 
reduction in the total number of CD4^ T cells accompanied by a significant increase in the 
percentage of CD4^ Treg cells. This refers to the suppressive effect of CD4^ Treg eells on 
the proliferation of CD4^ T cells or rather the tendency for naïve CD4^ T cells to differentiate 
into Treg sub-populations when driven by rMOMP (Taleb, Tedgui et al. 2010). As discussed 
above, IL-10 and TGF-p are both known for their ability to activate Treg cells via up- 
regulation of FoxP3 transcription. Thus, the altered cytokine milieu induced by MOMP
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immunisation, may be the cause of downstream effects such as CD4’*' T-cell differentiation 
and activation.
Immunisation with M  vaccac-rMOMP-SPS caused a significant reduction in the 
levels of HDL-c compared with the levels circulating in the plasma of animals treated with 
wild-type of M  vaccae. Reduction of HDL-c is likely to have been caused by a down- 
regulation of ABC 1-mediated cholesterol efflux eaused by raised IFN-y. In the context of 
atherosclerosis, this would be a negative effect, since HDL is considered an athero-protective 
lipoprotein (steinberg 1987; Reusch, Wagdy et al. 1996). Overall, it can be concluded that 
the effects of M  vacc<arc-rMOMP-SPS treatment on atherosclerosis development in apoE'^' 
mice were mediated mainly by suppression of the immune response. Alteration of the plasma 
lipid profile can be ruled out as an immuno-protective mechanism, since HDL levels were 
reduced and LDL levels remained unchanged. A summary of the effects caused by M. 
VflCcac-rMOMP-SPS is shown in Figure 7.1.
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Figure 7.1. Diagrammatic summary of the potential mechanisms of inflammation in 
atherosclerosis, induced upon M. vaccae-rMOMP-SPS treatment.
M. vaccae expressing MOMP w ithout SPS is introduced to the immune system via an APC (1). APC 
degrades M. i/accae-rM OM P-SPS before presenting peptides to C D A  T cells via MHC class-II. 
During this process MOMP decreases the percentage of APC s expressing CD40 (2). This effect 
suppresses the humoral im m une response by impeding B cell maturation and activation (3). Upon 
antigen presentation by APC s and recognition by CD4'' T cells (4.1) CD4"^T cells secrete IFN-y but 
can not activate APC s due to lack the 2"^ signal (CD40-CD40L) (4.2). rM OMP (-SPS) m ay induce 3 
different effects on CD4^ T cells; Increasing the percentage of CD4^ T cells expressing CTLA-4, 
which will inhibit CD4'' T clonal expansion and activation (5.1); enhancing the percentage o f cells 
expressing CD25 and inducing FoxPS expression (CD4+ Treg) (5.2); or driving CD4'" T  cell 
d ifferentiation into a Th2 immune response that secretes IL-4 (5.3). C D 4 ''T reg  cell w ill then induce 
SMC proliferation via TGF-(3 (6.1), induce proliferation o f other regulatory T cells via IL-10 and TGF-P 
(6.2) and inhibit CD4'" T cell activation and proliferation either by cell-cell contact or cytokine 
secretion (6.3). Secreted IFN-y down-regulates ABC1 expression leading to a reduction in HDL-c 
levels (7).
Treatment with rMOMP with SPS expressed by M. vaccac (M vaccae- 
rMOMP+SPS), had a lesser immuno-modulatory effect compared to M. vaccae-vMOM?- 
SPS. For example, M vr/ccae-rMOMP+SPS did not cause any noticeable changes to 
atherosclerosis development in the brachiocephalic artery nor in the aortic sinus. However, 
M vrrccrre-rMOMP+SPS treatment did elicit the same effects on cytokine profiles that were 
evoked by M. v<3ccae-rM0MP-SPS treatment. The only difference in the cytokine profile 
observed was that there was no effect on the levels of lL-4 secreted. M. vaccae- 
rMOMP+SPS also reduced the levels of HDL in the plasma, probably acting via the same
mechanism suggested for the truncated version MOMP. Despite, fewer changes to the 
cytokine profile, rMOMP with SPS was capable of enhancing not only the percentage of 
CD4^ Treg cells but also caused an increase the percentage of CD8  ^ T Treg cells in the 
population. It can therefore be concluded based on physiological evidence that rMOMP with 
SPS induces inefficient weak immune response that incapable of arresting atherosclerosis 
development. Figure 7.2 summarises the potential mechanisms involved in an M. vaccae- 
rMOMP+SPS induced immune-response.
Based on the evidence reported in the literature, a possible explanation for the 
differential effects of the two rMOMP variants is related to the function of signal peptide 
sequence. It has been found that signal peptide sequence effects the amount of protein 
expressed by M. vaccae either by causing mis-folding, intracellular protein sequestration or 
even by causing toxic effects on surrogate cells, reducing their viability and hence their 
capacity to express proteins (Koehler, Birkclund et al. 1992; Dascher, Roll et al. 1993; 
Manning and Stewart 1993; Hoelzle, Hoelzle et al. 2003). The toxic effect is most likely 
caused by translocation of the full length MOMP protein into the cell membrane of E. coli 
leading to membrane de-arrangement and fragility of the cells. As a result, the amount of 
expressed protein with signal peptide sequence may be less than that expressed without it 
(Koehler, Birkclund et al. 1992).
Another possible explanation for the disparity of effects mediated by full-length and 
truncated rMOMP is related to the consequence of rMOMP translocation to the cell 
membrane of M  vaccae. Membrane localisation of rMOMP results in altered cell membrane 
composition and possibly function. There are fundamental differences between the cell walls 
of Gram negative Chlamydiae and Gram positive M  vaccae and as yet, it is not known how 
rMOMP with SPS will be processed by M  vaccae. Whether rMOMP expressed by surrogate 
cells retained within the cell wall or released to the extra-cellular environment needs to be 
elucidated. Furthermore, evidence suggests that the conformation (folding) of MOMP effects 
its immunogenicity, and at present no data regarding the folding ability of MOMP in M. 
vaccae is available (Newhall 1988; Essig, Simnacher et al. 1999; Wolf, Fischer et al. 2001). 
Subsequently, the effect of rMOMP expression on the behaviour/activity of the surrogate cell 
may be combined with the immunological effects of rMOMP, both of which will influence 
the overall host immune response. This theory however needs further investigation to be 
confirmed.
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Figure 7.2. Diagrammatic summary of the potential mechanisms of inflammation in 
atherosclerosis, induced upon M. vaccae-rMOMP+SPS treatment. M. vaccae expressing MOMP 
with SPS is introduced to the immune system via APC  (1). APC degrades M. vaccae-rM O M P+SPS 
before presenting peptides into CD4^ T cells via MHC class-II (2). APC s present MOMP to CD4'" T 
cells via MHC class-II. Upon antigen presentation and recognition by CD4"^ T cells (4.1), CD4^ T cells 
secrete IFN-y to activate more APCs (3.1). rM OMP+SPS may induce d ifferent potential effects on 
CD4‘" T cells: Increasing the percentage o f CD4^ T cells expressing CTLA-4, which will inhibit CD4^ T 
clonal expansion; enhancing the percentage o f cells expressing CD25 and inducing FoxPS 
expression (CD4+ Treg and CDS'" Treg populations) (3.2). CTI_A-4 T cells, CD4^ Treg and CD8+ 
Treg cells inhibit CD4"' T cell clonal expansion via cell-cell contact or cytokine IL-10 or TGF-(3 
cytokine secretion (4). Secreted IFN-y down-regulates ABC1 expression, leading to a reduction in 
HDL-c levels (5).
In contrast to the previous results, pcDNA-MOMP showed no effect on 
atherosclerosis development, or on the immune response, although our previous results 
showed a subtle effect in the previous mentioned in  v ivo  and in  v itro  studies. The only 
observed effeet when using apoE"'^ ' mice was a reduction in the levels of triglycerides and 
HDL-e coneentrations compared to pcDNAS.l control-treated animals. A potential 
explanation is that protein expressed by DNA plasmids, which managed to eseape 
degradation either by extracellular enzymes (enzymatic hydrolysis) secreted into the harsh
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mucosal or by intracellular enzymes secreted inside cells. Thus, the quantity of active protein 
remaining may not have been sufficient to invoke an immune response and modulate 
atheroselerosis development. This explanation is plausible given that it has been 
demonstrated that administering naked DNA plasmids at mueosal sites may induce inefficient 
systemic immune responses due to local enzymatic degradation (Bamfield, Brew et al. 2000; 
Niedzinski, Chen et al. 2003). Moreover, the inefficient effect of this treatment may have 
been further augmented by the presence of the signal peptide sequence, which is theorised to 
cause further reductions in protein expression. pcDNA 3.1 was engineered to express the 
full length of MOMP, making expression of the truncated version unsuitable for this vector 
(Penttila, Tammiruusu et al. 2004). The potential immunological effects mediated by 
pcDNA-MOMP are summarised in Figure 7.3, but it needs to be recognised that these 
tentative mechanisms require further investigation.
One downfall of this study is that it failed to detect humoral immune responses 
induced by treatment, however antibody responses are difficult to detect, as has been 
confirmed by other research groups (Vanrompay, Vanloock et al. 2001; Penttila, Tammiruusu 
et al. 2004). After revising our results and performing a detailed review of the literature, we 
can speculate that the inhibitory effect of rMOMP on the CD40 molecule may have mediated 
an inhibition of humoral immune responses (Andrade, Portillo et al. 2005; Suttles and Stout 
2009). Such a down-regulation would have impeded detection of low antibody levels. An 
alternative explanation could be that the antibodies produced in the plasma of immunised 
mice were not able to detect rMOMP under the denaturing eonditions of the assay. This 
explanation relies on a previous observation that antibody detection of rMOMP depends 
mainly on the epitope conformation, which is prone to denaturing effects (Manning and 
Stewart 1993). Once again, the exact action of rMOMP on the humoral immune response 
requires further investigation.
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Figure 7.3. Diagrammatic summary of the potential mechanisms of inflammation in 
atherosclerosis, induced upon pcDNA-MOMP treatment. Two different scenarios are possible 
fo llow ing treatm ent with pcDNA-M OM P. In the scenario, insufficient am ounts o f DNA plasm id 
access the nuclei of APCs and rMOMP is not expressed (1.1). In the 2"'^ scenario, suffic ient pcDNA- 
MOMP is taken up by APC nuclei and rMOMP protein is expressed. rMOMP dow n-regula tes the 
expression o f CD40 on APCs, which leads to inhibition of the humoral im m une response (1.2). Next, 
APCs present rMOMP epitopes to two different T cell subtypes. APCs may present M OM P to CDS"^ 
T cells via MHC class-1 (2.1) or to CD4'" T cell via MHC class-II. Activation o f CDS'” T cells has no 
effect on atherosclerosis developm ent but activation o f CD4^ leads to a dow n-regulation o f CDS 
CD4"" T cell and reduces the ir proliferation (2.2). Additionally, this treatm ent reduces trig lyceride and 
HDL-c levels in the plasma.
Contrary to our expectations, analysis found that while treatments reduced 
atherosclerosis progression and enhanced plaque stability, there was a simultaneous negative 
effect on athero-protective HDL-c. Low levels of HDL-c combined with high levels of IFN- 
Y, were detected specifically in the plasma of animals immunised with rMOMP+/- SPS 
expressed by M vaccae. This result suggested a role of IFN-y in the down-regulation of 
cholesterol efflux. Previous studies have shown that IFN-y can reduce cholesterol efflux by 
down-regulating the expression of ABCl in macrophages (Wang, Zheng et al. 2001; Hao, 
Cao et al. 2009). Importantly, reduction of ABCl expression is positively correlated with the 
level of HDL-c detected in the plasma (Field, Watt et al. 2008). However, this interpretation
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needs further investigation. Despite this controversy, these results overwhelmingly 
demonstrate that MOMP has anti-inflammatory properties capable of arresting the 
progression of atherosclerosis via modulating inflammatory immune responses.
7.2. CONCLUDING REMARKS
There has been an extraordinary progress over the last two decades in the 
understanding of the inflammatory mechanisms involved in the development of 
atherosclerotic plaques (Libby, Ridker et al. 2002; Hansson and Hermansson 2011). 
However, now that it is known that inflammation and the immune system play key roles in 
atherogenesis, the focus has shifted to identify treatments to combat cardiovascular disease 
(Nilsson, Hansson et al. 2005). The use of immunosuppressive drugs and immunization have 
both been proposed (Nilsson, Hansson et al. 2005). Unfortunately, most of the 
immunosuppressive drugs available have adverse affects on cardiovascular risk factors such 
as dyslipidemia, hypertension, and diabetes (Nilsson, Hansson et al. 2005). Therefore, 
athero-protection using vaccines offers an attractive alternative (Nicoletti, Caligiuri et al. 
1999). The vaccination with antigens capable of enhancing Treg cell proliferation and the 
secretion of anti-inflammatory cytokines are amongst the most promising strategies (Binder, 
Horkko et al. 2003; Ait-Oufella, Horvat et al. 2007; Marchai 2011).
Our findings show that MOMP is a strong candidate to be used as a vaccine antigen 
to combat atherosclerosis development. The data presented herein shows that MOMP has 
anti-inflammatory properties that not only halt the progression of atherosclerosis but also 
enhance plaque stabilisation. This protective mechanism of MOMP may involve both the 
innate and the adaptive immune responses; increasing the synthesis of anti-inflammatory 
cytokines (IL-10, TGF-p and IL-4) and also the numbers of both CD4^ and CD8^ Tregs. The 
present study also indicates that MOMP may induce an immuno-suppressive mechanism used 
by Ch. pneumoniae to escape the host immune response and allow the long term survival of 
the bacterium within tissues, causing subclinical disease. This is an area that requires future 
investigation, but the inability to genetically manipulate Ch. pneumoniae makes it difficult to 
prove this assumption. Nevertheless, this study has paved a way for a new suppressive 
antigen (MOMP) that can be tested in other inflammatory diseases.
In this regard, we believe that our findings have made significant contributions to the 
current knowledge of Chlamydia biology, atherosclerosis and to vaccine development, but we 
also recognise a number of limitations to our approach. For example, our study did not assess
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the location of MOMP on the M. vaccae cell membrane or whether its translocation affected 
the integrity of the surrogate host cell’s membrane composition. Both are factors that could 
affect the immune response elicited (Rodriguez-Guell, Agusti et al. 2006). In addition, due to 
technical limitations, we were unable to assess the effect of MOMP on the molecular 
mechanisms associated with lipid metabolism in the context of atherosclerosis. These are 
areas that can form the basis of the next research endeavour to understand the mechanistic 
nature of atherosclerosis progression.
7.3. FUTURE WORK
This research has given rise to many questions in need of further investigation. 
Hence, further research is needed to examine the biological effect of MOMP’s signal peptide 
sequence on the composition of mycobacterial cell membranes as this could potentially 
stimulate differential immune responses. Since the final goal of our research is the use of this 
protein clinically, it should be investigated whether the suppressive effect in the experimental 
animal model also occurs in humans. Most importantly, we should investigate the effect of 
MOMP vaccination in conditions where a pre-existing infection with Chlamydia (subclinical) 
is known to exist. The latter is the closest to a real life scenario in which the protein product 
would be administered to individuals with sub-clinical atherosclerosis who may also 
potentially be infected with Ch. pneumoniae. Demonstration that the vaccine does not affect, 
or have a major adverse impact on pre-existing infections is crucial to validate its safety.
Strategies to enhance the immune response induced by MOMP expressed by a 
eukaryotic expression vector should also be studied. We suggest co-administering the 
plasmid with endonuclease inhibitors such as zinc and/or aurintricarboxylic acid that are 
capable of protecting the plasmid from degradation at the mucosal surfaces (Niedzinski, Chen 
et al. 2003). We should also investigate the most effective administration route (e.g. intra­
muscular or intravenous) for delivery of pcDNA-MOMP. Pursuing the use of a DNA based 
vector over other immunisation strategies is a worth while endeavour, despite its initial 
optimisation problems. Once effectively administered, DNA immunisation provides a 
continuous source of antigen through stable endogenous expression, minimising the need for 
repetitive boosters and making the procedure more cost efficient (Pardoll and Beckerleg 
1995).
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Appendix 1
T a b le  1. R e c ip e s  fo r  b a c ter ia l cu ltu re  m ed ia  an d  r e a g e n ts
Name compositions
LB broth 
LB agar 
NB2 broth 
NB2 agar
2gm Trypton, 1 gm yeast extract, 2gm NaCl in 200mL of H2O, PH 7.0.
2gm Trypton, Igm yeast extract, 2gm NaCl, 3gm bacto agar in 200mL H2O 
25gm NB2, SOGpL of Tween-80, 0.2% (v/v) glycerol, IL H2O 
1.2% (w/v) technical agar, 0.2% (v/v) glycerol, IL H2O
All reagents provided from Oxoid, UK
qjsl P rom oter
PSMT176
4563 bp
'H ir i III (14-
COLEI
Topo cloning site$ 1 1 (34:5)
t o H I ( 3 4 7 9 ) \  . f t / 1 (1 8)
a w  III (3 4 5 1 ) '
1 1 (54)
S m  B1 (245)
puc Origin
pCR-Blunt ll-TOPO 
3519 bp
Kanamycir
/  /  Tops cloning sfto
pet101d/-topo  
5 7 5 3  b p
F ig u r l. M ap o f  d ifferen t p la s m id s  u s e d  in th is  s tu d y . (A). Shows sequence m ap of 
eukaryotic expression vector (pcDNA3.1) used to express the full length o f rMOMP. (B). 
Shows sequence Map of the pC R -B lunt-ll-TO PO  cloning vector used as in term ediate stage 
to enhance the ligation process of PCR fragm ents encoding the MOMP genes into shuttle 
plasmids. (0 ). shows sequence map of psM T176 vector which used to express MOMP in M. 
vaccae. (D). sequence map o f pet101/-topo cloning vector which used express MOMP in 
E.coli.
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T a b le  2 .1  kb DNA la d d er  w h ic h  u s e d  a s  a  r e fe r e n c e  to  c a lc u la te  th e  a p p r o x im a te  s i z e  a fter  
e s t im a t io n  th e  q u a n tity  o f  v is u a liz e d  DNA
Fragment 
number from 
Top
Sizeof the fragment bp Amount per band (ng)
1 10 000 42 ng
2 8000 42 ng
3 6000 50 ng
4 5000 42 ng
5 4000 33 ng
6 3000 125 ng
7 2000 48 ng
8 1500 36 ng
9 1000 42 ng
10 500 42 ng
f
600
500
100
1500
250
253
100 bp  DNA 
la d d e r
0 7%aç^ «)se
1 K b DNA 
la d d e r
F igu re 2. 100  bp DNA and  Ik b  DNA la d d er  w h ic h  u s e d  a s  a r e fe r e n c e  to  e s t im a te  th e  a p p r o x im a te  
s iz e  an d  th e  q u a n tity  o f  v is u a liz e d  DNA.
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Appendix 2
T a b le  1. T h e  ty p e  an d  th e  w o rk in g  c o n c e n tr a t io n  o f  a n t ib o d ie s  u s e d  fo r  th is  s tu d y .
species Host Isotype Type Label FinalCone. WD Source
CDllb mouse rat Ig02b monoclonal PE 2pg/mL 1:50 Serotec, UK
capturc- mouse Rabbit - * - Ipg/mL 1:100 Peprotec, Uk
capture mouse Rabbit - * - 2pg/mL 1:100 Peprotec, Uk
capture
III mouse Rabbit - * - Igg/mL 1:100 Peprotec, Uk
capture
TGF-B mouse
* - * - * cBiosciences,UK
| | |g p i lb |g : mouse rat Ig02b monoclonal Alexa647 2gg/mL 1:50 Serotec, UK
CDllb mouse Rat - monoclonal - Ipg/10'cells - Serotec, UK
CDllb mouse Rat IgG2b monoclonal - lOpg/mL 1:100 serotec, UK
CD14 mouse rat IgGl monoclonal FITC 2gg/mL 1:50 Serotec, UK
CD16/32 mouse Rat - monoclonal - lpg/10'cells - Serotec, UK
CD25 mouse rat IgGl monoclonal PE 2pg/mL 1:50 Serotec, UK
CD36 mouse rat IgG2a monoclonal FITC 2pg/mL 1:50 Serotec, UK
CD4 mouse rat IgG2a monoclonal FITC 2pg/mL 1:50 Serotec, UK
CD4 mouse rat IgG2b monoclonal Alexa-647 Ipg/mL 1:50 Serotec, UK
CD4 mouse Rat - monoclonal - lpg/10'cells - Serotec, UK
| | | |< |p 4 0 | | | mouse rat Ig02a monoclonal FITC 2gg/mL 1:50 Serotec, UK
|||:.(|P3^":I: mouse rat IgG2a monoclonal FITC 2pg/mL 1:50 Serotec, UK
||:##D% |||i| mouse Rat - monoclonal - lpg/10'cells - Serotec, UK
lllicpgigi mouse rat Ig02a monoclonal FITC 2gg/mL 1:50 Serotec, UK
mouse rat JgG2a monoclonal FITC 2pg/mL 1:50 Serotec, UK
detection mouse Rabbit - * Biotin 0.5gg/mL 1:200 Peprotec, Uk
detection
IL-10 mouse Rabbit -
jc Biotin 0.25pg/mL 1:400 Peprotec, Uk
detection
IL-4 mouse Rabbit - * Biotin 0.5pg/mL 1:200 Peprotec, Uk
detection
TGF-B mouse
* - * Biotin * cBiosciences,UK
FoxP3 mouse mouse IgGl monoclonal Alexa-647 0.5pg/mL 1:100
cBiosciences,
UK
Ilis-Tag - mouse - Monoclonal HRP * 1:100 Abeam UK
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species Host Isotype Type Label FinalCone. WD Source
CDllb mouse rat IgG2b monoclonal PE 2pg/mL 1:50 Serotec, UK
IgA mouse Goat - Polyclonal Biotin 0.2pg/mL 1:2000 Sigma, UK
IgG mouse Goat - Monoclonal HRP 250pg/mL 1:300 Dako, UK
IgG rabbit Goat - Monoclonal HRP * 1:3000 Biorad, USA
IgG mouse goat - polyclonal Biotin * 1:200 Dako, UK
IgGl mouse Rat - Monoclonal Biotin 0.5pg/mL 1:2000 serotec, UK
IgG2a mouse Rat - Monoclonal Biotin 0.5pg/mL 1:2000 serotec, UK
lgG2b Rat Goat - monoclonal Alexa568 lOpmg/mL 1:200
Invitrogen,
UK
IgM mouse Rat - Monoclonal Biotin 0.5pg/mL 1:2000 serotec, UK
MHC-II mouse mouse IgM monoclonal FITC 2pg/mL 1:50 Serotec, UK
MOMP Œpneumoniae Rabbit - Polyclonal Biotin
* 1:5000
Dr E Hoelzle, 
University of 
Zurich
TLR-2 mouse mouse IgGl monoclonal Alexa-647 4pg/mL 1:125
Cambridge
Bioscences,
UK
TLR-4 mouse mouse IgGl monoclonal Alexa-488 4pg/mL 1:125
cBiosciences,
UK
a-actin mouse mouse Ig02a monoclonal - 20pg/mL 1:200 Sigma, UK
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